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Wound healing is a highly complex process that requires coordination of growth factors, 
cytokines, and cell types, in order to progress from an acute wound to a resolved scar. Healing 
complications, such as chronic wounds and scarring disorders, comprise a substantial health 
burden, and are linked to dysregulation of key growth factors and cytokines across multiple 
phases of healing. Standard care practices for these disorders are non-specific and often 
ineffective, and biologic treatments attempting to restore growth factor or cytokine balance 
to the wound have largely failed in the clinic, despite promising preclinical evidence.  
 This thesis aimed to identify why delivery of growth factors and cytokines for wound 
healing complications has thus failed, and to evaluate strategies for improving their delivery 
using biomaterials. The first of two comprehensive literature review summarised the fact that 
the large-scale clinical failure of growth factor and cytokine delivery to wounds is likely due 
to the additive effects of poor and variable trial design and reporting, the incompatibility of 
topical administration, and issues relating to regulation and manufacturing. Biomaterials are 
an emerging novel strategy for tailored phasic and multiphasic release of proteins to wounds 
and have been proposed to address some issues identified with topical delivery. A second 
comprehensive literature review concluded that a multifaceted approach using multiple 
proteins within a composite biomaterial system may potentially be more therapeutically 
efficacious than previous topical delivery of single proteins in the clinic. However, there is 
still a lack of evidence that biomaterials actually provide proteolytic protection and structural 
support within the wound, and accurate comparisons to prove that they have improved 
efficacy compared to topical delivery of growth factors and cytokines. Limitations in this 
area of research are centered around translatability, with inconsistent model choices and non-
human relevant outcome measures. Careful consideration needs to be applied when selecting 
which growth factors, cytokines and biomaterials to use, and these choices need to relate to 
targeting of multiple phases of wound healing and appropriate release kinetics.  
The second part of this thesis focused on development and testing of a biomaterial-
based composite VEGF-E and vIL-10 delivery system to enable phasic regulation of wound 
inflammation, repair, and scarring. A biphasic release pattern was observed in vitro, with 
burst release of vIL-10 from the alginate hydrogel by day 1, and cumulative release of VEGF-
E from lipid cubosome particles over 6 days. With only 52% release of VEGF-E and 2.3% 
release of vIL-10, more optimisation of protein loading is required. The lipid component of 
the system exhibited toxicity in human keratinocytes in vitro, but the hydrogel was well-
tolerated when applied to murine skin wounds, with no significant adverse effects observed. 
 iii 
Retention of hydrogels to the wound surface and cellular integration within the hydrogel were 
poor, so modifications are required to improve adherence and cell adhesion.  
Overall, this study highlighted many challenges in the development of growth factors 
and cytokines for the treatment of wound healing and scarring indications. A clear need was 
identified for streamlining of the preclinical and clinical pathways leading to approval. A 
more comprehensive and methodological approach to the development of growth factor and 
cytokine delivery systems that target the phasic dysregulation of chronic wounds or excessive 
scars was recommended as a strategy to facilitate the approval of much needed therapies for 
human wound indications.  
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 Skin Wound Healing and Complications  
1.1.1 Skin Structure and Function 
The skin is the body’s primary barrier against external insults, and is capable of withstanding 
mechanical injury and preventing microbial infiltration and infection[1]. Human skin consists 
of three main layers – the outer epidermis, which forms a junction with the dermis, which in 
turn borders the inner hypodermis (Fig. 1.1)[1]. The epidermis consists of the stratum basale, 
or regenerative basal layer, followed by the stratum spinosum, stratum granulosum, and the 
outer stratum corneum [1].   
The defensive functions of the skin are reliant on both mechanical and cellular functions. 
Firstly, the stratum corneum provides a layer of cornified keratinocytes surrounded by lipid-
rich matrix that prevents water loss[2]. The tight junctions between keratinocytes within the 
stratum granulosum provide a barrier against infiltrating microbes[1, 3]. Langerhans cells in 
the stratum spinosum provide further defence against microbes that penetrate the outer 
layers[3]. Keratinocytes provide cross-talk with the dermis, through growth factor and 
cytokine production[3].  
The dermis lies beneath the laminin- and collagen-rich epidermal basement 
membrane, and consists of sweat and sebaceous glands, hair follicles, blood vessels, neurons 
and muscle, embedded in extracellular matrix (ECM)[1]. Sebaceous glands have roles in 
inflammatory modulation and reported antimicrobial activities[4]. Small and densely packed 
collagen fibres make up the upper papillary dermis, and larger, more organised collagen and 
elastin bundles are found in the reticular dermis beneath[5]. Between 80-90% of the collagen 
found in the dermis is type I, and 10-20% is type III[5]. Fibroblasts are a key cell type in the 
dermis, and differ in function between the reticular and papillary layers[6]. Papillary 
Figure 1.1. The Structure of Human Skin. The outer epidermis consists of 4 primary layers, the stratum 
corneum, stratum granulosum, stratum spinosum and the stratum basale. The stratum basale associates with 
the epidermal basement membrane, below which lie the dermis and hypodermis. Made using Biorender. 
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fibroblasts are responsible for proteoglycan synthesis and modulate epidermis and hair 
follicle cycling, compared to reticular fibroblasts, which synthesise ECM thus contributing 
to skin integrity and tensile strength [6, 7]. Blood vessels reach into the papillary dermis so as 
to provide oxygen and nutrients to support epidermal cycling. Immune cells, such as 
macrophages and T cells, are also resident in the dermis, providing further surveillance of 
damage or infection[6]. 	
The hypodermis is a proteoglycan and glycosaminoglycan-rich layer of adipose tissue 
that contains adipocytes and their precursor cells, along with an immune cell presence similar 
to the dermal layer[6].  This adipose tissue is critical for temperature regulation[8], and has 
also been linked to hair follicle cycling[9, 10], in addition to the prevention of infection[11].  
Skin is designed to withstand mechanical disruption, possessing the ability to respond 
to wounds penetrating the skin layers. Breaching of the skin can be partial thickness, whereby 
the epidermal layer is disrupted, or full-thickness, where the wound may penetrate down to 
the hypodermal layer[12].  
 
1.1.2 Cutaneous Wound Healing 
Cutaneous wounding stimulates a complex series of events that regulate the progression of 
an acute wound to a resolved scar (Fig. 1.2). Successful wound healing requires transition 
through the phases of haemostasis, inflammation, granulation tissue formation, contraction 
and re-epithelialisation, remodelling, and ultimately wound closure. This process is highly 
regulated and of a phasic nature, with each stage involving a diverse number of cell types, 
ECM components, and regulatory molecules that direct their interactions[13]. Growth factors 
and cytokines play a significant role in the movement from one healing phase to the next, 
and any imbalance in this process introduces the potential for healing complications[14]. Of 
particular importance are the epidermal growth factor (EGF), colony stimulating factor (G-
CSF and GM-CSF), fibroblast growth factor (FGF), interleukin (IL), platelet-derived growth 
factor (PDGF), transforming growth factor beta (TGFb), and vascular endothelial growth 
factor (VEGF) families[15]. 
Immediately after injury, the skin must achieve haemostasis to prevent excessive 
haemorrhage before it can begin to heal (Fig. 1.2)[16]. Disruption of the endothelium exposes 
ECM components, which bind and activate platelet cascades to form a fibrin clot. Cleavage 
of fibrinogen by thrombin and release of fibronectin, thrombospondin, and vitronectin 
initiates platelet aggregation, forming a clot that prevents blood loss, protects from microbial 
infiltration and acts as a scaffold for the invasion of inflammatory cells in response to pro- 
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  Figure 1.2. The Wound Healing Response of the Skin. There are five key stages in the wound healing response: 
haemostasis (1), inflammation (2), granulation tissue formation (3), wound contraction and re-epithelialisation (4), and 
remodelling (5). Critical cell types, growth factors, and cytokines that regulate each stage of the wound healing response 
are indicated. Made using Biorender. 
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inflammatory cytokines, such as G-CSF and GM-CSF, which are released by platelets and 
damaged skin cells[14, 16].  
Endothelial adhesion molecules allow for adhesion and infiltration of neutrophils 
from the surrounding vasculature into the wound bed, facilitating their phagocytosis of debris 
and invading bacteria[17]. Damaged cells then produce pro-inflammatory cytokines, such as 
tumour necrosis factor (TNF)-⍺, IL-1β, IL-6, IL-8, and monocyte chemoattractant protein 
(MCP)-1, which recruit monocytes that differentiate into pro-inflammatory M1 
macrophages[18]. M1 macrophages produce matrix metalloproteinases (MMPs) that assist 
with ECM break down to allow cell migration into the clot[18]. 
  The transition of M1 macrophages into an anti-inflammatory M2 phenotype allows 
for the expression of anti-inflammatory cytokines such as IL-10 and TGF-b1 to dampen 
inflammatory cell activation[18]. Endothelial cells migrate into the wound bed in response to 
GM-CSF, VEGF-A and FGF-2 released by M2 macrophages and a range of skin cells, 
forming neovessel structures to restore blood flow to the wound[13]. ECM components 
synthesised by fibroblasts, such as fibrinogen, contribute to endothelial cell proliferation and 
migration, enhancing angiogenesis[19]. Urokinase plasminogen activator (uPA) and tissue 
plasminogen activator (tPA) are secreted by keratinocytes, endothelial cells, monocytes and 
fibroblasts[19], modulating fibrinolysis and ECM production.  Fibroblasts activated by TGF-
b1 and PDGF-bb secreted by M2 macrophages and activated platelets begin to produce a 
new collagen-rich ECM within the fibrin clot. Fibroblastic and angiogenic responses produce 
the highly vascularised and granular wound bed characteristic of this phase of healing[13].  
Once granulation tissue formation has commenced, wound closure occurs through re-
epithelialisation and contraction (Fig. 2) [13]. Keratinocytes at the wound edge proliferate and 
migrate in response to EGF produced by macrophages and fibroblasts, in order to re-
epithelialise the wound[20]. This process is assisted by TGF-b1-induced differentiation of 
fibroblasts, pericytes and mesenchymal stem cells into ⍺-smooth muscle actin (sma)-
expressing myofibroblasts, which support wound contraction to approximate the wound 
edges[21-23].  
The final phase of healing involves continued synthesis and maturation of the new 
collagen-rich ECM (Fig. 2). In this phase, cellular recruitment ceases, with much of the 
cellular infiltrate undergoing apoptosis[14]. TGF-b1-induced collagen synthesis by 
myofibroblasts is inhibited through M2 macrophage production of anti-fibrotic IL-10 and 
TGF-b3[15]. Pruning back of the newly formed vascular network, as well as recruitment of 
pericytes by PDGF-bb, allows for maturation of vascular function[22, 23]. Differentiation of 
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the epithelium into a cornified layer restores barrier function, however regeneration of hair 
follicles and sweat glands is minimal[20]. Fibroblasts continue to synthesise ECM, which 
transitions from type III to type I collagen, increasing tensile strength and structural integrity. 
PDGF-bb, TGF-b3, and MMPs produced by M2 macrophages regulate the realignment of 
collagen into highly organised bundles that strengthen the scar[24, 25].  
 
1.1.3 Cutaneous Wound Healing Complications  
While the response to cutaneous injury is well-conserved, a number of extrinsic and intrinsic 
factors can affect the successful healing of a wound. Wounding following surgery, trauma or 
burn injury can lead to a number of complications, many of which have accumulative effects 
that impact negatively on healing outcomes (Table 1.1).  
 
 Table 1.1. Overview of Prevalent Wound Healing Complications Affecting Current Wound Care  




Seroma Large collections of 
serum in the wound 
space[26] 







Biocolony or biofilm 
infection[31] 
Patient microbiome, age, 
diabetes mellitus, BMI, 
smoking, 
immunosuppressive 
medication, length of pre-




 Dehiscence Wounds closed by 
primary intention 
separate at the wound 
edge[35] 
Mechanical stress, age, 



















Gender, age, site of 
injury/wound, tension on 
wound[41-43] 
Contractures, lack of 





Excessive fibrotic scar 
that extends beyond 
the original wound 
boundary[44] 
Genetic predisposition in 
African populations[42, 45], 
tension on wound, site of 
injury/wound[46] 
 
Pain at the sight, 
need for surgical 
excision but 
associated with a 
high recurrence 
rate[46] 
*in the case of abdominal dehiscence only 
BMI, body mass index  
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Acute wounds in obese individuals can cause the formation of seromas[27-30], which put 
pressure on the wound edges, leading to dehiscence and wound infection[34, 35]. Wound 
breakdown and dehiscence can incite chronicity of the wound and delayed healing[39]. The 
reported prevalence of seroma formation varies from 15-81%[26], wound dehiscence between 
0.5-3.4%[47], and chronicity between 1-2%[48].  
 Intrinsic factors such as vascular disorders, diabetes, and age, can predispose patients 
to chronicity[14, 39, 49], causing ulcers, amputations, and mortality at high rates[48, 50-52]. Chronic 
wounds also have a high risk of recurrence, between 60-70%[38]. Prolonged hospitalisation, 
particularly associated with impaired movement, can promote formation of pressure 
ulcers[53], which has a prevalence between 6-18.5%[54].   
 Cases of over-healing, such as hypertrophic scars and keloids, culminate in excessive 
fibrotic scars[55, 56]. Hypertrophic scars are characterised by hyperproliferation of the ECM 
and surrounding vasculature, and form 1–3 months after tissue insult[41, 46]. Unlike keloid 
scars, they do not extend outside of the original wound boundary[46]. Hypertrophic scars 
emerge following tissue injury, with risk increasing based on the site of the wound 
(particularly shoulders, neck, knees and ankles[57]) and tension at the wound edges[41-43]. 
Keloid scars have a strong genetic link with a much higher incidence rate in dark-skinned 
individuals[45, 58], and while risk does increase following tissue injury, keloids can emerge 
with no previous history of tissue damage or up to several years after[55]. Hypertrophic scars 
have a reported prevalence of 40-70% following surgery, and up to 91% following burn 
injury[57]. Keloid scars have a reported prevalence between 4-16% in African populations[58].  
 
1.1.3.1 Impaired Healing: Chronic Wounds 
Impaired healing can emerge due to disruptions in the phasic process of wound healing[38]. 
Chronic wounds form when the transition between the inflammatory and proliferative phases 
does not occur, leaving the wound in a state of perpetual inflammation[39]. These types of 
wounds commonly emerge in patients with disorders such as vascular insufficiency and 
diabetic neuropathy, causing venous leg ulcers and diabetic foot ulcers, however chronicity 
can also emerge in acute wounds following seroma, infection, or dehiscence[59, 60].  
Inflammatory and oxidative complications are driven by excess platelet activation, 
neutrophil and monocyte recruitment, production of proinflammatory cytokines, lipid 
mediators, reactive oxygen species (ROS), as well as MMP-mediated degradation of key  
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Figure 1.3. Impaired or Excessive Healing of Skin Wounds. Impaired healing occurs due to inflammation and 
infection, resulting in wound chronicity (left panel). Excessive healing occurs due to sustained inflammation and 
myofibroblast abnormalities, resulting in impaired remodelling (right panel). Critical cell types, growth factors 
and cytokines that are dysregulated at each stage of the wound healing response are indicated. Made using 
Biorender. 
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growth factors and cytokines, and the ECM (Fig. 1.3)[14, 61, 62]. This dysregulation has been 
reported in chronic pressure ulcers[62, 63] and leg ulcers[64]. Damage to the vasculature results 
in a failure to deliver sufficient oxygen and nutrients to support repair. Persisting neutrophils 
and ROS production damages the ECM, causing cellular senescence[65]. M1 macrophage 
persistence is observed, as these cells fail to differentiate into the proresolving M2 
phenotype[18]. Transition to a chronic state is also associated with formation of antibiotic-
recalcitrant bacterial biofilm communities, which produce proteases that degrade growth 
factors and cytokines[39].  
Cumulatively, the failure to produce ECM impairs growth factor and cytokine 
function, leading to defective granulation tissue formation and a hyper-proliferative 
epidermis that prevents re-epithelialisation [14, 17].  
 
1.1.3.2 Excessive Healing: Hypertrophic and Keloid Scarring  
Where chronicity is defined as a lack of healing, excessive scarring is a case of exaggerated 
healing[41]. Hypertrophic scars emerge as a result of excessive inflammation and ECM 
deposition by myofibroblasts (Fig. 3)[55]. Mast cell infiltration and degranulation contributes 
to increased histamine, proteoglycans, proteinases, proinflammatory cytokine and TGF-b1, 
VEGF-A and FGF-2 levels. Excess in these mediators sustains the activation of M2 
macrophages, endothelial cells, and myofibroblasts[41, 56, 66-69]. Myofibroblasts in 
hypertrophic scars are phenotypically distinct to those in normal wounds, with increased 
resistance to apoptosis, allowing for sustained collagen deposition to drive excessive 
fibrosis[70, 71]. Normal, hypertrophic, and keloid scars, in turn, are associated with greater 
extent, persistence, and dysfunction of the vascular and fibrotic responses, which leads to 
pronounced type I collagen deposition and bundle thickening, resulting in a characteristic 
lack of flexibility[41, 56]. 
 
1.1.4 Current Methods of Wound Management 
Current management techniques for wound healing complications are described in Table 1.2. 
Interventions can be preventative or therapeutic, to treat the symptoms of a complication or 
attempt to remedy the complication. These strategies are largely non-specific, broad-
spectrum treatment options, and in some cases, evidence is limited and inconclusive.   
 Management of nutritional input has been suggested as a treatment strategy for 
chronic wounds, as poor nutritional status has been linked to impaired ECM regeneration and  
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Clinical Evidence   Issues  
Nutrition Chronicity  Both Poor nutritional status linked to 
impaired ECM deposition and 
blood vessel formation[60, 72, 73]. 
May increase efficacy of 
adjuvant therapies[72]. Single 
RCT showed that nutritional 
supplementation accelerated 
healing in human biopsies[74].  
Limited clinical 





Preventative Sutured edges should be fresh 
(bleeding) and no excessive 
tension applied as this is linked 
to hypertrophic scar 
formation[75]. Avoidance of 
dead space following surgery 
can reduce seroma incidence[76, 
77].  





Antiseptics  Infection Both 0.9% sodium chloride or 3% 
hydrogen peroxide used to 





fibrosis and no 
effect on bacterial 
load[78, 79].   
Antibiotics Infection Preventative Antibiotics can be applied 
topically or systemically to 
reduce bacterial load in the case 
of wound infection[80]. 
Topical antibiotics 
have no effect on 
chronic wound 
area and are 
associated with 
hypersensitivity 
and resistance[81].  
Offloading Chronicity Therapeutic Redistributing pressure off the 
wound to a more widespread 
area[82] via offloading devices 







rate of healing[82].  
Dressings Chronicity Preventative Dressings using cotton fibre 
gauze, occlusive dressings or 
impregnated gauze maintain a 
moist wound environment to 
promote re-epithelialisation[75, 
83, 84].  
Can require 
frequent changes 
depending on the 
type of dressing 
and wound 
complication[75].  
Hydrogels Chronicity Both Hydrogel dressings have a 
large capacity to absorb wound 
exudate and maintain a moist 
wound environment, which 
assists with cellular function[85]. 
They can be used to deliver 






NPWT Chronicity Therapeutic for 
chronic wounds  
Decreases oedema and 
bacterial count, increases 
VEGF and FGF-2 expression to 
promote granulation[86]. 







Chapter 1: Introduction 
 11 
vascularisation[72, 73] (Table 1.2). Evidence to support this is limited, with a single RCT 
reporting that nutritional supplementation accelerated healing of human wound biopsies[74]. 
 Incorrect surgical technique is associated with formation of seromas and chronic 
wounds[76, 77], thus maintaining correct surgical technique reduces the risk of complications 
occurring, however, it does not control for the wide variety of risk factors involved. 
Antiseptics and antibiotics have commonly been used to control infection, which is a 
common complication in chronic wounds[31]. Evidence to support the use of antiseptics, such 
as hydrogen peroxide, is very limited – instead showing an increased risk of cytotoxicity and 
fibrosis with no effect on bacterial load[78, 79]. Antibiotics can be applied topically to the 
surface of the wound or systemically, however evidence suggests that delivery of antibiotics 
has no effect on chronic wound area, and can instead lead to hypersensitivity and 
resistance[81].  
 Standard care for treatment of chronic wounds, in particular diabetic foot ulcers, is 
offloading – where pressure points causing ischaemic ulceration are mitigated by 
redistributing the weight to a more widespread area[82]. Unfortunately, offloading devices are 
heavy and disruptive to daily life, and surgical interventions have little evidence to support 
their use[82]. They also fail to address many of the other factors that may enhance healing, 
such as hydration at the wound surface, which can be achieved through dressings[75, 83, 84]. 
Cotton fibre gauze, occlusive dressings, or impregnated gauze can assist with maintaining 
hydration at the wound site to promote re-epithelialisation. However, standard dressings have 
high adherence to the wound which can be problematic considering their need for frequent 
replacement[75]. Hydrogels provide a good alternative, as these biomaterial-based dressings 
have a large capacity to absorb wound exudate, maintain hydration at the wound site, and do 
not adhere so much to the wound surface, making changes more comfortable for patients[85]. 
They can also be used to deliver bioactive substances to the wound in a controlled manner[85].  
 Negative pressure wound therapy (NPWT) is a treatment strategy by which constant 
negative pressure is applied to the surface of the chronic wound, promoting granulation tissue 
formation and providing drainage of exudate[86]. A Cochrane systematic review concluded 
that the limitations in clinical evidence means that the benefit of NPWT in the treatment of 
chronic wounds is still inconclusive[89].  
 Surgical technique is the initial factor that can influence scarring outcomes in acute 
wounds[75] (Table 1.3). Excessive tension at the wound edges can promote formation of 
hypertrophic scars, however, correct surgical technique will not completely prevent scar 
formation[41].  
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Silicone products are considered the first line therapy in emerging, immature or 
hypertrophic scars following injury or surgery [18]. The benefit of silicone dressings on 
emerging scars has been linked to hydration of the stratum corneum and wound occlusion[90, 
91], however the clinical evidence supporting their use for scar treatment is fairly weak[92-94].  
 







Clinical Evidence   Issues  
Surgical 
Technique  
Scarring Preventative Sutured edges should be fresh 
(bleeding) and no excessive 
tension applied as this is linked 
to hyper- and atrophic scar 
formation[75]. Avoidance of 
dead space following surgery 
can reduce seroma incidence[76, 
77].  







Scarring Therapeutic Improved phenotype linked to 
hydration of the stratum 
corneum and wound 








Scarring Therapeutic Shown to possess antibacterial 
and fibrinolytic activity[95, 96]. 
Reduction in scar presentation 
when used in combination with 







Scarring Therapeutic Decreases ECM production 
and fibroblast proliferation, 
reduces inflammation[101, 102].  
Associated with a 
number of side 
effects including 
pain at injection 
site, 
hypopigmentation, 




Laser Therapy  Scarring Therapeutic 585 nm pulsed dye lasers/high 
energy CO2 lasers decreased 





infection[105, 106].  
 
 
The second line treatment for hypertrophic scars is intralesional steroid injections, which 
target the excessive ECM deposition and fibroblast proliferation involved in hypertrophic 
scar formation[56, 101, 102]. While effective, intralesional steroid injections are associated with 
a slew of side effects that make it an unattractive therapy for many patients[103]. Laser therapy 
is associated with many of the same side effects[105, 106]. Extracts from Allium Cepa have 
antibacterial and fibrinolytic activity[95, 96], and data shows an improved scar phenotype when 
used in combination with silicone dressings, however, this data is of poor quality and 
conclusions cannot be drawn about its efficacy[97-100].  
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A distinct lack of therapies that accurately target the pathogenesis of these conditions – 
largely excessive inflammation and complex cell irregularities – means that patient outcomes 
are not often successful, shown by continued high prevalences, and in some cases, high 
associated mortalities[31, 40, 41, 47, 49, 52]. Large costs provide further stresses to patients and 
healthcare providers, with an estimated $28 billion annual cost for all wound types[48]. The 
failings in treatment of these complications makes it evident that new, more specific therapies 
are desperately needed for wound complications if there is to be a reduction in the clinical 
and economic burdens they present. 
 
1.1.5 Advanced Scar and Wound Management: Growth Factors and Cytokines in the 
Treatment of Human Wound Indications 
As previously emphasised, growth factors and cytokines are critical factors in regulating 
wound healing[13, 15]. Many have been shown to be crucial to skin repair in animal models 
and human wounds, with their dysregulation contributing to impaired or excessive healing 
(Fig. 1.3). In acute wounds, increased expression of EGF[107], FGF-2[108], TGF-b[109], 
PDGF[110], VEGF[111], IL-1 and -6[112] and  TNF-⍺[110] acts to mediate healing. In chronic 
wounds, expression of pro-inflammatory IL-1, IL-6 and TNF-⍺ has been observed[110, 113],	
which contributes to impaired healing when paired with decreased expression of EGF, FGF-
2, TGF-b, PDGF and VEGF[110, 114]. As such, direct growth factor or cytokine administration 
has been trialled as treatments for chronic ulcers, burns or scar-prone wounds[115]. However 
clinical trials thus far have been largely unsuccessful, with only a few treatments approved 
as wound healing products worldwide.  
The only FDA-approved growth treatment for neuropathic ulcers is recombinant 
human (rh)PDGF-bb delivered in a carboxymethylcellulose (CMC) hydrogel (Regranex)[116]. 
A biosimilar (Plermin) was launched in India in 2013[117]. Three products containing rhEGF 
are available for treatment of diabetic foot ulcers. Heberprot-P is registered in 15 countries 
and is administered by intralesional injection to recalcitrant ulcers[118]. Easyef is a topical 
spray approved for diabetic foot ulcers in four Asian countries[119]. Regen-D is a topical 
hydrogel commercialized in India[120]. A topical spray containing rhFGF-2 (Fiblast)[121] is 
marketed for skin ulcers in Japan.  
Many other growth factors and cytokines have been trialled in the clinic for wound 
indications, but have been unsuccessful[115]. For example, rhVEGF-A (Telbermin) showed 
good efficacy in rabbit ischaemic hind limb and db/db mouse models treated with VEGF-
A[122-126], accelerating both wound closure and restoration of the vasculature, but this 
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unfortunately failed to translate clinically. Telbermin failed to achieve complete wound 
closure in a Phase II clinical trial, and as a result it did not progress any further[127]. Leucomax 
(rhGM-CSF) is an FDA-approved immune stimulator administered following chemotherapy 
and bone marrow transplantation, while Neupogen and Granocyte (rhG-CSF) are indicated 
to reduce neutropenia[128]. Based on its immunomodulatory effects, rhG-CSF and rhGM-CSF 
have been trialled for a range of chronic ulcers[129, 130], but have not been approved for these 
indications. Anti-inflammatory and anti-fibrotic cytokine therapies, such as Avotermin 
(rhTGF-b3)[131-136] and Ilodecakin (IL-10)[137, 138], have been explored as anti-scarring 
therapies, but neither of these treatments completed clinical trials.  
It is not yet clear why growth factor and cytokine therapies have failed to achieve 
meaningful clinical outcomes for wound healing indications. Some reasons have been 
proposed, including difficulties in designing clinical trials for wound therapies, defining 
appropriate measures of treatment success[139, 140], reporting criteria, the costs associated with 
development and testing[141], and the efficacy and safety of direct protein administration [62, 
142, 143]. The validity of these reasons as contributing factors to growth factor and cytokine 
failures will be investigated in Chapter 2.  
 
 Biomaterials for Delivery of Growth Factors and Cytokines to Cutaneous Wounds 
The therapeutic efficacy of recombinant proteins can be compromised by the proteolytic 
nature of chronic wounds[144], and by systemic or immunogenic clearance[142, 145]. The net 
result is that growth factors and cytokines may not have been delivered to receptive wounds 
at therapeutically relevant levels. This issue can be overcome by increasing the frequency or 
dosage of the protein administered[115]. But these changes in the treatment regimen likely 
reduce patient compliance[59, 146, 147], and may exacerbate local hypersensitivity reactions and 
the risk of systemic action on healthy or cancerous tissue[145, 148]. A proposed solution for 
unsatisfactory topical delivery of biologics is the use of biomaterials, which has been 
suggested to provide protection and sustained release of biologics, for greater therapeutic 
efficacy (Fig 1.4). Biomaterials are polymeric substances that interact with the cellular 
environment in order to treat, augment, repair or replace a tissue function of the body[149]. 
Biomaterials can be classified into synthetic and natural polymers based on the origin of the 
material[149].  
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1.2.1 Synthetic Biomaterials 
Synthetic biomaterials encompass those materials that are synthesised artificially from 
synthetic polymers, and include polyurethane (PU), poly-L-lactic acid (PLA), poly (ethylene 
glycol) (PEG), polycaprolactone (PCL), poly (lactic-co-glycolic acid) (PLGA) and poly 
(vinyl alcohol) (PVA) (Table 1.4). They are often made in the form of hydrogels, 
nanoparticles, and fibres (Table 1.4). Producing synthetic biomaterials is considerably 
cheaper than natural materials, and the sustained uniformity of the product, mechanical 
stability and controlled degradation rate are obvious advantages[149].  
 PUs are composed of di-isocyanate and polyether components, the ratio of which can 
be altered to change its properties[149]. PU makes a good semipermeable dressing, providing 
a physical barrier against bacteria and fluid infiltration, while still allowing for oxygen 
penetration to the wound[150]. However, the non-adsorbent nature of PU introduces the 
possibility of exudate build-up beneath the dressing with no means of clearance[150]. In 
addition, the use of aromatic di-isocyanates are associated with toxic by-products[151]. Cell 
adherence of PU-based systems is also limited[150].  
  
Figure 1.4. Methods for Delivering Growth Factors and Cytokines to Skin Wounds. Direct delivery of growth 
factors or cytokines is achieved via topical application or intradermal injection (left), with only short-term 
bioactivity, due to proteolysis and an ECM not able to support their action. Biomaterial-based delivery is 
achieved through the incorporation of growth factors or cytokines into an ECM-like hydrogel, scaffold, 
sponge, or particle (right) that offers proteolytic protection and structural support for sustained bioactivity. 
Made using Biorender.  
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Table 1.4. Overview of Key Synthetic Biomaterials.  
Classification Biomaterial Properties Use in Wound Healing 
PU  
Hard di-isocyanate and soft 
polyether components[151].  
Suitable as semipermeable dressings, allow for oxygen 
permeation without bacteria and fluid permeation[149, 150]. 
Caution should be taken regarding toxic by-products[151]  
PLA  
Lactic acid and di-ester 
lactide monomers make up 
an aliphatic polyester[149].  
Suitable in combination with other polymers to make 
composite materials, but poor hydrophilicity makes it 
unsuitable as a monotherapy[149].  
PEG  
Hydrophilic oligomer or 
polymer derived from 
ethylene oxide[149, 152].   
Hydrophilic, non-toxic and non-immunogenic[149], 
commonly used in composite biomaterials as dressings 
and drug delivery scaffolds[152].  
PCL  




Commonly used in composite biomaterials with naturally-
derived biomaterials[149].  
PLGA  
Polymer synthesised by 
monomers of glycolic and 
lactic acids[149] 
Readily biodegradable, can be used in nanoparticles, 
microspheres, nanofibres, hydrogels[149, 150]. Can form 
polymer aggregates and has poor drug loading 
capacity[149].  
PVA 
Vinyl polymer which when 
crosslinked forms a 
hydrogel[153].  
Biologically inert[153] and used as wound dressings and 
drug delivery systems. Very hydrophilic, therefore 
unstable in water when used alone[153].  
PU, polyurethane; PLA, poly-L-lactic acid; PEG, poly (ethylene glycol); PCL, polycaprolactone; PLGA, poly 
(lactic-co-glycolic acid); PVA, poly (vinyl alcohol)  
 
PU derivatives such as PLA, PEG and PCL are more commonly used due to their 
increased biological inertness and decreased toxicity[149]. PLA is an aliphatic polyester and 
despite its absorbability and diverse mechanical properties, it is very hydrophobic, making it 
unsuitable as a dressing on its own[149]. PLA is often combined as a composite material with 
other natural and synthetic polymers[149]. PEG is an abundantly used polymer or oligomer, 
derived from ethylene oxide[152].  PEG is FDA-approved[154] for intravenous, oral and topical 
use in humans. It is hydrophilic, non-toxic and non-immunogenic[149]. PEG hydrogels have 
been used to promote wound healing, although largely as a part of composite materials in 
combination with other natural biomaterials. On its own, PEG hydrogels are able to 
encapsulate cells and growth factors, but the high water absorption produces quick 
degradation, and thus fast release[155]. PCL is another synthetic polymer extensively used in 
composite tissue scaffolds[156], with some data suggesting it may promote collagen 
production in wounded skin of rabbits and humans[157, 158]. PLGA enhances wound healing 
on its own due to lactate-driven angiogenesis, and makes for a highly tuneable drug carrier 
due to its tailorable biodegradability[159]. PLGA in the form of nanofibres, membranes, 
microspheres, hydrogels and nanoparticles has shown the capacity to carry a number of 
wound regulators including VEGF-A, FGF-2, defence peptides, and antibiotics[159].   
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 In summary, synthetic biomaterials are useful for healing due to their mechanical 
strength and tailorability of growth factor or cytokine release. However, some are associated 
with toxic by-products, and many are biologically inert – i.e., not interacting with cells to 
actively promote healing - rather requiring functionalising with natural sequences to enhance 
their cellular interactions.  
 
1.2.2 Natural Biomaterials 
While some synthetic biomaterials form the basis of wound healing products, it is much more 
common for them to be combined with natural biomaterials to form composite systems. 
Natural biomaterials are generally more biocompatible, with many mimicking natural 
ECM[149]. Natural biomaterials are highly diverse and delivery mechanisms can be tailored 
to the clinical need, including injection or surgical implantation[160]. Combining natural 
biomaterials with particulate systems such as nanoparticles, microspheres and liposomes, 
allows for specifically tailored release of one or more growth factors to the wound site. These 
systems are highly functionalisable and can be customised to chronic wounds, burns and 
scar-prone surgical incisions.  
Collagen is the most abundant ECM protein, and due to its extensive roles in cell 
signalling and ECM structure, it has a number of wound healing applications (Table 1.5)[149]. 
Human collagen is difficult to isolate, therefore key sources include bovine, porcine, avian 
and fish derivatives[149]. Despite animal-derived protein carrying many concerns regarding 
immunogenicity, recombinant collagen via bacterial and cell-derived transfection is in early 
stages and not yet surpassing the quality of animal-derived collagen[149, 161]. Collagen is 
resistant to proteolysis, but undergoes degradation via collagenases (MMP-1, -2, -8, -13 and 
-14), with breakdown products promoting migration of fibroblasts and proliferation of 
keratinocytes, epithelial cells, and macrophages via the a2b1 receptor[162-166].  
Gelatin-based hydrogels derived from collagen hydrolysis have also been extensively 
used as dressings and as carriers for growth factors and cytokines. Animal-derived collagens 
can be hydrolysed to gelatin via chemical, enzymatic or physical processes[149, 167]. Its shorter 
length makes it more soluble and less immunogenic than collagen, but less structurally sound 
– requiring cross-linking via physical and chemical means[167].  
Hyaluronic acid (HA) is a polysaccharide made up by repeated units of glucuronic 
acid and N-acetylglucosamine[168]. It is often produced by bacterial synthesis using strains of  
Agrobacterium spp., Lactococcus lactis, and E. coli[169]. HA is the main nonprotein 
component of the ECM, contributing to elastoviscosity, tissue hydration, and a number of 
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Table 1.5. Overview of Key Natural Biomaterials.  
Classification Biomaterial Properties Use in Wound Healing 
Collagen Abundant ECM protein[161]. 
Highly cross-linked therefore insoluble, biocompatible, 
promotes migration of fibroblasts, macrophages and 
endothelial cells[161]. Form highly flexible dressings, can be 
used as carriers for growth factors and cytokines[161]. 
Mechanically weak and animal-derived collagens pose 
immunogenicity risk[170].  
Gelatin 
Anionic, denatured form of 
collagen, similar structure 
with broken triple helix and 
no covalent interactions[149, 
167].  
Solubility enhanced compared to collagen, low 
immunogenicity, structurally weak therefore requires 
cross-linking[149, 167].  
HA 
Linear, nonsulfated GAG 
made up of glucuronic acid 
and N-
acetylglucosamine[168].  
Main nonprotein component of the ECM, contributing to a 
number of inflammatory and wound healing processes[171].  
Should be noted that low molecular weight HA possesses 
pro-inflammatory effects[149].  
Fibrin 
Anionic protein component 
of ECM, derived from 
thrombin-mediated 
cleavage of fibrinogen[149].  
Biocompatible, mediates a number of cell-matrix and 
matrix-matrix interactions, promotes proliferation of 
fibroblasts, monocytes and keratinocytes[172]. Heparin 
binding allows for growth factor and cytokine 
encapsulation[172]. Quickly biodegrades[172].  
Chitosan 
Linear polysaccharide made 
up of (1,4,)-linked 2-amino-
deoxy-β-D-glucan, formed 
via alkaline deacetylation of 
chitin[149]  
Biocompatible, anti-microbial, non-toxic, substrate for 
cell-mediated proteolysis, biodegradability tailorable based 
on its deacetylation[149, 173]. Can form highly modifiable 
hydrogels, sponges, films and nanoparticles[174]. Influences 
multiple stages of wound healing to promote repair[174].  
Alginate 
Block copolymer composed 
of d-mannuronic (D block) 
and L-guluronate (M Block) 
residues. Crosslinks with 
Ca2+ in an egg-box motif[175] 
to form a hydrogel[176].  
Highly modifiable, non-toxic, non-immunogenic[177], high 
water uptake. Can be used in hydrogels, films, nanofibres 
and  foams[176].  
 
cellular functions including proliferation, migration and inflammation[168]. The properties of  
HA are dependent on the molecular weight, with high molecular weight HA showing anti- 
inflammatory properties, but low molecular weight HA showing pro-inflammatory 
properties[178]. While high MW HA retains the benefits of HA as a wound treatment including 
high water absorption, keratinocyte proliferation and migration and good 
biocompatibility[179, 180], its breakdown into smaller molecular weight products that possess 
pro-inflammatory actions could cause complications when treating wound complications that 
are driven by inflammatory imbalances[181, 182].  
Another commonly used biomaterial is fibrin, a structural protein involved in the 
clotting process that is formed by polymerisation of the plasma protein, fibrinogen[183]. Fibrin 
is the primary component in clots and provides a natural scaffold for infiltrating blood and 
skin cells. Fibrin has been shown to influence endothelial cells, fibroblasts, keratinocytes, 
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and a number of inflammatory cells including granulocytes and monocytes[183]. The use of 
fibrin sealants, or fibrin ‘glues’ – which combine fibrinogen and thrombin to produce a fibrin 
clot in situ[183] – have been extensively investigated[172, 184]. Fibrin sealants can be used to 
produce scaffolds and nanoparticles to deliver cells, growth factors and cytokines to the 
wound site to promote repair[172].  
In contrast to the above ECM components, chitosan, derived from the exoskeletons 
of crustaceans and cell walls of fungi, is a linear aminopolysaccharide that has been 
extensively used in wound dressings and in controlled delivery of growth factors, cytokines, 
and drugs[174]. Chitosan has been shown to enhance wound repair in a number of forms[174, 
185]. This effect has been linked to the activation of polymorphonuclear neutrophils and 
macrophages, and to the induction of granulation tissue formation via fibroblast 
proliferation[186-188]. Chitosan also has a positive effect on scar phenotype, upregulating pro-
fibrotic TGF-b1 and collagen deposition in early healing phases before decreasing its 
expression in later phases, allowing for scar resolution[187, 189].  
Alginates, derived from brown seaweed, are absorbent, gel-forming materials with an 
alginic acid backbone[190]. Alginic acid is a block copolymer composed of D-mannuronate 
and L-guluronate residues, and is structurally analogous to cellulose, with the only difference 
being the presence of a carboxyl group in the location of the alcohol group[191]. These blocks 
include G-blocks (L-guluronate only), M-blocks (D-mannuronate only) and a combination 
GMGM block. In the presence of ionic calcium (Ca2+), sodium alginate salts within G-block 
polymer instantly crosslink with calcium cations, coagulating to form a hydrogel[190, 191]. 
Alginate hydrogels were proposed to be a potential wound therapy after it was shown they 
were able to maintain hydration at the wound surface, and that this accelerated wound 
closure[191, 192]. Similar to other hydrogels, alginate gels have a high capacity to absorb water, 
meaning they can absorb wound exudate and reduce the incidence of bacterial infection, as 
well as assisting with re-epithelialisation and vascularisation as granulation tissue forms[176]. 
Alginate gels have diverse capabilities including biocompatibility, a high water content, and 
in addition to wound healing effects on their own, alginates may be used to load and release 
bioactive compounds[170, 193]. The high water absorption capacity of alginate means that it 
degrades relatively quickly for fast release, but the degree of crosslinking can influence its 
absorption capacity and thus its degradation rate[170, 193]. Alginate-based hydrogels have been 
used to deliver growth factors, antibiotics and others directly into the wound site with general 
success[194-196].  
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1.2.3 Composite Biomaterials  
More sustained release of growth factors and cytokines can be achieved by combining 
different biomaterials and fabrication techniques to form composite materials. Natural 
biomaterials combined with stronger synthetic biomaterials allows for enhanced stability 
while retaining their biomimetic properties[197]. Addition of heparin and fibronectin 
fragments can immobilise growth factors within scaffold systems[198-201]. Furthermore, 
natural/synthetic combinations can incorporate nanocarriers for phasic release of one or more 
growth factors or cytokines (Fig 1.5).  
 
 
As shown in Figure 1.5.,  hydrogels containing growth factors or cytokines allow for burst 
release into the wound bed upon absorption of the wound fluid. Nanoparticles encapsulating 
therapeutic proteins could show more sustained release, coinciding with the degradation of 
the nanoparticle. Hybrid biomaterials, consisting of a hydrogel encapsulating free protein and 
nanoparticle-encapsulated protein, may allow for biphasic release following degradation of 
the hydrogel, releasing one protein, followed by the nanoparticle, releasing the next. 
Nanoparticles include liposomes, microspheres and beads[202]. They can be made from both 
natural and synthetic biomaterials, are able to diffuse across membranes and can carry 
bioactives, such as growth factors and cytokines[202]. Liposomes are composed of a natural 
Figure 1.5. Tailored Release of Growth Factors and Cytokines to Skin Wounds Using Composite 
Biomaterials. Hydrogels containing GF or cytokines allow for rapid diffusion into the wound bed upon 
absorption of wound fluids (left panel). NPS encapsulating GFs or cytokines allow for sustained release 
coinciding with degradation of the NP (centre panel). Hybrid biomaterials consisting of a hydrogel 
encapsulating free protein and nanoparticle-encapsulated protein allows for biphasic release following 
degradation of the hydrogel then the nanoparticle (right panel). Made using Biorender.  
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or synthetic phospholipid shell, and can entrap hydrophilic growth factors and cytokines 
within their aqueous core[203].  These include cubosomes, which are lipid-based nanoparticles 
formed in the lipid bicontinuous cubic phase[204]. Biodegradable microspheres are derived 
from either natural or synthetic materials such as PLGA, and are also able to load, protect 
and control the release of growth factors and cytokines[160]. Passive delivery can occur with 
diffusion of the protein through the biomaterial as they degrade[160].  
The diversity of combinations when forming composite biomaterials opens provides 
a number of opportunities to match the system to the indication in an extremely specific 
manner, and these systems can be as simple or complex as needed[149, 197]. Where simple 
systems may encapsulate one therapeutic protein within a hydrogel, scaffold, membrane or 
film, release of proteins can be advanced by layering different biomaterials and nanoparticles 
to produce a specific phasic release. However, it is not known which biomaterial, growth 
factor and cytokine combinations are best suited to different types of impaired healing, such 
as treatment of chronicity or excessive scarring. The evidence supporting different 
biomaterial delivery to wounds to improve healing will be investigated in Chapter 3.  
 
 Orf Virus as a Source of Growth Factors and Cytokines for Wound Healing 
Orf Virus (OV) is the prototypical member of the Parapoxvirus genus from the Poxviridae 
family[205]. OV produces large, hyperproliferative skin lesions in sheep and humans, which 
are characterised by epidermal hyperplasia and vascular proliferation (Fig 1.6)[206, 207]. 
However, lesions resolve with minimal signs of inflammation and scarring[208]. It has been 
shown that OV encodes growth factor and cytokine homologues which manipulate the 
healing response in infected hosts[205]. The homologue of VEGF-A produced by OV, VEGF-
E, has been linked to its hyperproliferative skin response[207, 209]. The lack of inflammation 
and scarring in response to OV infection has been linked to the production of an IL-10 
homologue, vIL-10. It has been shown that in the absence of OV infection, VEGF-E and vIL-
10 are able to modulate skin repair and scarring processes.   
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1.3.1 Orf Virus VEGF-E as a Reparative Treatment for Cutaneous Wounds  
Parapoxvirus VEGF-E proteins share between 22-57% identity with human VEGF-A, but 
retain high structural similarity sharing a dimeric disulfide-linked cystine knot motif[210-212]. 
VEGF-E may, however, have greater clinical application than VEGF-A, due to its biased 
ligand signalling[213]. Activation of VEGFR-1 by VEGF-A recruits monocytes and drives 
inflammatory responses[214], while activation of VEGFR-2 induces angiogenesis[215]. 
Sustained VEGF-A exposure has been linked to formation of dysfunctional vascular 
networks, scar tissue formation, and oedema, culminating in negative healing outcomes, and 
these responses have been linked to processes downstream of VEGFR-1[44, 216, 217].  
By contrast, VEGF-E selectively binds VEGFR-2[218], specifically driving beneficial 
angiogenic processes, without activation of inflammatory VEGFR-1 pathways[213, 218]. In 
vitro, VEGF-E has been shown to more potently induce endothelial cell proliferation 
(C) (D) (E) 
(A) (B) 
Figure 1.6. Gross Anatomy of an Orf Virus Lesion. Orf virus produces highly proliferative lesions 
characterised by epidermal hyperplasia and vascular proliferation, which resolve with minimal scarring. (A) 
gross anatomy of an Orf virus lesion (B) previously affected skin following resolution of the lesion. (C) 
extensive vascularisation in Orf virus lesion revealed by von Willebrand factor (vWF) staining of paraffin-
embedded sections of virus lesions taken at 10 days post-infection. (D) immune cells blocked from entering 
Orf virus lesion revealed by major histocompatibility class (MHC) II staining of paraffin-embedded sections 
of virus lesions taken at 10 days post-infection. (E) proliferative epidermis infected by Orf virus revealed by 
Giesma staining of paraffin-embedded sections of virus lesions taken at 22 days post-infection. Images A 
and B provided with permission from Gurel et al, (2002). Giant orf on the nose. Eur J Dermatol 12: 183-
185.  
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compared to VEGF-A[212]. VEGF-E also induces keratinocyte migration and proliferation in 
vitro, and this effect has been demonstrated to be VEGFR-2-specific[219]. VEGF-E injected 
intradermally into sheep skin enhanced angiogenic responses and increased epidermal 
thickening[212] in full-thickness excisional mouse wounds[219]. Subcutaneous administration 
of VEGF-E to cutaneous full-thickness excisional wounds in mice enhanced wound re-
epithelialisation and closure, as well as improved the number of newly formed and mature 
blood vessels[213, 219]. This treatment also increased IL-10 expression and reduced 
macrophage infiltration, cytokine production, and myofibroblast differentiation leading to 
reduced scar tissue formation and improved collagen bundling[219]. Vascular permeability, 
oedema and inflammation was also decreased in guinea pigs[212, 218] and mice[220]. This data 
suggests that VEGF-E makes for a promising reparative treatment for cutaneous wounds.  
 
1.3.2 Orf Virus Interleukin-10 (vIL-10) as a Preventative Treatment for Cutaneous 
Scarring 
OV-derived vIL-10 shows 67% homology to human IL-10[221], but is predicted to share a 
dimeric structure consisting of interconnecting four-helix-bundles[222]. Human IL-10 acts via 
a joint complex of IL-10R1 and IL-10R2[223], which vIL-10 is predicted to share[222].  In vitro, 
vIL-10 is capable of inhibiting fibrotic and inflammatory gene expression in monocytes, 
dendritic cells, and fibroblasts[222, 224-226]. When administered by intradermal or subcutaneous 
injection to inflamed or wounded murine skin, respectively, vIL-10 inhibited pro-
inflammatory cytokine production and reduced the inflammatory infiltrate[227, 228]. 
Subcutaneous administration of vIL-10 to full-thickness mouse skin wounds, also enhanced 
wound closure, reducing the macrophage infiltration, myofibroblast differentiation, and scar 
tissue formation[229].  This data indicates that vIL-10 may provide an anti-inflammatory 
treatment for the prevention of scarring following cutaneous wounding.  
 
1.3.3 VEGF-E and vIL-10 as a Combination Therapy for Cutaneous Wounds 
VEGF-E and vIL-10 demonstrate good individual efficacies as wound healing and scar 
therapies, so it was hypothesised that when combined as a therapy, they would exert 
beneficial effects on wound inflammation, repair and fibrotic scarring (Fig. 1.7)[182, 229, 230].  
In a mouse full-thickness excisional wound model, when delivered by subcutaneous 
injection every second day until healed, the viral protein combination enhanced wound 
closure, increasing the rate of re-epithelialisation and vascularisation[229]. The treatment also 
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decreased the macrophage infiltrate and myofibroblast differentiation, decreasing the scar 
size[229]. In the same model, a combination of murine VEGF-A and IL-10, were equally as 
effective at enhancing wound closure and reducing fibrotic responses[229], but without the 
vascular maturation, and collagen bundle quality associated with the viral protein therapy[229]. 
These properties were distinct from the murine protein combination, meaning that the viral 
equivalents may represent a better treatment for cutaneous wound indications. This was also 
the first evidence of a growth factor and cytokine combination showing synergistic effects to 
improve both healing and scarring outcomes. 
 The efficacy of VEGF-E and vIL-10 was tested in chronic wounds, experimentally 
introduced to the limbs of horses[230]. Subcutaneous delivery of the proteins to the wounds 
four times over eight days post injury was insufficient to improve the healing rate, but did 
transiently dampen pro-inflammatory cytokine production and the innate immune cell 
influx[230]. It was suggested that sustained delivery of VEGF-E and vIL-10 would increase 
their efficacy in this model[230]. In order to provide sustained delivery of the proteins, a 
collagen-HA-based hydrogel (HyStem) containing VEGF-E and vIL-10 was applied 
topically to bandaged equine limb wounds[182], which are prone to the development of 
exuberant granulation tissue (EGT) formation. The fibroproliferative lesion formed in horses 
have been equated with keloid formation in humans[182, 231]. While wound re-epithelialisation 
and blood vessel functionality associated with VEGF-E activity was increased in wounds 
treated with the protein hydrogel relative to controls, no inflammatory cell infiltration and 
Figure 1.7. Stages of Healing Affected by Treatment with VEGF-E and vIL-10. The anti-inflammatory 
properties of vIL-10 modulates the inflammatory phase of healing, reducing the expression of pro-
inflammatory genes by monocytes, reducing pro-inflammatory cytokine production and inflammatory 
infiltrate. Made using Biorender. 
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gene expression suppression associated with vIL-10 was observed[182].  These findings are 
obviously conflicting with studies where VEGF-E and vIL-10 were delivered intradermally 
or subcutaneously[227, 228]. It was hypothesised that the delayed release of the vIL-10 from the 
hydrogel, or inflammatory breakdown products of HA, may have limited the anti-
inflammatory effects of the therapy[182]. Although the reparative effects of VEGF-E were 
observed, the negligible change in wound closure rate indicated that more sustained delivery 
was required[182]. It was proposed that short term delivery of vIL-10 paired with long-term 
delivery of VEGF-E would be the optimal time frame of delivery for maximal efficacy of 
these proteins, however, the most appropriate delivery system to do so is still unknown. The 
suitability of a cubosome-alginate hydrogel for controlled delivery of these proteins will be 
assessed in Chapters 4 and 5. 
 
 Thesis Aims and Objectives 
Current methods of treatment for cutaneous wound indications are non-specific and 
ineffective, with a clear clinical need for treatments that more specifically target the 
pathogenesis of wound complications. Topical delivery of growth factors and cytokines 
showed great preclinical promise for healing chronic wounds and preventing scar tissue 
formation but have largely failed in the clinic. An understanding of potential reasons why 
these have failed in the clinic is still required.  
Biomaterials should provide a repository for controlled delivery of growth factors and 
cytokines to cutaneous wounds, and could be easily tailored to not only specific proteins, but 
to specific stages and complications associated with healing. More research is required to 
ascertain whether biomaterial-based strategies offer more efficacy than topical protein.  
A combination of Orf Virus proteins VEGF-E and vIL-10 have shown promising 
wound reparative and scar preventative effects. But for clinical translation, rapid delivery of 
vIL-10 may be most appropriate, with sustained release of VEGF-E required. A composite 
biomaterial must therefore be developed to provide tailored delivery for each protein.  
 
1.4.1 Aims  
This thesis aims to identify the strategies, challenges, and limitations of growth factors and 
cytokines wound administration, then use this knowledge to develop a composite delivery 
system to provide safe and effective phasic delivery of vIL-10 and VEGF-E to skin wounds.  
 
Chapter 1: Introduction 
 26 
1.4.2 Objectives  
Objective 1: Conduct systematic literature reviews to:  
a) Identify reasons behind the clinical trial failures of growth factor and cytokine 
treatments for wound healing complications. 
b) Evaluate present strategies and challenges in the development of biomaterial-
based delivery of growth factors and cytokines to address wound healing 
complications. 
 
Objective 2: Develop and test a composite VEGF-E and vIL-10 delivery system to enable 
phasic regulation of wound inflammation, repair, and scarring.  
a) Prepare a delivery system consisting of a hydrogel encompassing vIL-10 and 
nanoparticles laden with VEGF-E.  
b) Test protein release and biocompatibility in vitro.  
c) Evaluate the safety and practicality of the delivery system in a murine full-
thickness excisional wound model. 
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As previously mentioned, despite a large number of clinical trials being conducted to assess 
the efficacy of growth factor or cytokine delivery to wounds, only three growth factor-
derived therapies are currently approved for use in patients – rhPDGF-bb (becaplermin), 
rhFGF-2 (Fiblast) and rhEGF (Heberprot-P, Regen-D, Easyef)[116]. These therapies are only 
approved in diabetic ulcers, with no growth factor or cytokine therapies improving healing 
outcomes in pressure ulcers, traumatic, infected and burn wounds, or improving scar quality 
following experimental or surgical incisions. In order to understand why growth factor or 
cytokine therapies have not been successful for these indications, it is important to identify 
the reasons as to why they failed.  
The objective of this chapter was to identify factors that may have contributed to the 
failure of growth factor and cytokine therapies to treat wound and scarring complications by 
conducting a systematic literature review. A comprehensive literature search was conducted 
in order to assess randomised clinical trials investigating growth factor and cytokine 
treatments for cutaneous wound and scarring indications. The papers were screened for study 
design and outcome parameters, and assessed for quality using the CONSORT checklist.  
 
 Methods 
2.2.1 Eligibility Criteria  
Randomised controlled trials (RCTs), focusing on growth factor and cytokine interventions 
to treat skin wound and scarring complications were included in the analysis. This 
encompassed surgical incisions, diabetic, venous and pressure ulcers, as well as burns, grafts 
and scarring abnormalities in human patients. The approach for the clinical trial selection is 
summarised in Table 3.1. based on the PICO framework[232], describing the population, 
interventions, comparators and outcomes of interest. In the analysis, systematic reviews were 
excluded, but these were used to identify relevant RCTs.  
 
Table 2.1. PICO Framework Strategy for the Literature Search.  
Population Interventions Comparator(s) Outcome 
Human patients with 
acute or chronic skin 
wounds or post-injury 
scarring 
Delivery of growth 
factors and cytokines 
Placebo and standard 
care 
 Time to complete 
healing, healing rate, re-
epithelialisation rate, 
healing quality, scar 
quality, infection rate 
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2.2.2 Search Strategy 
Comprehensive literature searches were conducted across PubMed, Embase and Cochrane 
Databases. The search terms were limited to human patients and randomised controlled trials. 
The search terms included key words relating to wound care and growth factor or cytokine 
interventions (see Table 2.2). The literature search comprised two rounds – the first 
encompassed a literature search using the set search terms, and the second involved a 
backward citation-searching strategy using Web of Science and Google Scholar citation 
searches.  
 
Table 2.2. Search Terms Used to Collect RCTs for Quality Analysis. 
Search Term 
1 Wound 7 Chronic 
2 Wound Healing 8 Human 
3 Skin 9 Clinical Trial 
4 Ulcer 10 Randomised / Randomized 
5 Burn  11 Growth factor 
6 Scar  12 Cytokine 
 
2.2.3 Screening 
Screening was conducted by two reviewers (Lyn Wise, Caitlin Berry-Kilgour) independently 
to confirm that the selected papers met the eligibility criteria.  
 
2.2.4 Data Items  
Subsequently, the reviewer pair independently read each article and abstracted relevant data. 
Differences in abstraction were resolved by discussion. Data items included study 
characteristics (e.g., type of study design, locality, interventions and comparators examined), 
patient characteristics (e.g., clinical population, wound types), treatment (PDGF-bb, EGF, 
FGF-1, FGF-2, VEGF-A, TGF-b3, IL-10), delivery method (topical cream, 
intradermal/subcutaneous injection, topical spray, topical hydrogel, sponge) and clinical 
outcomes (e.g., complete healing, healing and re-epithelialisation rate, scarring quality, 
infection incidence).  
 
2.2.5 Methodological Quality Appraisal  
The CONSORT (Consolidated Standards of Reporting Trials) statement was originally 
published in 1996, after the identification of a need for a standardised, high quality guideline 
for reporting of clinical trials[233]. The most recent revision, CONSORT 2010, provides a 
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detailed 25-part checklist and flow diagram describing each item on the list[233]. The 
methodological quality of the included articles were appraised using this checklist[233]. The 
process of point-allocating and scoring is described in Figure 2.1. Items with two parts were 
allocated 0.5 points per part, while items with single parts were allocated 1 point, making the 
total score 25. Data items were scored as completed (Yes), unclear or not completed (No). 
Scoring was conducted by a single reviewer (Caitlin Berry-Kilgour) to maintain subjectivity 
of scoring and avoid inconsistencies across scorers.  
 
 Results 
2.3.1 Literature Search  
The literature search identified 111 clinical trials, of which 38 were excluded as they 
presented reviews, systematic reviews, or trials without randomisation or controls (Fig. 2.2).  
Of the 73 potentially relevant full-text articles that were screened, 25 were excluded after the 
decision to eliminate trials investigating the use of insulin, NGF-2, platelet-rich plasma, 
lactoferrin and IFN a2a, as they did not meet the finalised eligibility criteria for ‘growth 
factor’ or ‘cytokine’.  
Figure 2.1. Flowchart of Point Allocation and Scoring for CONSORT Analysis of Clinical Trials. Items 
separated into (a) and (b) criteria were allocated 0.5 points for each part. Items with one criterion were 
allocated 1 point. Criteria were scored as fulfilled, unclear or not fulfilled, with the total attainable score 
being 25 points. Made using Biorender.   
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2.3.2 Study and Patient Characteristics  
The trials were conducted between 1989-2019, with 40% taking place from 2010 onwards 
(Table 2.3). The clinical trials were largely located in Asia (22 of 48 trials), North America 
(13) and Europe (12).  
 A large number of wound types were investigated, including venous, diabetic, 
hypertensive and chronic pressure ulcers, infected diabetic foot ulcers, diabetic foot infection, 
burns, skin grafts, traumatic wounds, incisions, scar revision surgeries and once case of 
bilateral varicose vein surgery. The most commonly examined wound type was the diabetic 
ulcer (14 of 48 trials), followed by chronic pressure ulcers (7) and burns (6). A total of 9 
different growth factors or cytokines were included, and of these, the most commonly 
investigated was PDGF-bb (9 of 48 trials), followed by EGF and FGF-2 (8 each). The most 
common method of delivery was via topical hydrogel (14 of 48 trials), followed by injection 
(including intradermal, subcutaneous and intralesional, 13 trials). The most common primary 
outcome was complete wound healing (21 of 48 trials). 
Figure 2.2. Workflow for Trial Selection. The flow of information through the different phases of the 
selection process is detailed. The flow describes the number of trials identified, included and excluded, 
and the reasons for their exclusion. Made using Biorender.  
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Table 2.3. Study and Patient Characteristics for 48 RCTs Selected for Analysis.  
Characteristic Number of Trials (n=48) 
Year  
     1980-2000 13 
     2001-2004 5 
     2005-2009 11 
     2010-2014 14 
     2015-2019 5 
Country of Conduct  
     Europe 12 
     North America 13 
     Australasia (Australia, New Zealand) 0 
     Asia (Malaysia, China, India, Taiwan, Japan) 22 
     South America 1 
Type of Wound  
     Mixed Ulcer 3 
     Venous Leg Ulcer 2 
     Diabetic Ulcer 14 
     Chronic Pressure Ulcer 7 
     Hypertensive Ulcer 1 
     Infected Diabetic Foot Ulcer 3 
     Diabetic Foot Infection 1 
     Burn 6 
     Skin Graft 1 
     Traumatic Wound  2 
     Incision 5 
     Scar Revision Surgery 2 
     Bilateral Varicose Vein Surgery 1 
Growth Factor or Cytokine  
     PDGF-bb 9 
     EGF 8 
     FGF-1 4 
     FGF-2 8 
     VEGF-A 1 
     G-CSF 4 
     GM-CSF 6 
     TGF-b 6 
     IL-10 2 
Method of Delivery  
     Topical Spray 11 
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2.3.3 Methodological quality appraisal 
Of the 48 articles examined, most received quality scores of between 14-16 out of a total of 
25 (33.3%, Fig. 2.3A). There were higher quality clinical trial reports, with 25% receiving 
scores between 16-18, and 10.4% above 18. There were also lower quality clinical trial 
reports, with 27% of articles scoring between 10-14, and  4.1% below 10. The highest scoring 
paper was Park et al[119], investigating topical EGF spray (Easyef®) for diabetic foot ulcers 
and receiving a score of 22.25/25. The two lowest-scoring papers were Akita et al[234], 
looking at FGF-2 in a collagen for lower leg wound healing,  and Yönem et al[235], 
investigating subcutaneous G-CSF for diabetic foot infection. Both of these papers received 
a score of 9.75/25 (table 2.4).  
     Topical Hydrogel  14 
     Cream 4 
     Injection 13 
     Topical 2 
     Other 3 
Primary Outcome  
     Wound Volume 4 
     Complete Healing 21 
     Wound Surface Area 4 
     Percentage Re-epithelialisation 1 
     Wagner’s Grade 1 
     Granulation Tissue Formation 1 
     Time to Resolution of Infection 2 
     Resolution of Infection 1 
     Resolution of Cellulitis 1 
     Vancouver Scar Scale 2 
     Colour Uniformity 1 
     Global Scar Comparison Scale (monthly) 1 
     Visual Assessment of Scar Using Lay Panel (12 months) 2 
     Visual Assessment of Scar Using Lay Panel (6 and 12 months) 1 
     Visual Assessment of Scar Using Lay Panel (6 weeks and 7 months) 1 
     Visual Assessment of Scar Using Lay Panel (1-6 months) 1 
     Visual Assessment of Scar Using Lay Panel (1-7 months) 1 
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Figure 2.3. The Literature Reporting Growth Factor or Cytokine Therapies for Wound and Scar 
Complications Only Moderately Adhere to CONSORT Reporting Criteria. Articles were scored out of 25 
according to the CONSORT criteria checklist. Data presented as (A) total CONSORT scores of 48 trials 
stratified into high, low and moderate scoring groups (B) number of trials fulfilling, partially fulfilling or 
not fulfilling key categories in the CONSORT checklist.  
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Table 2.4. Adherence of 48 RCT Reports to CONSORT Checklist Criteria.  
Checklist item Complete Unclear Not 
Complete 
Title and Abstract    
1a: identification as a randomised trial in the title  27 1 20 
1b: structured summary of trial design, methods, results and 
conclusions 
2 1 45 
Introduction    
2a: scientific background and explanation of rationale  0 2 46 
2b: specific objectives or hypotheses  0 2 46 
Methods    
3a: Description of trial design, including allocation ratio 8 15 25 
3b: Important changes to methods after trial commencement, 
with reasons 
38 0 10 
4a: eligibility criteria for participants 4 1 43 
4b: Settings and locations where data were collected  6 23 19 
5: the interventions for each group with sufficient details to 
allow replication 
0 3 45 
6a: completely defined pre-specified primary and secondary 
outcome measures, including how and when they were 
assessed 
4 22 22 
6b: any changes to trial outcomes after the trial commenced, 
with reasons 
41 1 6 
7a: how sample size was determined 9 9 30 
7b: when applicable, explanation of any interim analyses and 
stopping guidelines 
46 1 1 
8a: methods used to generate the random allocation sequence 25 0 23 
8b: type of randomisation; details of any restriction  46 0 2 
9: mechanism used to implement the random allocation 
sequence, describing any steps taken to conceal the sequence 
until interventions were assigned  
34 2 12 
10: who generated the random allocation sequence, who 
enrolled participants, and who assigned participants to 
interventions 
31 7 10 
11a: if done, who was blinded after assignment to 
interventions and how 
11 12 25 
11b: if relevant, description of the similarity of interventions 35 3 10 
12a: statistical methods used to compare groups for primary 
and secondary outcomes 
2 1 45 
12b: methods for additional analyses, such as subgroup 
analyses and adjusted analyses  
2 1 45 
Results    
13a: For each group, the numbers of participants who were 
randomly assigned, received intended treatment, and were 
analysed for the primary outcome 
0 5 42 
13b: For each group, losses and exclusions after 
randomisation, together with reasons 
6 8 34 
14a: dates defining the periods of recruitment and follow-up 23 1 24 
14b: Why the trial ended or was stopped 43 0 5 
15: A table showing baseline demographic and clinical 
characteristics for each group 
7 8 33 
16: For each group, number of participants (denominator) 
included in each analysis and whether the analysis was by 
original assigned groups 
5 5 38 
17a: For each primary and secondary outcome, results for 
each group, and the estimated effect size and its precision 
1 21 26 
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17b: for binary outcomes, presentation of both absolute and 
relative effect sizes is recommended 
43 0 5 
18: results of any other analyses performed, including 
subgroup analyses and adjusted analyses, distinguishing pre-
specified from exploratory 
0 11 37 
19: All important harms or unintended effects in each group 10 9 29 
Discussion    
20: Trial limitations, addressing sources of potential bias, 
imprecision, and, if relevant, multiplicity of analyses 
9 17 22 
21: Generalisability of the trial findings 3 1 44 
22: Interpretation consistent with results, balancing benefits 
and harms, and considering other relevant evidence 
0 3 45 
Other Information    
23: Registration and name of trial registry 36 1 11 
24: Where the full trial protocol can be accessed, if available 45 2 1 
25: sources of funding and other support, role of funders 16 0 32 
*not completed = not completed in any capacity 
  unclear = completed in part or unclearly 
 completed = completed in full, with all subsections achieved  
 
According to the CONSORT checklist[233], identification as a randomised trial in the 
title and a structured summary of trial design, methods, results and conclusions are 
important in clinical trial reports. Of the 48 clinical trials scored, 70% achieved an unclear 
rating (Fig. 2.3B). A large contributing factor to this was that 27 of the 48 papers failed to 
state the randomised nature of the trials in the title (table 2.4). However, 94% of reports 
provided a complete abstract containing a structured summary of the trial itself.  
Further CONSORT criteria are to explain the scientific background and rationale and  
provide specific objectives or hypotheses. These criteria were well adhered to, with 92% of 
the clinical trials achieving a completed rating, and the remaining 8% an unclear (Fig. 2.3B). 
These criterial were completed in 46 papers and unclear in two, although the two poorly 
scoring papers differed in their fulfillment of the subcriteria (table 2.4).   
The methods section of the CONSORT checklist has 17 subsections, covering trial 
design, details of randomisation, grouping and interventions, as well as blinding and 
statistical methods. All clinical trials received unclear ratings in this section; unsurprising 
considering its size and variation (Fig. 2.3B). The most commonly completed subsection 
related to statistical analyses, with 94% of papers completing this section (table 2.4). Only 
two papers failed this section; Kieran et al[138] and Yönem et al[235] (table 2.4). The other two 
commonly completed subsections, related to eligibility criteria (90% completed), and 
interventions (94% completed) (Fig. 2.3B). The most neglected subsections were those 
concerning changes to methods and outcomes after commencement of the trial  (table 2.4). 
Details surrounding randomisation were also poorly reported, with 96% of trials failing to 
Chapter 2: A Systematic Review to Identify Reasons for Clinical Failures 
of Growth Factor and Cytokine Treatments for Wound Healing Complications 
 
 37 
report the type of randomisation used, and 71% neglecting to describe the mechanism used 
to implement the random allocation sequence (table 2.4).  
The results section of the CONSORT checklist has 10 subsections, and calls for 
adequate reporting of participant recruitment and descriptive analyses, as well as appropriate 
reporting of primary and secondary outcomes and unintended effects[233]. Similar to the 
methods section, the size and variation of this section produced unclear ratings for all studies 
(Fig. 2.3B). The most commonly completed subsection related to stating participant numbers 
per group and their associated analyses, with 88% of papers completing this (table 2.4). 
Exclusions or losses after randomisation were stated in 17% of papers, while 12.5% did not. 
An unclear rating was allocated in papers such as Bush et al[133], who failed to include a 
statement on participant loss or exclusion, but stated in their safety analysis that ‘no subjects 
withdrew due to adverse events”. The most commonly neglected subsection related to 
explanations of why trials ended or were stopped. This is particularly concerning in relation 
to studies such as Hanft et al[236] and Ferguson et al[131]; where the respective failures of 
Telbermin and Avotermin are widely recognized and yet, the clinical trials surrounding these 
failures do not clearly state exactly why the trials were ceased (table 2.4).  
The discussion section of the CONSORT checklist calls for authors to critically 
analyse the limitations, generalisability and clinical relevance of their results[233]. This section 
was relatively well executed, with 92% of trials adequately discussing the generalisability of 
their findings and 94% interpreting their results and discussing clinical benefits and harms 
(table 2.4). It should be noted, however, that only 46% of the papers completed the subsection 
relating to the analysis and discussion of the trial limitations, and potential sources of bias or 
imprecision (table 2.4).  
The section regarding other information was the most poorly executed, with 29% of 
papers failing to complete this section at all, and 69% receiving an unclear score for this 
section (Fig. 2.3B). While 67% of papers were able to comment on sources of funding or 
other support that they may have received, 94% failed to provide information as to where the 
full protocol could be accessed, and 75% failed to provide the clinical trial registration 
number and the name of the trial registry (table 2.4). This makes accessing supplementary 
information on details of the trial difficult, particularly with low-scoring trials that neglected 
to properly report in other sections.  
 The analyses above allow for the assessment of report quality over time. While Park 
et al[119] was the most recently published paper featured in the analysis, the other top-scoring 
papers varied across time, including Gough et al[237], which was published in 1997. The 
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lowest scoring papers had a similar spread, comprising papers published from 1999 to 
2008[121, 234, 235, 238]. While it would be easy to assume that with growing knowledge and 
technology the quality of clinical trial reports may be improving, the variability observed 
within top and bottom scoring categories suggests that no such trend is occurring (table 2.4).   
 
2.3.4 Clinical Outcomes for Growth Factor and Cytokine Therapies 
2.3.4.1 PDGF-bb 
The only FDA-approved growth factor treatment for neuropathic ulcers is recombinant 
human (rh)PDGF-bb delivered in a carboxymethylcellulose (CMC) hydrogel (Regranex)[116]. 
A biosimilar (Plermin) was launched in India in 2013. Once or twice daily application of 
rhPDGF-ββ hydrogel led to more complete healing of nonhealing diabetic foot ulcers (Table 
2.5)[239-241] with a trend toward faster healing in pressure ulcers[242, 243] but not hypertensive 
ulcers[244].  
 
Table 2.5. RCTs of Cutaneous Wound and Scar Treatments Utilising PDGF-bb with Their Associated 
CONSORT Scores.  
Treatment Clinical 
indication 








Topical spray,  
daily for 28 days 








2X daily for 16 
weeks* 
Faster and more complete healing 
than hydrogel control[243] 
15.25 
 Diabetic foot 
ulcers (1-
100cm2) 
Topical hydrogel,  
daily for 20 
weeks* 
Complete healing increased 
relative to hydrogel control[240] 
18 





daily for 20 weeks 
Complete healing increased 
relative to hydrogel control[239] 
13.75 






daily for 20 
weeks* 
Faster and more complete healing 
than hydrogel control[241] 
17 




daily for 8 weeks 
No change in healing relative to 






Faster re-epithelialisation relative 





Topical hydrogel No change in healing relative to 
control[245] 
11.5 
 Diabetic foot 
ulcers  
Topical hydrogel, 
daily for 12 weeks 
Faster healing relative to 
control[246] 
11.75 
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Faster re-epithelialisation of traumatic wounds was also observed following hydrogel 
treatment[117]. In these trials, there was extensive variability in wound closure rates for 
placebo and standard care controls, and in response to rhPDGF-ββ hydrogel, meaning that 
large trials were needed to demonstrate a treatment effect[116]. 
Some of the papers in this section attained high CONSORT standards scores, including 
D’Hemecourt et al[239], Senet et al[244] and Langer et al[117]. However, Jaiswal et al[245] and 
Agrawal et al[246] both received low scores. The variability in wound type, trial design and 
outcome measures also makes it difficult to make accurate comparisons between these trials. 
Ulcer type varied between pressure ulcers[242, 243], diabetic foot ulcers[239-241, 245, 246], 
hypertensive ulcers[244] and traumatic wounds[117]. Outcome measures included complete 
healing at week 12[246], week 10[245], week 8[244], week 16[243] and week 20[240, 241]. One paper 
looked at the time taken for appearance of granulation tissue[117] and ulcer volume after 28 
days[242]. Doses varied across all trials, with some using PLERMIN 0.01% gel[117, 243-246], 
100ug/g or 30ug/g gel[241], 300 or 100 ug/mL gel[242], 10 ug/g[245] and 2.2 ug/cm2 wound 
surface area[240]. It should also be noted that an increased risk of death from cancer was 
observed[148], which was hypothesised to result from systemic leakage of PDGF-ββ from the 
wound, stimulating the growth of preexisting cancers expressing its receptor. As a result, 
Regranex was issued a black-box warning by the FDA in 2008, but this was removed in 2018 




Three products containing rhEGF are available for treatment of diabetic foot ulcers. 
Heberprot-P is registered in 15 countries and is administered by intralesional injection to 
recalcitrant ulcers[118]. Easyef is a topical spray approved for diabetic foot ulcers in four Asian 
countries[119]. Regen-D is a topical hydrogel commercialized in India[120]. An early clinical 
study with rhEGF administered topically once or twice daily to diabetic foot ulcers showed 
more complete healing than the cream control (table 2.6)[248].  
Complete healing of superficial ulcers in diabetic patients was also accelerated by 
rhEGF when administered by twice daily topical spray[119] or intralesional injection three 
times per week[118], with variable findings from the topical hydrogel[120, 249]. Short-term topical 
administration of rhEGF in thyroidectomy incisions led to improvements in scar parameters 
relating to pliability and thickness[250]. 
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Delivery  Clinical outcome CONSORT 
standards  
Total score /25[233] 
EGF Diabetic foot 
ulcers (I-II) 
Actovegin cream,  
daily for 12 
weeks*  
Complete healing increased 
relative to cream control[248]  
15.75 




daily for 15 
weeks* 
Complete healing increased 
relative to hydrogel control[120]  
15.25 





3X weekly for 8 
weeks 
Complete healing increased 
relative to vehicle control[118]  
15 




2X daily for 12 
weeks* 
Complete healing increased 
relative to saline control[119]  
22.25 




daily for 30 days   
Trend towards faster healing 





daily for 4 days 
Trend towards improved scar 
pliability and thickness relative 




graft donor site  
Topical cream Faster re-epithelialisation 
relative to control[238] 
10.75 
 Diabetic foot 
ulcers 
Topical cream, 
daily for 28 days 




Park et al[119] received the highest CONSORT score across all 48 papers, with a total of 
22.5/25. This study was investigating Easyef® spray, an approved growth factor treatment. 
The lowest scoring EGF paper was Brown et al[238], investigating a topical EGF cream for 
skin graft donor sites. Most papers looked at complete healing in diabetic foot ulcers, with 
an significant result in 4 papers [118-120, 248]. These papers all used dramatically different 
dosing regimens, ranging from 1ug/g[251] up to 150mg/g[120], with efficacy observed in low 
and high doses[118-120, 248]. One study looked at the effect of topical EGF on scar pliability and 
thickness, following thyroidectomy incision, seeing a trend towards an enhanced 
response[250].  
 
2.3.4.3 FGF-1 and FGF-2 
A topical spray containing rhFGF-2 (Fiblast) is marketed for skin ulcers in Japan, while 
rhFGF-1 has been evaluated for skin ulcers and burns. Following daily application of rhFGF-
2 using topical sprays (Table 2.7), severe pressure ulcers showed trends toward faster 
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healing[252, 253], while diabetic patients with neuropathic ulcers of mixed severity showed no 
change in healing[254]. Treatment of partial-thickness burns with topical rhFGF-2 spray, also 
elicited improvements in healing rate and scar flexibility[255]. Daily topical administration of 
rhFGF-1 accelerated healing in partial-thickness burns and skin graft donor sites (table 
2.7)[256] and showed greater healing improvements than rhFGF-2 in chronic wounds of 
diabetic patients[257]. FGF-2 delivered via a collagen sponge to traumatic wounds enhanced 
complete healing when compared to standard care[258]. 
 













Topical spray,  
daily for 3 weeks 








daily for 6 weeks 
Faster healing than FGF-2 
control[257] 
14.5 
 Mixed lower 
leg ulcers 













Topical spray,  
tiered dosing and 
length 
Trend towards faster healing than 





Topical spray,  
daily for 35 days 
Faster healing than vehicle 
control[252]  
12.5 
 Diabetic foot 
ulcers (I-III) 
– neuropathic  
Topical spray, 
daily for 6 weeks, 
2X daily for 12 
weeks 
No change in healing relative to 




Collagen sponge△ Complete healing increased 
relative to standard care[258]  
17.5 





Faster healing than standard care, 
with improved scar extension and 
elasticity[255] 
13 
 Chronic skin 
ulcers 
Collagen sponge Improved re-epithelialisation 
compared to control[259] 
17.5 
 Adult burns Topical spray 
(Fiblast®) 






once daily for 35 
days 
Enhanced wound closure 
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Akita et al[234] received the lowest score for all 48 papers, with a total score of 9.75/25. 
There was a wide variety of wound types investigated, including burns, diabetic chronic 
wounds, pressure ulcers, traumatic wounds, chronic and venous ulcers (Table 2.7). Other 
studies received between 10-18 out of 25, While most studies reported accelerated healing, 
the diversity in wound indications that were treated makes it difficult to make direct 
comparisons between studies.  
FGF-1 studies used varying doses and two studies were ambiguous with stating their 
treatment regimens[121, 234]. This variability was similar with FGF-2 studies, with dosing 
length either not stated, from 35 days[252, 261] up to 12 weeks[254]. Primary outcome measures 
and delivery methods also varied.  Two studies looked at the effect of topical Fiblast® spray 
on scarring following burns, with improved scar quality reported by both studies, although 




A topical hydrogel administering rhVEGF-A (Telbermin) was discontinued following a 
Phase II trial. Diabetic foot ulcers only showed a trend toward faster healing following 
treatment every second day with this hydrogel[236] (Table 2.8). This indicates the lack of 
progression for Telbermin and may relate to the treatment's failure to achieve complete 
wound closure, its primary outcome. This paper received a mid-range score of 16.5/25 on the 
CONSORT checklist. It should be noted that the authors of Hanft et al[236] failed to adequately 
comment on the limitations of the study, which makes it difficult to initiate further 
improvements in subsequent study.  
 
Table 2.8. RCTs of Cutaneous Wound Treatment Utilising VEGF-A with Their Associated CONSORT Scores. 
Treatment Clinical 
indication 









every 2 days for 6 
weeks 




2.3.4.5 GM-CSF and G-CSF 
Leucomax (rhGM-CSF) is an FDA-approved immune stimulator administered following 
chemotherapy and bone marrow transplantation, while Neupogen and Granocyte (rhG-CSF) 
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are indicated to reduce neutropenia. Trials in patients with infected diabetic foot ulcers 
yielded inconsistent results following daily treatment with rhG-CSF (Table 2.9)[237, 262, 263].  
 
Table 2.9. RCTs of Cutaneous Wound and Scar Treatments Utilising GM-CSF and G-CSF with Their 
Associated CONSORT Scores. 
Treatment Clinical 
indication 









daily for 7 days 








daily for 21 days 
No change in infection or rate of 








daily for 10 days 
No change in infection, but trend 
towards faster healing than saline 
control[263] 
14.75 
 Diabetic foot 
infection 
SC injection, daily Improved neutrophil numbers, no 

















weekly for 4 
weeks* 
Complete healing increased 






daily for 35 days 
No change in healing relative to 





Alginate dressing△ Faster healing and lower pain 
score than GM-CSF paste control 
and standard care[264]  
13.5 





Complete healing increased 
relative to hydrogel control[265] 
18 





Faster and more complete healing 
than hydrogel control[266] 
13.75 





Faster and more complete healing 
than vehicle control[267] 
14.5 
 
Treatment of chronic and pressure ulcers with rhGM-CSF also yielded variable results[252, 
263], but complete healing was observed with venous ulcers following weekly 
administration[130]. GM-CSF delivery with an alginate dressing was trialled in chronic 
ulcers[264] and a GM-CSF-gelatin hydrogel accelerated closure of partial thickness burns 
when applied daily[264]. These inconsistent results may, in part, be due to the production of 
neutralizing antibodies against the rhGM-CSF, which have been observed following repeated 
subcutaneous administrations to immune-competent individuals[142]. 
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The lowest-scoring paper for this section was Yönem et al[235], also one of the lowest 
scoring papers across all 48 of the trials investigated. Other papers looking at GM-CSF and 
G-CSF [130, 237] received higher scores of 19.25 and 18.75. All studies investigating G-CSF 
did so in regard to infected diabetic foot ulcers but did so with varied timeframes and primary 
outcomes[235, 237, 262, 263]. GM-CSF was investigated in a variety of indications including 
chronic ulcers, venous ulcers, pressure ulcers and burns, with different delivery methods, and 
timeframes[129, 130, 252, 264-267]. Quality of reporting varying from 9.25-19.25.  
 
2.3.4.6 TGF-β3 
Other cytokines have been explored as antiscarring therapies. Avotermin, a rhTGF-β3 
preparation, showed promise in Phase II trials, but failed to improve scar appearance 
following scar-revision surgery in Phase III trials[268]. rhTGF-β3 was first trialled in pressure 
ulcers, with accelerated healing observed following daily administration with a topical 
silicone-hyaluronate hydrogel[237]. Intradermal administration of rhTGF-β3, before and after 
skin incisions, varicose vein, or scar revision surgery improved scar aesthetics for 5–12 
months[133, 134, 136] (Table 2.10).  
 
Table 2.10. RCTs of Cutaneous Wound and Scar Treatments Utilising TGF-β3 with Their Associated 
CONSORT Scores.  
Treatment Clinical 
indication 







Topical hydrogel,  
daily for 16 
weeks* 
Faster healing than hydrogel 
control[237] 
12.5 
 Incisions ID injection 
(Avotermin),  
prior to + after 
incision 
Scar score improved relative to 
vehicle control[131] 
17.75 
 Incisions ID injection 
(Avotermin),  
prior to + after 
incision 









Scar score improved relative to 
vehicle control[134] 
17 




prior to + after 
incision 
Scar score transiently improved 






2X daily for 12 
weeks 
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Avotermin (rhTGF-B3) was a leading candidate in anti-scarring treatment[135], but 
failed to progress further than Phase III clinical trials[131]. A clear statement on why the trials 
ended is not available[131]. All studies used drastically different dosing regimens and primary 
outcomes, although this is not discussed as a limitation in any of the papers published[131-134, 
136]. The range of total consort scores retrieved across the papers lay within the low-mid 
range, with the lowest being 12.5/25[132]  and the highest score being 18.5/25[136].  
 
2.3.4.7 IL-10 
Another cytokine explored for antiscarring purposes is IL-10 (Ilodecakin), which following 
a Phase II trial did not progress further after Avotermin failed. Intradermal administration of 
rhIL-10, before or after skin incisions, showed a reduced scar width and transient 
improvements in scar aesthetics at selected doses[137, 138] (Table 2.11). Both trials scored in 
the low-mid range in the CONSORT analysis (Table 3.10). It should be noted that treatment 
regimens differed for these two studies, with the 2013 study using two dosing groups: group 
1 (1, 5, 50 and 1000 ng/100mL/linear centimetre, and group 2 (125, 500 and 2000 
ng/100mL/linear centimetre)[137]. In both groups, one injection was given prior to incision, 
and a second injection 24 hours after[137]. In the 2014 study, doses of 5, 25, 100 and 250 
ng/100mL/linear centimetre were delivered in two injections, one immediately after incision, 
and one 24 hours after incision[138]. The differences in dosing regimen makes it difficult to 
accurately compare the two.  
 








IL-10 Incisions ID injection 
(Ilodecakin),  
prior to + after 
incision 
Scar score and redness improved 
relative to vehicle control[137] 
15.25 
 Incisions ID injection 
(Ilodecakin),  
2X after incision 
Trend towards reduced scar width 
and transient improvement in scar 
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The comprehensive literature search identified 48 clinical trial papers meeting the inclusion 
and exclusion criteria, from the initial pool of 111 papers. These papers investigated clinical 
delivery of growth factors and cytokines for a variety of wound healing indications, including 
chronic wounds and scarring disorders. When scored according to the CONSORT 
checklist[233], total CONSORT scores were variable, ranging from 9.75-22.5/25. Issues were 
identified with the reporting of methodology, results and discussion around limitations of the 
studies. There did not appear to be a link with success of growth factors (i.e., clinical 
approval) and average CONSORT score across the groups, with PDGF-bb, EGF and FGF 
trials having varied CONSORT scores across the low and high ranges.  
 It became evident that there was a large amount of variability in treatment regimens, 
delivery methods, wound types and outcome measures, not only between different growth 
factor or cytokine treatments, but within treatments also. This makes it difficult to make 
comparisons of efficacy between two potential treatments for the same indication, and to 
make decisions regarding what may be the best candidate moving forward. Methodologies, 
study design and outcomes need to be streamlined to produce a standard pathway for clinical 
research that would allow for these comparisons to be made. Acknowledging bias towards 
reporting successful trials is also a factor that may contribute to failures[269], as the lack of 
understanding of trials with negative results makes preventing further failures difficult[269].  
 The clinical failings of growth factor and cytokine treatments could also be explained 
by considering other confounding factors identified in the failures of selected treatments. For 
example, trials with rhGM-CSF for another disorder documented immunogenicity issues that 
prevented further development[142]. Additional factors that should be considered include 
interpatient variability, which can be problematic particularly when wounds of mixed 
aetiologies are combined into a single study[129, 234, 264]. Strict FDA endpoints that require 
complete healing, rather than partial endpoints such as reduced wound area, resolution of 
infection or granulation, also makes it difficult for therapies to be approved[139, 140], as shown 
in rhVEGF-A trials[236].  
The research community may not be able to control the decisions of regulatory 
agencies or the cost of drug production. But researchers should be able to control study design 
by using consistent patient groups, treatment regimens, and outcome measures, to allow for 
easier cross-study comparisons, thereby increasing the power of meta-analyses. Another 
aspect that can be controlled is for researchers to publish good quality, critically analysed 
and well-reported data. For example, better adherence to the criteria stated in the CONSORT 
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checklist will not only encourage more intentional study design and execution, but increase 
the power of meta-analyses by allowing for more accurate comparisons between studies, as 
this has been a limiting factor in previous meta-analyses[270]. As a consequence of improved 
and more consistent study design and reporting, more informed decisions can be made to 
improve growth factors or cytokines interventions and the clinical protocols used to evaluate 
them. This will likely contribute to greater success in the development of growth factors or 
cytokines for wound healing indications.
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As previously discussed, biomaterials are becoming an increasingly popular mechanism for 
protected and sustained release of protein-based therapeutics. Biomaterials can be classified 
into synthetic and natural polymers[149]. While synthetic materials are less expensive to 
produce and more consistent between batches, naturally-derived biomaterials are considered 
more appropriate for wound healing indications as they are perceived as more 
biocompatible[149]. Natural biomaterials have been proposed to function as a three-
dimensional biomimetic ECM, simulating the architecture and regulatory role of their native 
counterpart. Natural materials are often hybridised with mechanically stronger synthetic 
materials with the intent of increasing their structural support. The biomaterials may provide 
protection against degradation and systemic spread relative to topical protein 
administration[160]. Combining different biomaterial structures has also proposed as a means 
of loading growth factors and cytokines to be released in a controlled manner[160]. Phasic 
delivery of multiple growth factors to target different phases of healing may offer further 
therapeutic advantages. Thus biomaterials that provide structural support, promoting skin 
reconstruction, while simultaneously supplying growth factors or cytokines, is this an 
attractive strategy to promote wound repair.  
The aim of this chapter was to assess how biomaterial-based systems are used to 
deliver growth factors and cytokines, and to ascertain whether they are in fact improving on 
the shortcomings of topical delivery, by allowing for tailored wound delivery and protection 




3.2.1 Search Strategy  
Papers for this section were found using a back-citation method in Web of Science using the 
48 RCTs found in section 2.2. Key words of interest included ‘delivery’, ‘biomaterial’, and 
the natural biomaterials of interest including ‘chitosan’, ‘collagen’, ‘alginate’, ‘hyaluronic 
acid’, ‘gelatin’ and ‘fibrin’; with 37 papers selected based on this criteria, encompassing 
natural or hybrid biomaterials. 
 
3.2.2 Screening 
Screening was conducted by two reviewers (Lyn Wise, Caitlin Berry-Kilgour) independently 
to confirm that the selected papers met the eligibility criteria.  
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3.2.3 Data Items 
Subsequently, the reviewer pair independently read each article and abstracted relevant data. 
Differences in abstraction were resolved by discussion. Data items included study 
characteristics (e.g., interventions and comparators examined), treatment (PDGF-bb, EGF, 
FGF-1, FGF-2, FGF-7, VEGF-A, GM-CSF, G-CSF, TGF-b, VEGF-E, vIL-10), biomaterial 
type (e.g., chitosan, collagen, alginate, HA, gelatin, fibrin), and biomaterial structure (film, 
gel, membrane, scaffold, sponge, bead, microsphere, sheet, composite).  
 
 Results 
3.3.1 Study Characteristics 
Study characteristics are outlined below in Table 3.1. 43% of studies were published after 
2015, and 48% of the studies specifically related their treatments to chronic wounds. The 
most prominent growth factors that were delivered were EGF (27%), VEGF-A (30%) and 
FGF-2 (40%). The most commonly used biomaterial was collagen (27%) and excluding 
composite systems, the most common delivery method was hydrogel (16%). The most 
common composite system was nanoparticles of various types, incorporated within a 
hydrogel for controlled release of one or more factors. Rats were the most commonly used 
species, and the most common model was a full-thickness excisional wound model.  
 
Table 3.1. Study Characteristics for 37 Laboratory or Pre-Clinical Trials Selected for Analysis.  
Characteristic Number of Trials (n=37) 
Year  
     1980-2000 1 
     2001-2004 4 
     2005-2009 12 
     2010-2014 4 
     2015-2019 16 
Proposed Clinical Target  
     Chronic Wound 18 
     Burn 4 
     Scar Prevention 2 
     Not Stated 12 
     Other 1 
Growth Factor or Cytokine*  
     PDGF-bb 4 
     EGF 10 
     FGF-1 0 
     FGF-2 15 
     VEGF-A 11 
     G-CSF 1 
     GM-CSF 1 
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*n > 37 due to combined treatments 
     TGF-b 0 
     FGF-7 1 
     VEGF-E 1 
     vIL-10 1 
Biomaterial Type   
     Chitosan 9 
     Collagen  10 
     Alginate 4 
     Hyaluronic Acid 2 
     Gelatin 4 
     Fibrin 7 
     Lipid 1 
Biomaterial Structure   
     Film 2 
     Gel 6 
     Membrane 1 
     Scaffold 2 
     Sponge 2 
     Bead 1 
     Microsphere 2 
     Sheet 1 
     Composite 20 
In Vitro Testing Method  
     PBS 19 
     PBS + Enzyme 3 
     PBS + Culture Medium 1 
     Serum 3 
     Culture Medium + Serum + Enzyme 1 
     Wound Fluid 1 
     Not Tested 9 
In Vivo Testing Method   
     Mouse Full-Thickness Excisional Wound  4 
     Mouse Splinted Full-Thickness Excisional Wound 1 
     Mouse Implant  2 
     Mouse Partial-Thickness Burn 1 
     Mouse db/db Full-Thickness Excisional Wound  5 
     Rat Full-Thickness Excisional Wound 7 
     Rat Splinted Full-Thickness Excisional Wound 1 
     Rat Infected Splinted Full-Thickness Excisional Wound 1 
     Rat Implant 1 
     Rat Partial-Thickness Burn 2 
     Rat Full-Thickness Burn 1 
     Rat STZ-Diabetic Full-Thickness Excisional Wound 2 
     Rat Ischaemic Hind Limb 1 
     Rabbit Full-Thickness Excisional Wound 1 
     Rabbit Ischaemic Full-Thickness Excisional Wound 1 
     Equine Bandaged Limb 1 
     Porcine Full-Thickness Excisional Wound 1 
     Not Tested 4 
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3.3.2 Natural Biomaterials for Tailored Delivery of Growth Factors and Cytokines to 
Wounds 
3.3.2.1 Chitosan 
Chitosan is a linear aminopolysaccharide derived from the exoskeletons of crustaceans and 
cell walls of fungi; it has been extensively used in wound dressings and in controlled delivery 
of growth factors, cytokines and drugs[174]. Chitosan has been fabricated into films to deliver 
EGF[271] and FGF-2[272], and hydrogels containing EGF[273], FGF-2[274, 275] and heparin[275] 
(Table 3.2). These systems provided release of EGF within 24 h[273]. Chitosan-based delivery 
of EGF into porcine full-thickness excisional wounds[271] and rat partial-thickness burns[273] 
enhanced re-epithelialisation and healing compared to chitosan alone. Delivery of FGF-2 into 
diabetic[272, 274] and ischaemic[275] rodent models of impaired healing led to faster 
vascularisation and wound repair compared to their biomaterial controls.   
 




delivered Experimental parameters tested and outcomes 
Film EGF 
In vitro release in phosphate buffer (32oC) – within 24 h 
Porcine full-thickness excisional wound model – daily treatment 
led to faster healing and granulation tissue formation relative to 
film and untreated controls[271] 
Film FGF-2 
Storage conditions, – stable at 5oC and 25oC for 3 weeks 
Diabetic db/db mouse full-thickness excisional wound model – 
treatment 3 times per week led to faster healing relative to gel and 
untreated controls[272] 
Gel EGF 
In vitro release in phosphate buffer (pH5.8, 32oC) – within 3 h 
Rat partial-thickness thermal burn – daily treatment increased 
epithelialisation relative to gel and EGF controls[273]  
Gel FGF-2  
Diabetic db/db mouse full-thickness excisional wound model – 
single treatment led to faster healing and increased granulation 
tissue formation and vascularisation relative to gel and untreated 
controls[274] 
Gel FGF-2 + heparin Rat ischaemic hind limb model – single treatment led to increased vascularisation relative to gel and gel + IO4-heparin controls[275] 
 
3.3.2.2 Collagen  
Collagen is the most abundant ECM protein, and due to its extensive roles in cell signalling 
and ECM structure, it is commonly used in wound healing applications[149]. Collagen has 
been formulated into hydrogels for delivery of FGF-2[276], membranes to delivery PDGF-
bb[277], scaffolds to deliver VEGF-A[278] and EGF[279], and sponges to deliver EGF[280] and 
FGF-2[281] (Table 3.3). EGF delivered in a collagen sponge in the presence of collagenase 
showed sustained release over 30 days[280]. Collagen supported migration of fibroblasts[279, 
280], keratinocytes[279] and endothelial cells[281], showing good biocompatibility and safety. 
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Collagen has shown tailorable delivery of EGF to wounds, with release as early as 8 h[279] 
with cross-linking extending release to 30 days[280]. FGF-2 delivered in a sponge provided an 
initial burst release followed by sustained cumulative release over 18 days[281].  Gel release 
of FGF-2 enhanced healing in murine full-thickness excisional wounds, compared with 
controls[276]. Collagen-based delivery also mediated vascular enhancement via PDGF-bb 
conjugated to a collagen-binding domain (CBD)[277] and VEGF-A[278] in rabbit and rat models 
of impaired healing, relative to collagen-only controls. Unconjugated PDGF-bb in a collagen 
scaffold was less efficacious than CBD-conjugated PDGF-bb[277]. Non-immobilised VEGF-
A control was less efficacious than immobilised VEGF-A within the collagen scaffold[278].   
 




delivered Experimental parameters tested and outcomes 
Gel FGF-2 
In vitro retention of FGF-2, and attachment of adipocytes  
Mouse full-thickness excisional wound model – single treatment led 
to faster healing relative to gel and untreated controls[276] 
Membrane CBD-PDGF-bb  
Rabbit ischaemic full-thickness excisional wound model – single 
treatment led to faster re-epithelialisation, granulation tissue 
formation and vascularisation relative to membrane and membrane 
+ unconjugated PDGF-ßß controls[277] 
Scaffold VEGF-A 
Rat SC implant model - reduced scaffold degradation and increased 
vascularisation relative to scaffold and unconjugated VEGF-A 
controls[278] 
Scaffold EGF 
In vitro release in phosphate buffer – within 8 h 
In vitro culture supported fibroblast and keratinocyte proliferation, 
demonstrating good biocompatibility 
Rat full-thickness excisional wound model – single treatment led to 
enhanced cellularity within healing wound relative to scaffold and 
untreated controls[279] 
Sponge EGF 
In vitro release in collagenase (pH 7.4, 37oC) – cumulative over 30 
days with increased cross-linking, induces fibroblast 
proliferation[280]  
TCA-sponge FGF-2 In vitro release in culture medium – burst within 4 days, cumulative over 18 days, induces endothelial cell proliferation[281]  
 
3.3.2.3 Alginate  
Alginate is a seaweed-derived polysaccharide that when crosslinked with cationic 
compounds, can form highly modifiable hydrogels[190, 191]. Alginate has been formulated into 
beads[282] and hydrogels[283] for controlled release of VEGF-A (Table 3.4). Alginate has 
shown modifiable release kinetics, with alginate beads releasing VEGF-A in a sustained 
manner in serum over 14 days[282], and an alginate hydrogel releasing VEGF-A within 1 h[283]. 
In a subcutaneous implant model, alginate hydrogel-mediated release of VEGF-A was able 
to increase granulation formation and vascularisation relative to controls[283]. Enhanced 
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vascularisation was also seen in a mouse hind limb ischaemia model when VEGF-A was 
released from the same alginate hydrogel[283]. 
 




delivered Experimental parameters tested and outcomes 
Bead VEGF-A In vitro release in phosphate buffer and serum (25
oC) – cumulative 
over 14 days[282] 
Gel VEGF-A 
In vitro release +/- mechanical stimulation – gradual or pulsatile over 
1 hr 
Mouse SC implant model – daily mechanical stimulation increased 
granulation tissue formation and vascularisation relative to placebo 
and stimulation controls 
Mouse hind limb ischaemia model – daily stimulation increased 
vascularisation relative to placebo and stimulation controls[283] 
 
3.3.2.4 Hyaluronic Acid  
HA a polysaccharide comprising the main nonprotein component of the ECM, contributing 
to elastoviscosity, tissue hydration, and a number of cellular functions including 
proliferation, migration and inflammation[168]. An HA hydrogel has been used to deliver 
FGF-2 in a sustained manner in the presence of serum and hyaluronidase over 14 days[284] 
(Table 3.5). The effect of this gel in vivo was not tested.   
 









In vitro release in culture medium + serum + hyaluronidase – 
cumulative over 14 days, promotes fibroblast proliferation[284]  
 
3.3.2.5 Gelatin 
Gelatin-based hydrogels derived from collagen hydrolysis have also been extensively used 
as dressings and as carriers for growth factors and cytokines[167]. Gelatin has been fabricated 
into microspheres to deliver FGF-2[285] and VEGF-A[286], and gelatin sheets have been used 
to deliver FGF-2[287] (Table 3.6). Release of VEGF-A from gelatin was shown to be 
cumulative over 14 days[286], and addition of collagenase accelerated the release to 24 h. In a 
diabetic db/db excisional wound model, controlled delivery of FGF-2 via microspheres[285, 
286] and sheets[287] increased re-epithelialisation and  vascularisation compared to their 
biomaterial controls. This sustained release was observed in the presence of plasma.  
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delivered Experimental parameters tested and outcomes 
Microsphere FGF-2 
Diabetic db/db mouse full-thickness excisional wound model – single 
injection led to dose-dependent increase in re-epithelialisation, 
vascularisation and myofibroblast apoptosis relative to microsphere 
control[285] 
Microsphere VEGF-A In vitro release in phosphate buffer (37
oC) – cumulative over 14 days, 
reduced to 24 h by collagenase digestion[286] 
Sheet FGF2 
Diabetic db/db mouse full-thickness excisional wound model – 
cumulative over 7 days in plasma, single treatment led to reduced 
wound area and increased re-epithelialisation, vascularisation and 
granulation tissue formation relative to sheet and gel controls[287] 
 
3.3.2.6 Fibrin 
Fibrin, a by-product of fibrinogen polymerisation, is a biomaterial that can be used to produce 
scaffolds and nanoparticles to deliver cells, growth factors and cytokines to the wound site 
to promote repair[172]. Delivery of VEGF-A and factor XIIIa substrate from a fibrin hydrogel 
showed cumulative release of VEGF-A over 7 days, and a dose-dependent increase in 
vascularisation in both a mouse IM implant model and mouse ischaemic hind limb model[288] 
(Table 3.7).   
 




delivered Experimental parameters tested and outcomes 
Gel VEGF-A + Factor XIIIa substrate 
In vitro release in phosphate buffer – cumulative over 7 days  
Mouse IM implant model – single treatment led to dose-dependent 
increase in mature vasculature  
Mouse ischaemic hind limb and skin flap models – single treatment 
led to dose-dependent increase in vascularisation relative to gel 
control[288] 
 
3.3.3 Incorporation of Nanoparticle Systems with Biomaterials for Controlled Release of 
Growth Factors and Cytokines 
While natural biomaterials alone have shown the ability to deliver growth factors and 
cytokines, they have also been combined in hybrid systems. These consisting of two or more 
biomaterials, which may be natural or synthetic in origin. A summary of natural hybrids can 
be found in table 3.8, and natural and synthetic hybrids in table 3.9. 
 
3.3.3.1 Natural Hybrids 
Chitosan has been combined with carboxymethylcellulose (CMC) nanoparticles for 
sustained release of EGF[289]. In the presence of proteinases, EGF was released within 48 h 
and induced fibroblast proliferation in vitro. In vivo, enhanced healing was seen with this 
Chapter 3: A Systematic Review of Developments in Biomaterial-Based 
Growth Factor and Cytokine Delivery Systems  
 
 56 
system compared to the chitosan hydrogel alone, and chitosan hydrogel + unencapsulated 
EGF[289] (table 3.8).  
 










EGF In vitro release + proteinases – within 48 h, 
induced fibroblast proliferation 
STZ-induced diabetic rat full-thickness 
excisional wound model – treatment every 2 
days led to faster healing relative to hydrogel 
and hydrogel + EGF controls[289] 




GM-CSF In vitro release – within 48 h 
Rat full-thickness excisional wound model - 
treatment every 2 days led to faster healing, 
improved re-epithelialisation and granulation 
tissue formation relative to nanoparticle + 
composite control[290] 
Alginate CMC Hydrogel  EGF In vitro release – within 12 h, non-toxic to 
fibroblasts, induces RBC clotting  
Rat partial-thickness scald burn model – 
daily treatment led to faster healing relative 
to hydrogel and EGF controls[291] 
Gelatin Gelatin Microspheres 
+ sponge 
EGF Rat full-thickness excisional wound model – 
single treatment led to faster healing, with 
increased tensile strength relative to sponge 
control[292]  
 Collagen Microspheres, 
hydrogel + 
matrix 
EGF In vitro release – cumulative over 14 days  
In vitro culture – enhanced proliferation of 
keratinocytes relative to fibroblasts 
Rat full-thickness excisional wound model - 
single treatment led to faster healing relative 








VEGF-A Mouse splinted full-thickness excisional 
wound model - single treatment led to faster 







VEGF-A In vitro release in serum – cumulative over 15 
days, induces endothelial cell migration 
In vitro culture – supported growth of 
keratinocytes, fibroblasts and enhanced that 
of endothelial cells 
Mouse full-thickness excisional wound 
model - single treatment led to faster healing 
relative to hydrogel and hydrogel + VEGF-A 
controls[295] 
Lipid Silk fibroid Liposome + 
SF core  
FGF-2 In vitro release + wound fluid – protection, 
supported fibroblast survival  
Mouse partial-thickness thermal burn - 
treatment every 3 days led to faster healing 
and better collagen phenotype relative to 
FGF2 control[296] 
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An HA hydrogel reinforced with cellulose and containing GM-CSF encapsulated within 
chitosan nanoparticles showed delayed release of GM-CSF in vitro up to 48 h, and in vivo 
this system promoted better re-epithelialisation and granulation tissue formation compared 
to HA-cellulose hydrogel + chitosan nanoparticles alone[290].  
 A dual crosslinked hydrogel derived from alginate and CMC was developed for 
release of EGF[291]. Fast release was observed within 12 h, and the hydrogel was non-toxic 
to fibroblasts and induced RBC clotting. In a rat partial-thickness scald model, the EGF-
containing hydrogel enhanced healing compared to the hydrogel alone and topical EGF 
spray[291].  
 A gelatin sponge combined with gelatin microsphere-encapsulated EGF enhanced 
healing in  diabetic and non-diabetic rat full-thickness excisional wound models, and the 
tensile strength of the healing scar was significant with this system compared to moistened 
gauze and the gelatin sponge alone[292]. A gelatin hydrogel containing gelatin microsphere-
encapsulated EGF, when paired with a collagen-based tissue-engineered ECM, produced 
sustained release of EGF up to 14 days[293]. This sustained release was attributable to the 
microsphere, as EGF within the hydrogel + matrix alone released within 3 days. In vitro, the 
composite system enhanced proliferation of both fibroblasts and keratinocytes, although 
preferential to fibroblasts[293]. In a rat full-thickness excisional wound model, wounds treated 
with the composite system healed faster than those treated with EGF + hydrogel + matrix, or 
matrix alone[293].  
 Fibrin was combined with HA to make a composite hydrogel, and when combined 
with VEGF-A-nanoparticle, healing of a mouse splinted full-thickness excisional wound 
model was enhanced compared to the hydrogel alone[294]. A fibrin hydrogel was combined 
with a macromer derived from an anti-VEGF-aptamer and fibrinogen for controlled release 
of VEGF-A[295]. The system showed release of VEGF-A in serum over 14 days, and in vitro 
the gel promoted proliferation of fibroblasts, keratinocytes and endothelial cells. In a mouse 
full-thickness excisional wound model, single treatment led to a faster healing rate compared 
to the hydrogel without VEGF-A, and the hydrogel without the anti-VEGF-A-aptamer[295].  
 FGF-2 encapsulated within a skin-permeable liposome[296] showed enhanced stability 
in wound fluid containing MMP-9 compared to free FGF-2 – with 64% of encapsulated FGF-
2 remaining after 24 hours, and only 2.1% of free FGF-2. In a murine partial-thickness 
thermal burn model, hair follicle regeneration was enhanced in liposome-treated animals, and 
this was associated with reduced scar phenotype and vascularisation[296].  
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3.3.3.2 Natural/Synthetic Hybrids 
Chitosan was combined with the synthetic polymer PVA and the natural biomaterial gelatin, 
in order to enhance structural by PVA addition, and enhance cellular interactions due to the 
gelatin[297]. The addition of PCL microsphere-encapsulated FGF-2 showed sustained release 
over 25 days (table 3.9)[297]. In rat full-thickness excisional wounds, single treatment with 
this composite hydrogel system enhanced healing in comparison to the hydrogel control[297]. 
A chitosan hydrogel was combined with carbon nano diamonds for controlled release of 
VEGF-A[298]. In vitro, VEGF-A was released within 3 days, and this system was non-toxic 
to endothelial cells, and did not promote production of inflammatory or apoptotic 
markers[298].  
 




Treatment(s)  Experimental parameters tested and 
outcomes 





FGF-2 In vitro release – cumulative over 25 days, 
non-toxic for fibroblasts 
Rat full-thickness excisional wound model - 
single treatment led to faster healing relative 
to hydrogel and dressed controls[297] 




VEGF-A In vitro release – within 3 days, induces 
endothelial cell attachment and proliferation, 






+ hydrogel  
FGF-2 In vitro release – burst release within 48 h, 
cumulative over 12 days, induces fibroblast 
proliferation  
Rat full-thickness thermal burn model – 
single treatment led to faster healing relative 
to hydrogel and hydrogel + FGF-2 
controls[299] 
HA Heparin + 
PEGDA 
Hydrogel FGF-2 In vitro release + hyaluronidase – cumulative 
over 35 days, increases fibroblast 
proliferation[300] 




G-CSF In vitro release – cumulative over 15 days, 
non-toxic for mesenchymal stem cells 
Rat full-thickness excisional wound model – 
single treatment led to faster healing relative 
to nanofibre control[301] 
 
Alginate was fabricated into microspheres in order to encapsulate FGF-2 for sustained release 
from a CMC-chitosan-PVA hydrogel[299]. This composite system facilitated an initial burst 
release within 48 h, and cumulative release over 12 days. In a rat full-thickness thermal burn 
model, treatment led to faster healing relative to hydrogel alone or unencapsulated FGF-2 
hydrogels[299].  
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Thiol-modified hyaluronic acid hydrogels were crosslinked with PEGDA in the 
presence of thiolated heparin[300]. Addition of PEGDA provided structural stability to support 
sustained release[300]. Heparin binding of FGF-2 allowed for encapsulation within the 
hydrogel and sustained release of the growth factor over 35 days in the presence of 
hyaluronidase. In vitro, HA-hydrogels stimulated fibroblast proliferation, showing good 
biocompatibility[300].  
 A collagen hydrogel encompassing PCL-nanofibres, to add structural stability, and 
chitosan nanoparticle-encapsulated G-CSF, for delayed release, showed sustained release of 
G-CSF over 15 days[301]. In vivo, faster healing was observed in rat full-thickness excisional 
wounds treated with the G-CSF-containing system compared to the nanofibres alone[301].   
  
3.3.4 Complex Delivery Systems  
Composite biomaterial systems have been complexified by incorporating multiple growth 
factors for release, or combining growth factors or cytokines with skin cells or drugs for 
enhanced efficacy (Fig. 3.1). A summary of these complex composite systems can be found 
in Table 3.10. 
Figure 3.1. Hybrid Biomaterials for Delivery of Growth Factors, Cytokines, Drugs and/or Cells to Skin 
Wounds. Examples include delivery of: PDGF-ββ with fibroblasts in a fibrin sealant to enhance GT 
formation[305], FGF-2 and rifamycin in alginate microparticles for combined targeting of wound re-
epithelialisation and biofilm infection[306] and delivery of multiple GFs to enhance both epidermal and dermal 
repair using collagen nanofibers containing EGF and PDGF-ββ-NPs, and HA nanofibers containing FGF-2 
and VEGF-A-NPs[303]. Made using Biorender.  
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Table 3.10. Complex Composite Delivery Systems Evaluated for Cutaneous Wound and Scarring Indications   
Biomaterial(s) Fabrication 
method(s) 










In vitro release – within 24 h, 
cumulative over 8 days  
Mouse full-thickness excisional wound 
model – single treatment led to 
prolonged vascularisation relative to 
matrix + GFs, matrix + sealant and 
matrix controls[302] 
 Fibrin + 
Fibrinogen 
fragments 
Matrix VEGF-A + 
PDGF-bb 
In vitro culture – supports tubule 
formation by endothelial cells or sprout 
formation by smooth muscle cells 
Diabetic db/db mouse full-thickness 
excisional wound model – single 
treatment led to faster healing relative to 
matrix, matrix + FN and matrix + GF 
controls[200] 
 Collagen Membrane  FGF-2 + 
FGF-7 
In vitro release – cumulative over 28 
days 
Rat full-thickness splinted excisional 
wound model – single treatment lead to 
faster healing relative to membrane, 
membrane + FGF-2 or FGF-7 
controls[303] 
 Collagen + HA Hydrogel VEGF-E + 
vIL-10 
Horse bandaged full thickness 
excisional limb wound model – single 
treatment lead to faster repair processes 
and resolution of exuberant granulation 
tissue formation relative to hydrogel 
control[182] 
 Collagen + HA 
+ Gelatin  
Nanofibres + 
NP 
EGF + FGF-2 
+ PDGF-bb + 
VEGF-A 
In vitro release – within 5 days for FGF-
2 and cumulative over 25 days for 
others, in vitro culture – supports 
endothelial cell tubule formation 
STZ-induced diabetic rat full-thickness 
excisional wound model – single 
treatment lead to faster healing, re-
epithelialisation, collagen deposition 
and vasculature formation relative to 
nanofibres, nanofibres + FGF-2/EGF 
controls[304] 
GF + cells  Fibrin + 
Fibrinogen 
fragments 
Matrix   EGF + 
keratinocytes 
In vitro release – burst within 24 h, 
cumulative over 7 days  
Mouse full-thickness excisional wound 
model – single treatment led to faster 
healing relative to keratinocytes + 
matrix, EGF + matrix and matrix 
controls[305] 
 Fibrin Sealant  PDGF-bb + 
fibroblasts 
Rabbit full-thickness excisional wound 
model – single treatment led to faster 






Microparticle  FGF-2 + 
rifamycin 
In vitro release in serum—induced 
fibroblast proliferation and migration 
Rat full-thickness excisional wound 
model—single treatment led to faster 
healing than untreated control[307] 
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 Chitosan + 
polyacrylamide 
Hydrogel EGF + 
piperacillin 
In vitro release – antibiotic within 10 h, 
EGF cumulative over 10 days, increase 
in fibroblast proliferation[308] 






In vitro release—antibiotic and VEGF 
cumulative over 7 and 20 days 
Infected rat full-thickness splinted 
excisional wound model—single 
treatment led to faster healing, with 
increased granulation tissue relative to 




For example, Lai et al[304] constructed a highly sophisticated, multifactor delivery 
system involving four growth factors and two different types of fibres, aimed at enhancing 
the proliferative phase of healing. Collagen fibres containing free FGF-2 and nanoparticle-
encapsulated VEGF-A released the proteins over 5 and 25 days, respectively. Additional HA 
fibres released EGF and nanoparticle-encapsulated PDGF-bb over 25 days[304]. This complex 
system, targeting multiple aspects of the wound healing cascade, was able to successfully 
enhance re-epithelialisation, collagen deposition and vasculature formation in streptozotocin-
induced diabetic rats[304]. Composite systems have also been used for dual delivery of a 
number of growth factors, including FGF-2 + VEGF-A in a fibrin sealant/collagen matrix[302]. 
This composite system showed an initial burst release within 24 hours, which was sustained 
for 8 days. In a mouse full-thickness excisional wound model, single treatment led to 
prolonged vascularisation relative to the matrix alone, topical growth factors and growth 
factors within the collagen matrix[302]. Dual delivery of VEGF-A and PDGF-bb via a fibrin 
matrix containing fibrinogen fragments supported vascularisation processes in vitro, and in 
a diabetic mouse full-thickness excisional model, faster healing was observed with the system 
compared to matrix alone, matrix + fibrinogen or matrix + growth factors[200]. Delivery of 
FGF-2 and FGF-7 by a collagen membrane showed sustained release in vitro over 28 days, 
and in a rat full-thickness splinted excisional wound model, treatment with the membrane 
enhanced healing compared to the membrane alone or membrane containing only FGF-2 or 
FGF-7[303].  
 Delivery of the virally-derived proteins VEGF-E and vIL-10 by a collagen + HA 
hydrogel was designed for targeting of two phases of healing – both the proliferative phase, 
by the VEGF-E, and the inflammatory phase, by vIL-10, thereby acting to promote healing 
and reduce scarring within a single system[182]. This was the only growth factor/cytokine 
combination in this analysis that targeted two distinct phases of healing. In a horse bandaged 
full-thickness excisional limb wound model, treatment with this hydrogel promoted faster 
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repair processes and resolution of the exuberant granulation tissue formation compared to the 
hydrogel alone[182]. 
Composite biomaterials have been tested that encompassed not only growth factors 
or cytokines, but also antibiotics, aimed at targeting wound infections, which contribute to 
negative healing outcomes. A chitosan/polyacrylamide hydrogel showed release of 
piperacillin-tazobactam within 10 h, and cumulative release of EGF over 10 days[308]. 
Alginate microparticles tailored for individual release of rifamycin and FGF-2 enhanced 
healing of a rat full-thickness excisional wound model[307]. VEGF-A loaded PLGA 
microspheres within a chitosan-HA hydrogel containing vancomycin showed cumulative 
release of the antibiotic and protein over 7 and 20 days, respectively[309]. It should be noted, 
however, that none of these systems were tested in infected models of healing.  
Incorporation of skin cells into composite biomaterial systems in parallel with growth 
factors and cytokines, has also been conducted so as to enhance both cell viability and healing 
responses. For example, encapsulation of keratinocytes and EGF within a fibrin matrix 
demonstrated a burst release of EGF within 24 h and sustained release over 7 days, promoting 
faster healing in a murine full-thickness excisional wound model relative to the matrix and 
cellular controls[305]. Delivery of PDGF-bb and fibroblasts within a fibrin sealant enhanced 
healing responses in a rabbit full-thickness excisional model compared to sealant and cellular 
controls[306].  
 
3.3.5 Biomaterials May Prevent Proteolytic Degradation of Growth Factors and 
Cytokines 
The wound environment is harsh on directly applied proteins due to excessive production of 
proteases. Biomaterials that offer proteolytic protection would therefore allow more 
physiologically relevant doses to be administered. In providing this protection, biomaterials 
will also aid the retention of the growth factors and cytokines within the wound, thus 
preventing their systemic distribution and risk of inducing the malignancy or 
immunogenicity.  
The biomaterials described above were examined for evidence of proteolytic 
protection, and while this has frequently been claimed as a benefit, very few studies provided 
evidence to support this. Growth factor and cytokine release profiles from the biomaterials 
were generally evaluated in vitro rather than in vivo or in a proteolytic environment. Most 
studies that evaluated release kinetics in vitro did so using standard physiological buffers, 
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while some made physiologically-relevant additions, such as MMP-containing serum[282] or 
culture media[281, 284, 295, 307], and in one case, wound fluid[296].  
Limited studies directly evaluated protein release from biomaterials within animal 
wounds, however FGF-2 released from gelatin sheets within diabetic mouse wounds was 
shown to be stable for 7 days[287], and liposome-encapsulated EGF remained present in rat 
incisional wounds as far as five days[310]. Stability of growth factors or cytokines within a 
wound is a critical requirement, particularly in the case of infected chronic wounds, due to 
the high levels of proteases[39, 64].  
While some studies ascertained protein release, systemic distribution of the proteins 
was not studied. In addition, there were no attempts to detect antibody production in response 
to short- or long-term exposure to the biomaterial or growth factors/cytokines incorporated. 
Therefore, further analyses are required to determine whether biomaterials do indeed provide 
protection and retention of growth factors and cytokines within acute or chronic wounds.  
 
3.3.6 Biomaterials May Provide Structural Supports for Growth Factor and Cytokine 
Activity  
The success of growth factor and cytokine delivery is dependent on their interactions with 
the ECM, but an altered ECM structure in pathological healing states may influence treatment 
outcomes. Natural biomaterials may provide an added advantage to growth factor and 
cytokine delivery systems, as their ECM-mimicking scaffolds, hydrogels and sponges may 
support the migration and proliferation of key skin cell types involved in healing.  
Many of the studies looked at the biocompatibility of their systems, particularly in 
the support of fibroblasts, endothelial cells and keratinocytes. None of the studies reported 
toxicity to these cells, and some studies reported increased proliferative responses in these 
cells[289, 293, 295, 298-300, 307, 308]. One study reported a preferential response with a fibrin 
hydrogel, which enhanced proliferation of endothelial cells over keratinocytes and 
fibroblasts[295]. Of the many growth factors and cytokine delivery systems developed, only a 
few were directly assessed for their ability to support skin cell attachment or migration in 
vitro. For example, an alginate-chitosan hydrogel containing EGF was incubated with red 
blood cells to demonstrate clotting and haemostatic efficacies[289], and cell attachment 
demonstrated using FGF-2 containing collagen hydrogels[276] and VEGF-A-NP encapsulated 
chitosan/gelatin hydrogels[298]. Further to this, Martino et al. demonstrated that a fibrin matrix 
containing VEGF-A and PDGF-bb supported both endothelial cell and smooth muscle 
function in vitro[311].  
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The limited quantity of these studies means that it is not yet clear which biomaterials 
are most biocompatible and provide the best support for the growth of different skin layers. 
One study by Zhao et al[295] showed preferential enhancement of endothelial cells while still 
supporting growth of fibroblasts and keratinocytes – reporting these specific cell responses 
may assist in making such decisions. Furthermore, the impact of different biomaterials on 
inflammatory processes has not been compared – a critical factor moving forward due to the 
large causative role of inflammation in negative healing outcomes. 
 
3.3.7 Biomaterials May Enhance the Efficacy of Biologics Compared to Topical Delivery  
Of the 37 papers that were examined, 31 assessed the efficacy of a biomaterial-based delivery 
system in vivo. All 31 in vivo papers reported a positive healing outcome in treated animals 
compared to those treated with control.  
The effect of biomaterial-based growth factor and cytokine delivery on healing 
outcomes was tested in mice, rats, rabbits and pigs. Models were commonly full-thickness 
excisional wounds, with the limitations of rodent healing addressed in a few papers[294, 303, 
309] by introducing splints, which limits contraction, thus enabling macroscopic 
measurements of re-epithelialisation[312]. Db/db mice, STZ-diabetic rats and ischaemic 
models were used to better represent chronic healing pathologies, though it should be noted 
that these do not fully represent the complex aetiology of chronic wounds[313]. One paper also 
accounted for the infection in chronic wounds by using an infected splinted model in the 
rat[309].  While all the papers cited either improved healing, re-epithelialisation, granulation 
tissue formation or vascularisation, the diverse range of animal models makes it difficult to 
make comparisons, when there was no specific species, wound type, area or depth used 
routinely across trials. The data collected in these studies suggested that the selected 
biomaterials make an appropriate delivery vehicle for growth factors and cytokines, 
enhancing healing compared to their controls. However, it should be noted only two 
studies[291, 302] included topical protein as a control, with the others only comparing to other 
biomaterial groups. It is therefore not possible to determine if biomaterial delivery improved 
the efficacy of the growth factor or cytokine therapy, nor improve their clinical utility.  
The effect of biomaterial-based growth factor and cytokine delivery on scarring 
outcomes was rarely tested, with only a few studies looking at scarring outcomes or 
processes[182, 285, 292]. Models used for this included a rat full-thickness excisional wound 
model[292], a db/db mouse model and an EGT equine bandaged limb model[182]. It should be 
noted that rodent models heal with very little scarring due to their loose skin[314]. However, 
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the horse model that produces exuberant granulation tissue formation[182], heals in a manner 
more representative of pathological scarring. Outcome measures were largely mechanistic, 
relating to wound closure or rate based on histological analyses, neglecting to investigate 
clinically relevant outcomes such as tensile strength.  One paper reported enhanced tensile 
strength of the healed scar[292].   
None of these studies compared their treatment to topical protein as a control, and 
while scarring could be modulated, the small number of studies and restricted outcomes mean 
that conclusions cannot be drawn about the impact of biomaterials for controlled delivery of 
growth factors and cytokines for scarring indications.  
While controlled delivery of growth factors and cytokines using biomaterials was 
able to modulate healing in many cases, in order to ascertain whether it is indeed a better 
therapeutic strategy than topical delivery alone, future studies should be conducted with more 
appropriate controls, in more relevant animal models and in a more consistent manner to 
enable more accurate comparisons between studies.  
 
 Summary  
Natural biomaterials have demonstrated the capacity to deliver growth factors and cytokines 
to wounds to promote healing. Collagen was the most commonly used biomaterial, delivering 
a wide range of growth factors, most often aimed at promoting proliferative responses. 
Chitosan was also used to target the proliferative phase of healing, most often with FGF-2 
and EGF. Alginate, HA, gelatin and fibrin were largely used to target angiogenic processes 
via delivery of VEGF-A and FGF-2. Most of these biomaterials were structured as hydrogels, 
films or sponges. Release profiles in combination with inherent properties of the biomaterials 
suggest that materials such as alginate and chitosan may be appropriate for chronic wounds, 
while materials such as gelatin and fibrin may be better suited to fast release in acute wounds. 
Systems can be functionalised, and delivery tailored even further by hybridising natural 
materials with synthetic biomaterials and nanoparticle systems, in order to control 
degradation rate and enable release of multiple growth factors, cytokines, cell types and 
drugs. The most common approach for this appears to be nanoparticles and nanofibres 
incorporated into a hydrogel, however the mechanism by which tailored release was tested – 
often in vitro and in the absence of proteolytic factors – needs to be optimised to be more 
relevant to the wound environment. While many of the systems looked at biocompatibility 
in the form of cell proliferation, more complex cell functions such as migration and adhesion 
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must be assessed before biomaterials can be proven as structural support for cell growth in 
vivo.  
A multifaceted approach using multiple proteins within a biomaterial system has been 
suggested to be more therapeutically efficacious compared to the previous topical delivery 
of single proteins in the clinic. However, evidence supporting this is lacking, as only a few 
were assessed in models that exhibit impaired or excessive healing, and no comparisons 
between different topical and biomaterial delivery were made. In addition, no studies 
examined the retention of growth factors or cytokines within the biomaterial or the wound 
site nor did they evaluate the immunogenicity for delivery system components. As such, there 
is insufficient evidence to conclude whether growth factor and cytokine delivery systems will 
offer greater clinical success than the direct therapies that were originally trialled.
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 In Vitro Techniques 
4.1.1 Purification and Quantification of VEGF-E and vIL-10 Proteins 
4.1.1.1 General Reagents 
Anti-FLAG® M2 Affinity Gel  Sigma-Aldrich, A2220, stored at -20oC 
10% Ammonium Persulphate 0.5g ammonium persulphate (Calbiochem MERUS2300-
25GM) in 5mL distilled water, aliquot and store at -20oC.  
1% Bovine Serum Albumin (BSA)  10 mg BSA (Gibco 30060-487) in 1mL 1x PBS 
1 mg/mL Carbonic Anhydrase (CA)  1 mg CA (Sigma-Aldrich, C2273-1Vl) in 1 mL of PBS, 
stored at -20oC 
Coomassie Blue Stain   0.5 g Coomassie Blue R-250 (AppliChem A10920025), 200 
mL methanol (Millipore MER1060092500), 25 mL glacial 
acetic acid (FischerSci A/0400/PB17), in 500 mL of milliQ 
water.  
Coomassie Blue Destain  150 mL methanol, 50 mL glacial acetic acid in 300 mL of 
milliQ water.  
Dulbecco’s Modified Eagle Medium 
(DMEM) 
1 packet of DMEM (Life Technologies 12800-017), 37 g 
NaHCO3 (Merck MER1063290500), 4.77 g HEPES (Gibco 
11344-041), 1.5 µL β-mercaptoethanol (2-ME, Calbiochem 
MERUS1444203-250ML) in 950 mL milliQ water, pH 7.4 
using concentrated HCl (32%), filter sterilise using 0.22 µM 
filter, store at 4oC.  
FLAG® Peptide  Millipore, F3290, stored at -20oC 
Foetal Bovine Serum (FBS) Sigma-Aldrich F8067-500mL, heat-inactivated at 50oC for 
20 minutes, stored at -20oC.  
50 mg/mL Gentamycin  50 mg gentamycin sulfate in 1 mL milliQ water (AppliChem 
APPA14920025), filter sterilised using 0.22 µM filter 
(MUN760502), stored at -20oC.  
Glycine HCl, pH 3.5 0.75 g glycine (ThermoFisher AJA10835KG) in 100 mL of 
distilled water, with pH adjusted to 3.5 with concentrated 
HCL, stored at 4oC.  
HEK293 Medium 20 mL heat-inactivated FBS (sigma F8067-500mL), 200 µL 
gentamycin, 400 µL hygromycin-B (ThermoFisher 
10687010), 2 mL PSK per 200 mL of DMEM. 
L-Glutamine 1.46 g L-glutamine in 50 mL milliQ water, filter sterilised 
using 0.22 µM filter, stored at -20oC.  
5M NaCl 146.1 g NaCl (Merck 1064045000) in 500 mL distilled 
water.  
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10x Phosphate-Buffered Saline (PBS) 80 g NaCl, 2 g KCl (Merck 7447-40-7), 11.35 g Na2H2PO4 
(Merck 7558794), 2 g KH2PO4 (Merck 7778770) in 1L of 
milliQ water.  
PBS  100 mL 10x PBS in 900 mL of milliQ water. 
1% Penicillin/Streptomycin/Kanamycin 
(PSK) 
100 mL penicillin-streptomycin (Gibco 15070063), 1 g 
kanamycin (Gibco, 11815-082), stored at -20oC.  
Reducing Sample Buffer  1 mL sample buffer, 50 µL 2-ME (Calbiochem, 
MERUS1444203-250ML).  
Resolving Buffer 27.23 g TRIS base, 150 mL milliQ water, with pH adjusted 
to 8.8 using concentrated HCl (32%). 
10x Running Buffer  30 g TRIS base, 144 g glycine, 10 g SDS in 1L of milliQ 
water. 
Sample Buffer 8.4 mL 0.05% bromophenol blue (Sigma-Aldrich 114391-
5G), 2 mL 0.5M TRIS-HCl, pH 6.8, 1.6 mL glycerol, with 
3.2 mL 10% SDS, stored at -20oC.  
1% Sodium Azide 10mg sodium azide (Sigma S2002-25g) in 1mL milliQ 
water.   
10% Sodium dodecyl sulfate (SDS)  5 g sodium dodecyl sulfate (ThermoFisher FSBBP166-500) 
in 50 mL milliQ water.  
Stacking Buffer 6 g TRIS base in 150 mL milliQ water, with pH adjusted to 
8.8 using concentrated HCl (32%).  
Tris-Buffered Saline (TBS) pH 7.4 8 g NaCl, 0.2 g KCl, 3 g TRIS base (NeoFroxx 125KG001), 
in 1 L of milliQ water. Adjusted to pH 7.4 using 
concentrated HCl (32%).  
TBS-GA 25 mL TBS with 25mL 50% glycerol and 1mL of 1% 
sodium azide (Sigma-Aldrich S2202-25g), stored at 4oC.  
TBS-T 500 mL TBS with 1 mL of 10% Tween 20. 
TEMED Sigma T9281-25mL, stored at 4oC.  
0.5M Tris-HCl  60.55g TRIS dissolved in 1L distilled water, pH 7.6 using 
concentrated HCl (32%).  
10% Tween-20 5 mL Tween-20 (NeoFroxx 8506LT001) in 45 mL of milliQ 
water.  
 
4.1.1.2 Protein Purification using Affinity Chromatography 
HEK293 cell-lines secreting FLAG-tagged Orf virus VEGF-E and vIL-10 proteins were 
cultured at 37oC (5% CO2) in T-175 flasks until 80% confluency. Supernatant containing the 
proteins was collected, clarified by centrifugation using the Eppendorf 5810R centrifuge, 
placed in 50 mL tubes then stored at -80oC. For affinity chromatography, the cell supernatant 
was defrosted, then 1.5 mL of 5M NaCl was added to each 50 mL aliquot.  
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 Next affinity gel was prepared for purification of the proteins. A 10 mL purification 
column (Poly-Prep® chromatography column, BioRad 7311550) was rinsed twice with ice-
cold TBS, before adding 250 µL ANTI-FLAG® M2 Affinity Gel (Sigma-Aldrich, A2220). 
The drained gel bed was rinsed 3x with 10 mL glycine HCl, pH 3.5, followed by 5x 10 mL 
washes with cold TBS. The gel was then resuspended in 1 mL TBS within the stoppered 
column, before adding 250 µL of diluted gel to each supernatant tube. The supernatant/gel 
mixture was placed on DLAB MX-T6-PRO rollers at speed setting 10 overnight at 4oC.  
 To collect the gel and its bound proteins, the 50 mL tubes of cell supernatant were 
centrifuged at 3725 ´ g for 5 min at 4oC. All but 5 mL of supernatant was removed, then 
transferred to a fresh 50 mL tube. The gel pellet was resuspended in the remaining 5 mL of 
supernatant, then placed into the column to drain and add to the supernatant. The pellet tube 
was then rinsed with TBS-T, which was then placed in the column to collect any residual gel. 
The drained liquid was then added into the tubes with supernatant, which were stored at -
80oC for up to three further rounds of purification. The drained gel was rinsed 4x with 10 mL 
cold TBS-T, with the last wash performed for 10 min in the stoppered column on the Ratek 
platform mixer at 25RPM.  
So as to displace the proteins from the gel, 50 µL of FLAG® Peptide (Millipore, 
F3290) was added to the drained gel in 1 mL TBS-T. The column was again stoppered, and 
placed in the shaking platform for 10 min. The eluted protein was then collected in a 15 mL 
tube. The gel was then rinsed with 2 mL cold TBS-T, which was collected with the eluted 
protein.  
 The affinity gel was washed immediately so as to allow for up to 4 rounds of 
purification. Room temperature Glycine HCl, pH 3.5 (5 mL) was added to the column, which 
was stoppered and placed on the shaking platform for 5 min. The gel was then drained, before 
3x washes with cold TBS-T. A final 5 mL volume of cold TBS-GA was added to gel, then 
the column was stored at 4oC for future use.  
 
4.1.1.3 Protein Concentration  
For concentration of the VEGF-E protein, a Vivaspin 500 centrifugal concentrator (Sartorius 
VS0101 10 KDa molecular weight cut-off (MWCO)) was prepared by coating with 1% BSA 
for 2 hours. The concentrator was then thoroughly rinsed with PBS, then the addition of 500 
µL milliQ water and centrifugation using the Biofuge Fresco centrifuge at 16000 ´ g for 15 
min at 4oC. Eluted VEGF-E protein was added to the concentrator in 500 µL volumes, each 
with centrifugation for 15 min at 4oC. The concentrated protein was then collected, adjusted 
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to 200 µL with PBS, then 10 µL aliquots were placed into microcentrifuge tubes which were 
stored at -80oC.  
 For concentration of the vIL-10 protein, a 50 mL centrifugal concentrator (Amicon® 
Ultra-15 10K Centrifugal filter device) was prepared by thoroughly washing with milliQ 
water, filling with milliQ water, then centrifugation in the Eppendorf 5810R centrifuge at 
2600 ´ g for 30 min at 4oC. Eluted IL-10 protein was then added to the concentrator with 
centrifugation for 15 min at 4oC. When the sample volume was less than 250 µL, 1.5mL of 
PBS was added, with further centrifugation 2600 ´ g for 15 min at 4oC. The concentrated 
protein was then collected, adjusted to 200 µL with PBS, and 10µL aliquots were placed into 
microcentrifuge tubes which were stored at -80oC.  
 
4.1.1.4 SDS-Polyacrylamide Gel Electrophoresis (PAGE)  
SDS-PAGE was used to confirm the purified VEGF-E and vIL-10 proteins were the correct 
size, and to ascertain a concentration by comparing to a known standard curve. A Mini-
Protean Tetra System (BioRad) was used to cast and conduct SDS-PAGE so as to separate 
and analyse the purified proteins. Gradient gels were made in which the resolving gel 
consisted of two equal layers, the bottom containing 15% acrylamide and the top containing 
10% acrylamide. A 3% acrylamide stacking gel was used on top of the resolving gels (see 
table 4.1). 
 
Table 4.1. Recipe for Upper Stacking and Lower Resolving Gels used for SDS-PAGE Analysis  
 
Aliquots of VEGF-E and vIL-10 (20 µL) were thawed then combined with 20µL of reducing 
sample buffer. As a protein standard of known concentration, 20 µL 1mg/mL CA was also 
combined with 20 µL of reducing sample buffer. Samples were boiled for 10 min prior to 
loading into wells within SDS-PAGE gels. In the first well of each gel, 3 µL of full-range 
rainbow marker (Amersham RPN800E) was loaded. For each sample, 3 µL, 8 µL and 20 µL 
Reagent Upper Stacking Gel                                     Lower Resolving Gel 
 3% 10% 15% 
Distilled Water 3.25mL 3.47mL 1.8mL 
10% SDS 50µL 100µL 100µL 
50% Glycerol - 200µL 200µL 
Resolving Buffer - 2.5mL 2.5mL 
Stacking Buffer 1.25mL - - 
30% Acrylamide 0.5mL 3.33mL 5mL 
10% Ammonium Persulfate 30µL 60µL 60µL 
TEMED 15µL 30µL 30µL 
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volumes were loaded into consecutive wells. The volume per well was then made up to a 
total of 20 µL, through the addition of reducing sample buffer combined 1:1 with PBS. The 
gels were then loaded into the tank, which was filled with running buffer. Proteins within the 
gel were then separated by electrophoresis at 100 V for 2 h. 
 
4.1.1.5 Coomassie Blue Staining of Proteins  
SDS-PAGE gels were placed in Coomassie blue stain, then incubated on a shaking platform 
for 1 h at room temperature. The gels were then moved into destaining solution, with 
incubation on a shaking platform at RT. The destain was continually replaced as it became 
saturated with Coomassie blue, and until the stained proteins were visible. The gel was next 
incubated in distilled water overnight at RT, then imaged using the BioRad GS-710 calibrated 
imaging densitometer.  
 
4.1.1.6 Quantification of VEGF-E and vIL-10 Proteins 
ImageJ (https://imagej.nih.gov/ij/) was used to quantify the integrated density of the stained 
protein bands and the background gel. A standard curve was then constructed based on the 
known concentration and integrated density of the bands corresponding to CA.  The 
integrated densities for the bands corresponding to the VEGF-E and vIL-10 proteins were 
then converted into concentration using the standard curve.  
 
4.1.2 Fluorescent Labelling of Protein 
4.1.2.1 General Reagents  
BSA BSA (Gibco 30060-487), stored at 4oC 
CA CA (Sigma-Aldrich, C2273-1Vl), stored at 4oC 
Dylight®594 NHS Ester 
Fluorophore 
ThermoFisher, No. 46412, 1mg ester in 1mL PBS, stored at -20oC in 
the dark 
Dylight®488 NHS Ester 
Fluorophore 
ThermoFisher, No. 46402, 1mg ester in 1mL PBS, stored at -20oC in 
the dark 
Nitrocellulose Membrane Amersham™Protran™ 0.45µM nitrocellulose membrane (10600016).  
PBS 100 mL 10x PBS (see section 2.1.1.i) in 900 mL of milliQ water. 
Rainbow Marker Amersham RPN800E, stored at -20oC 
10x Transfer Buffer 30.3g TRIS base, 144glycine, 200 mL methanol, adjusted to 1L with 
milliQ water. 
Transfer Buffer 100mL 10X Transfer Buffer in 900mL of milliQ water 
Western Blotting Wash Buffer 1L TBS containing 2 mL of 10% Tween 20.  
Western Blotting Blocking Buffer 40 µL 10% Tween 20, 1g skim milk powder per 20 mL of TBS.  
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4.1.2.2 Fluorophore Conjugation to Proteins 
In order to visualise the release of proteins from the hydrogel, proteins were conjugated to 
Dylight®594 and Dylight®488 NHS Ester Fluorophores (ThermoFisher, No. 46412, No. 
46402).  The conjugation protocol was optimised using the readily available control proteins 
BSA and CA. CA was chosen to mimic slow-release of VEGF-E, and BSA to mimic the fast-
release of IL-10. To optimise the labelling reaction, three different protocols were chosen, 
each using increasing amounts of protein from 5µg to 100 µg with a constant amount of 
fluorophore (80 µg) (Table 4.2).  
 
Table 4.2.  Quantities of Dye-Protein Used in Conjugation Reactions 
 
Protein, fluorophore and PBS were combined to a total volume of 500 uL, before being 
vortexed and incubated for 1 h at room temperature in the dark. The mixture was then added 
to pre-prepared Vivaspin concentrators, which were then centrifuged using the Biofuge 
Fresco centrifuge at 16000 ´ g for 15 min at 4oC. The labelled protein was then removed 
from the Vivaspin concentrator and aliquoted into 0.65mL tubes for storage at -20oC. Degree 
of fluorophore conjugation was determined using the DeNovix DS-11 FX+ 
spectrophotometer and fluorometer (Dnature). The molecular weight and extinction 
coefficient of the protein was entered, then 2 µL of the corresponding protein was placed in 
the fluorometer. Absorbance was read at 280 nm to ascertain protein concentration, and at 
594 nm (BSA) or 488 nm (CA) to analyse fluorescent conjugation.  
 This protocol was designed to be optimised with BSA and CA, then repeated with 
VEGF-E and vIL-10. This was not possible due to lack of reagents.  
 
4.1.2.3 SDS-PAGE and Western Blotting Analysis of Fluorescently Labelled Proteins 
The conjugated BSA and CA were first resolved on SDS-PAGE gels. Gradient gels were 














BSA (1) 5 uL 80 µg 594 Ester 1:16 415 µL 500 µL 
BSA (2) 20 µL 80 µg 594 Ester 1:4 400 µL 500 µL 
BSA (3) 100 µL 80 µg 594 Ester 5:4 320 µL 500 µL 
CA (1) 5 µL 80 µg 488 Ester 1:16 415 µL 500 µL 
CA (2) 20 µL 80 µg 488 Ester 1:4 400 µL 500 µL 
CA (3) 100 µL 80 µg 488 Ester 5:4 320 µL 500 µL 
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volume) loaded into a well, alongside 3 µL of full-range rainbow marker. Proteins were then 
separated by electrophoresis at 100 V for 2 h. 
 Prior to assembly of the western transfer equipment (BioRad), sponge pads, blotting 
paper (8x pieces), nitrocellulose membrane and SDS-PAGE gel were soaked in 4oC transfer 
buffer for 15 min. The blot was assembled by placing the gel and the membrane with four 
pieces of blotting paper on either side, sandwiched by the sponges on either side. Once 
assembled, the transfer was run at 100V for 1 h in cold transfer buffer. Blots were then 
imaged for the presence of fluorescently labelled proteins using the BioRad Versadoc MP 
Imager, with the excitation-emission wavelengths of 493-518nm and 593-618 nm for 
Dylight®488 and Dylight®594-conjugated proteins, respectively. Visualising differences in 
fluorescence potency allowed for selection of the protocol producing the highest fluorescing 
product for optimal detection.  
 
4.1.3 Development of an In Vitro Release Profile to Model VEGF-E and vIL-10 Release 
from Calcium Alginate Cubogels  
4.1.3.1 General Reagents 
33% Acetic Acid FischerSci A/0400/PB17 
Alamar Blue Dye AlamarBlue™ (Thermofisher A50100), stored at 4oC 
in the dark 
Anti-FLAG® M2-Horseradish peroxidase (HRP) -
conjugated antibody  
Sigma Aldrich F3165, stored at -20oC in the dark 
Anti-FLAG® M2 Affinity Gel  Sigma-Aldrich, A2220, stored at -20oC 
Anti-human IgG-HRP antibody Invitrogen G-21234, stored at 4oC in the dark 
Ba/F3 Medium 20 mL heat-inactivated FBS, 8 mL geneticin (Gibco 
10131-035), 400 uL heparin (Sigma-Aldrich H-608), 
per 200 mL of DMEM 
Blocking Buffer 40 µL 10% Tween 20, 1g skim milk powder per 20 
mL of TBS. 
5% Calcium Chloride Solution 5g Calcium Chloride in 100mL milliQ water 
Coating Buffer 0.159 g sodium carbonate (Merck 
MER1063920500), 0.293 sodium bicarbonate 
(Merck MER1063290500), made up to 100 mL with 
milliQ water, then pH adjusted to 9.6 using 
concentrated HCl (32%). 
Chloroform Merck 107024, stored at RT 
0.025% Crystal Violet  0.25g crystal violet (Sigma-Aldrich C0775-25G) in 
1000mL milliQ water.  
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Tris-EDTA Buffer 1.21g TRIS base, 0.37g EDTA (Thermofisher 10080-
500g), 1L distilled water, 0.5mL 10% Tween20 
Foetal Bovine Serum (FBS) Sigma-Aldrich F8067-500mL, heat-inactivated at 
50oC for 20 minutes, stored at -20oC.  
Geneticin Gibco 10131-035, stored at 4oC.  
1mg/mL Heparin 1mg heparin (Sigma H-3393) in 1mL milliQ, filter-
sterilised in 0.22µM filter, stored at 4oC.  
HaCaT Medium 20 mL heat-inactivated FBS (sigma F8067-500mL), 
200 µL gentamycin, 400 µL hygromycin-B 
(ThermoFisher 10687010), 2 mL PSK per 200 mL of 
DMEM. 
Methanol Merck 106009, stored at RT.  
Monoolein Sapphire Bioscience, JBS0001672, stored at -20oC in 
a tube flooded with argon gas 
PBS 100 mL 10x PBS in 900 mL of milliQ water. 
PBS (Tissue Culture)  1 tablet per 100mL milliQ water, filter sterilised in 
0.22 µM filter, stored at RT.  
PBS-T 100 µL 10x PBS, 5 mL 10% Tween 20, in 900µL of 
distilled water. 
Pierce™ ECL Western Blotting Substrate  Thermo Scientific, 32106, stored at RT in the dark 
Poloxamer 127 (Pluronic F127) Sigma-Aldrich 9003-11-6, 0.3 %, stored at RT 
Reducing Sample Buffer  1 mL sample buffer, 50 µL 2-ME (Calbiochem, 
MERUS1444203-250ML).  
Sodium Alginate ECP Limited 420911, stored at RT 
Tris-Buffered Saline (TBS) pH 7.4 8 g NaCl, 0.2 g KCl, 3 g Tris base (NeoFroxx 
125KG001), in 1 L of milliQ water. Adjusted to pH 
7.4 using concentrated HCl (32%). 
TMB Substrate BD OptEIA 555214, stored at 4oC in the dark 
0.25%Trypsin  1 PBS tablet (Oxoid BR00146), 0.25 g trypsin 
(Sigma-Aldrich T4799-10G), 80 uL EDTA 
(ThermoFisher 10080-500g) In 100 mL milliQ.  
VEGFR-2-Ig Fusion Protein RnD Systems, 357-KD-050/CF 
Wash Buffer 1L TBS containing 2 mL of 10% Tween 20. 
WEHI-3 Medium  20 mL heat inactivated FBS, 2 mL PSK per 200 mL 
of DMEM. 
WEHI-3 Cellular Supernatant Filter sterilised using 0.22µM filter, stored at 4oC.  
 
4.1.3.2 Cubosome Synthesis  
Cubosomes were synthesised using a physical mixtures method[315] by melting 100 µg 
monoolein (Sapphire Bioscience, JBS0001672) in a 40oC water bath, then adding 40 µg 
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Pluronic F127 (Sigma-Aldrich 9003-11-6, 0.3 %). The mixture was dissolved in 500 µL 
chloroform and then evaporated in a fume hood using argon gas. To encapsulate protein, the 
cubosome mixture was added to a protein solution (500 µL), followed by vortexing for 5 
min. To examine release profiles, cubosome mixes were prepared containing 250 µg 
Dylight®488-CA or 10 µg VEGF-E. For animal studies, cubosome mixes containing 50 µg 
VEGF-E were prepared.  Control cubosomes were prepared in a similar manner using 500 
µL milliQ water.  
 
4.1.3.3 Hydrogel Preparation 
Hydrogels were prepared by dissolving 25 µg sodium alginate (ECP Limited 420911) in 
500µL milliQ water. The hydrogel mix was then added to an equal volume of cubosome mix 
or milliQ water, with the resulting solution vortexed until fully combined. Then 80 µL 
aliquots were made into 6 mm punch molds within a silicon sheet (Figure 4.1). Each gel 
contained 25 µg Dylight®488-CA, 1mg VEGF-E, or 5 µg VEGF-E for animal studies. Blank 
gels contained no protein. Molds were frozen overnight at -20oC before being placed in a 
glass desiccator to freeze dry for 4 hours. The alginate solutions were then physically 
crosslinked by the addition of 15 µL of 5% CaCl2, then frozen overnight and dried again. The 
hydrogel films were then stored in sterile bags at -20oC. 
 
Immediately prior to release, lyophilised gels were rehydrated using either 15 µL PBS, 30 
µg Dylight®594 BSA, 1mg vIL-10 or 400ng vIL-10 for animal studies. Each solution was 




Figure 4.1. Protein-Cubosome-Alginate Hydrogels Within 6mm Silicone Sheet Molds Prior to Freezing.  
Gels undergo lyophilisation, crosslinking with CaCl2 then further lyophilisation.   
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4.1.3.4 Protein Release In Vitro 
In vitro release experiments allowed for direct measurement of protein release from calcium 
alginate cubogel and contributed to the formation of an in vitro release profile for the delivery 
system. In vitro protein release experiments were set up in glass universals with steel mesh 
bottoms, underneath which was a flea magnet stir bar set to 100 rpm (Figure 4.2). The 
hydrated hydrogels with fluorescent proteins were added individually with 5 mL of PBS. 
Then to increase the sensitivity of detection, hydrated hydrogels with VEGF-E and vIL-10 
were added in triplicate to glass universals with 3 mL of PBS. For each experiment, 
cubosome-containing alginate hydrogels lacking protein (blank) were used as controls.  
 
 
The temperature was maintained at 37oC using a Heidolph MR Hei-Standard heat block for 
the entirety of the experiment, with tin foil used to prevent light quenching. Aliquots (1mL) 
were taken over the course of 6 days. For each sample taken, 1mL of PBS was added to the 
glass universal to replace that sample. In a further experiment to assess toxicity, the full 3 
mL was collected at 24 h, with the replacement volume collected at 72 h. Samples were stored 
at -80oC, prior to analysis. 
 
Figure 4.2. Experimental arrangement to Assess Protein Release from Cubosome-Alginate Hydrogels In 
Vitro. Three gels from the same preparation batch were hydrated with PBS, as indicated containing 
Dylight®594-BSA or vIL-10. The hydrogels were then incubated in PBS at 37oC with stirring for 6 days, with 
aliquots taken and replaced with fresh PBS over time.  
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4.1.3.5 Quantification of Fluorescently-Labelled Protein in Release Samples 
The amount of fluorescently-conjugated protein release across time was calculated using 
standard curves. Two serial dilutions were prepared with the Dylight®594-BSA and 
Dylight®488-CA, ranging from 100 µg/mL to 3.125 µg/mL in PBS. Absorbance at the Amax 
of each dye (Amax 488-493 nm and Amax 594-595 nm, respectively) was measured using the 
DeNovix DS-11 FX+ fluorometer (dnature).  A standard curve was plotted using Microsoft 
Excel, accompanied with the slope equation and R2 value for each curve.  
 Absorbance readings for fluorescent release samples were measured on the DeNovix 
DS-11 FX+ fluorometer. Each release sample underwent two readings – one for 
Dylight®594-BSA (Amax 594-595nm) and one for Dylight®488-CA (Amax 488-493nm). 
Readings for each were inserted into the equation calculated from the standard curves above 
to ascertain the amount of protein per release sample. Both actual and cumulative release 
values were calculated, where actual release represented the total amount of protein released 
per time point across three replicates, and cumulative release represented the total amount of 
protein released over the course of the experiment across three replicates.  
 
4.1.3.6 Quantification of  VEGF-E in Release Samples – Competitive VEGFR-2 binding 
ELISA 
A competitive VEGFR-2 binding ELISA was used as a replacement detection method for 
fluorescent VEGF-E labelling after they couldn’t be continued. This previously established 
method[212] allows for detection of VEGF-E in a release sample by premixing the release 
sample VEGFR-2-Ig fusion protein, and then adding the mixture to plate precoated with 
VEGF-A (Fig. 4.3). Remaining free receptor binds to the plate, and by washing off pre-bound 
VEGF-E-VEGFR2-Ig mix, VEGF-A bound receptor can be detected using an anti-IgG-HRP 
antibody. A higher signal would reflect low amounts of VEGF-E in the release sample, 
whereas lower signal indicates higher amounts. 
This protocol was first conducted using VEGF-E and VEGF-A titrations to ensure 
protein detection. Maxisorp 96-well immunoplates (Nunc) were coated with 50µL of 
400ng/mL VEGF-A diluted in coating buffer, leaving one column uncoated as a control. The 
plate was incubated overnight at 4oC, shaking, then washed with wash buffer, before 
incubation in blocking buffer for 45 min at 37oC, on a shaking platform. In a separate non-
adsorbent plate, VEGF-E and VEGF-A (positive controls) were titrated in duplicate from 
5000 ng/mL to 0.7 ng/mL in  75 µL PBS-T. Samples were incubated with 75 µL  of 300 
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ng/mL VEGFR-2-Ig fusion protein diluted in binding buffer for 1 h, at room temperature, on 
a shaking platform. This allowed for the VEGF samples to bind the VEGFR-2 protein. The 
VEGF-VEGFR-2 mixtures were then transferred to the coated and blocked wells, and 
incubated for 20 minutes. The wells were thoroughly washed to remove the soluble VEGF-
VEGFR complexes leaving only the VEGFR bound to the VEGF-A-coated well. The Ig-tag 
on the VEGFR-2 fusion protein was next detected using 50µL anti-human IgG-HRP antibody 
(Invitrogen G-21234, diluted 1:500 in PBS-T), following incubation for 1 h or 20 min, at 
room temperature, on a shaking platform. TMB substrate (BD OptEIA 555214, 50 µL/well) 
was then added, and the plate incubated in the dark for 5-15 min to obtain a mid-blue colour 
with an optical density of 1.0 in the positive control column. The reaction was stopped with 
50 µL/well 2M H2SO4, and the absorbance of the plate read at 450 nm.   
 This method was not used to detect VEGF-E from calcium alginate cubogel release 
samples, due to its lack of sensitivity.  
 
4.1.3.7 Quantification of VEGF-E in Release Samples – VEGFR-2- Ba/F3 -bioassay 
A bioassay using VEGFR-2 Ba/F3 cells was trialled as an alternative to the competitive 
VEGR-2 binding ELISA after adequate sensitivity could not be reached. Ba/F3 cells are a B 
cell line that proliferate in response to IL-3, which can be provided via the supernatant of 
WEHI-3 cells[316]. Modified Ba/F3 cells expressing a fused VEGFR-2-erythropoietin 
receptor can proliferate in the absence of IL-3, provided there is activation of the VEGFR-2 
receptor[317]. Therefore, VEGF-E contained in release samples can be measured in the form 
Figure 4.3. Schematic Representation of Competitive VEGFR-2 Binding ELISA. (1) a 96-well plate is coated 
with 400ng VEGF-A (2) a pre-mixture of VEGFR-2-Ig and VEGF-E is added to the coated plate, such that 
unbound R-Ig will bind to VEGF-A coating the plate (3) VEGF-E-VEGFR-2-Ig mixture is washed off with 
wash buffer, leaving the R-Ig bound to the VEGF-A on the bottom of the plate. Signal can be detected using 
anti-IgG-HRP antibody, such that more VEGF-E in the sample is proportional to a lower signal. Made using 
Biorender.    
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of a proliferative response observed in Ba/F3 cells. AlamarBlue™ is a blue non-fluorescent 
dye that is permeable to cell membranes and is converted by metabolically active cells to 
pink fluorescent resorufin[318]. Proliferation of Ba/F3 cells can therefore be measured via the 
fluorescence intensity of the resorufin product. Ba/F3 cells were cultured in DMEM 
supplemented with heat-inactivated FBS, geneticin and heparin, in flasks kept at 37oC (5% 
CO2)  
VEGF-E (positive control) was serially diluted in triplicate from 1000 ng/mL to 0.06 
ng/mL in 100 µL PBS in a sterile flat-bottom 96-well tissue culture plate (CellStar 655180). 
Release samples from cubosome-hydrogels containing VEGF-E (24 h) were also serially 
diluted in triplicate.  
 VEGFR-2- Ba/F3 cells (1.25x104 in Ba/F3 Medium) were added to each well of a 
sterile tissue culture plate, before transferring  100 µL of the VEGF-E and release sample 
dilutions to the cells. One column of cells was treated with Ba/F3 media containing 10 µL/mL 
WEHI-3 cellular supernatant as a positive control. Plates were then incubated in a humidity 
chamber for 48 h at 37oC with 5% CO2. Afterwards, 10 uL of AlamarBlue™ (Thermofisher 
A50100) was added to each well, then the cells were incubated for a further 4 h. Fluorescence 
intensity of the resorufin product was measured on the ClarioStar multi-mode microplate 
reader (BMG Labtech, Alphatech Systems, Ltd. NZ) at an excitation-emission wavelength 
of 560-590 nm.  
 In order to calculate cell number in the above experiment, a standard curve of cell 
number was conducted using cell densities of 2´106 cells/mL to 6.725´104 cells/mL. BaF3 
cells were collected and diluted to 2´106 cells/mL in Ba/F3 medium, before being titrated 
1/2 in Ba/F3 medium. A no-cell, medium-only control was used to measure any background 
fluorescence. 10 µL/well AlamarBlue™ was added to each well and incubated for 4 hours, 
before measuring the fluorescence intensity at an excitation-emission wavelength of 560-590 
nm. A standard curve was plotted using Microsoft Excel, accompanied with the slope 
equation and R2 value for each curve. Fluorescence readings from VEGF-E and release 
sample-treated wells were inserted into the equation calculated by the standard curve to 
ascertain cell number.  
 
4.1.3.8 Quantification of VEGF-E and vIL-10 in Release Samples – Immunoprecipitation, 
SDS-PAGE and Western Blotting 
Immunoprecipitation using Anti-FLAG® M2 Affinity gel allowed for concentration of the 
protein contained in release samples, which could then be measured using SDS-PAGE and 
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western blotting. By measuring concentrated amounts of protein from a large volume, the 
sensitivity of detection of protein could be enhanced.  Release samples (550 µL) were 
incubated with 10µL of ANTI-FLAG® M2 Affinity gel at room temperature, for 2 h, on a 
shaking platform. The gel and bound FLAG-tagged proteins were pelleted by centrifugation 
using the Biofuge Fresco centrifuge at 16000 ´ g  for 5 min, the supernatant removed and 20 
µL of reducing sample buffer added. Boiled samples (20 µL),  VEGF-E and vIL-10 control 
proteins (600 - 4.69 ng) and full-range rainbow marker (3 µL) were then loaded into an SDS-
PAGE gel and subjected to electrophoresis as previously described.    
Western transfer equipment was assembled, and the proteins transferred to a 
nitrocellulose membrane as previously described. After transfer, the membrane was 
incubated in blocking buffer overnight at 4oC, on a shaking platform. The next day, the 
membrane was rinsed 3x in wash buffer for 5 min, before adding 3 µL anti-FLAG® M2-
Horseradish peroxidase (HRP)-conjugated antibody (Sigma Aldrich F3165 diluted in 10 mL 
wash buffer), followed by incubation for 1 h at room temperature, on a shaking platform. The 
membrane was then rinsed 3x in wash buffer for 5 min. FLAG-tagged proteins were then 
visualised using the Pierce™ ECL Western Blotting Substrate (Thermo Scientific, 32106), 
with 1 mL of each substrate added 5 min prior to imaging. Chemiluminescent signals were 
imaged using the BioRad Versadoc MP Imager. The integrated densities of the control and 
released FLAG-tagged proteins were measured using ImageJ.  
Standard curves for VEGF-E and vIL-10 were plotted using Microsoft Excel based 
on the known concentration and integrated density of the VEGF-E and vIL-10 proteins. The 
slope equation and R2 value for each curve allowed for calculation of protein amounts in each 
of the release samples by inserting their integrated densities into the equation. Background 
densities were included for all measurements and subtracted from the protein bands. To 
control for blot-to-blot variation, 200 ng of each control protein was included on each gel 
and the values normalised to those of the standard. Both actual and cumulative release values 
were calculated, where actual release represented the total amount of protein released per 
time point across the replicates, and cumulative release represented by the total amount of 
protein released over the course of the experiment across the replicates. 
 
4.1.3.9 Toxicity of Release Samples on Human Skin Cells   
To assess whether the cubogels were safe for human skin cells, a crystal violet assay was 
conducted using HaCaT keratinocytes, a commonly used immortalized keratinocyte cell 
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line[319]. Keratinocytes are the predominant cell type in the epidermal layer and as such they 
are a good cell type to assess skin toxicity[1, 319].  
HaCaTs were cultured in DMEM supplemented with heat-inactivated FBS, 
gentamycin, hygromycin and PSK, in flasks kept at 37oC (5% CO2). Viability of HaCaTs 
treated with release samples was measured using crystal violet, a dye that binds to proteins 
and DNA within the cell[320]. This assay is used to indirectly assess death of adherent cells, 
based on the principle that dead cells detach from the plate and are removed, prior to fixing 
and staining[320].  
To assess the viability of keratinocytes treated with cubogel release samples, HaCaTs 
were trypsinised, counted and seeded at a density of 1x105 cells/well in 100 µL HaCaT 
medium into a sterile 96-well plate, and incubated for 24 hours at 37oC (5% CO2) to allow 
for attachment. Cubogel components, including pluronic F127, sodium alginate, calcium 
chloride and monoolein cubosomes were titrated in 100 µL PBS  according to Table 4.3. A 
monoolein cubosome suspension containing PF127 was used instead of direct monoolein, as 
the viscosity of the monoolein made it difficult to accurately measure.  
 
Table 4.3. Components of Cubosome-Alginate Hydrogels and Their Estimated Concentrations Per Release 
Preparation* 
Component Amount Added Per Hydrogel  
Estimated Concentration per mL 
of Release Sample 
Concentration 
Range Tested 
Pluronic F127 4 mg 4 mg/mL 0 - 32 mg/mL  
Sodium alginate 2.5 mg 2.5 mg/mL 0 – 20 mg/mL 
Calcium chloride 15 µL of 5% solution (750 µg) 750 µg/mL 0 – 6 mg/mL 
Monoolein cubosomes 
(MO + PF127) 
 
10 mg 10 mg/mL 0 – 40 mg/mL  
 *Each release preparation consisted of three cubogels in 3mL PBS 
 
After 24 hours, fresh HaCaT medium replaced the existing media before adding 100 µL of 
each sample dilution to the HaCaT cells. Control cells were treated with 100 µL PBS. The 
plate was incubated for 48 h at 37oC (5% CO2). The media was then discarded, and the wells 
were washed 3x with PBS. The plate was dried on a piece of tissue paper, before fixing the 
cells with 100% methanol (50µL per well) for 3 min. The wells were washed again with PBS 
then 0.025% crystal violet was added for 5 min so as to stain cellular protein and nucleic 
acids. The wells were then washed and dried thoroughly in the fume hood. Finally, 33% 
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acetic acid was added to solubilise the crystal violet dye, and the absorbance of wells was 
read immediately at 595 nm.  
In order to calculate cell number in the above experiment, a standard curve of cell number 
was conducted using cell densities of 3.2´106 cells/mL to 1´105 cells/mL. HaCaT cells were 
trypsinised and diluted to 2´106 cells/mL in HaCaT medium, before being titrated 1/2 in 
HaCaT medium. A no-cell, medium-only control was used to measure any background 
absorbance – this was subtracted from all absorbance readings prior to calculating cell 
number. Cells were incubated for 6 hours until attached to the plate, before fixing and staining 
as previously described. A standard curve was plotted using Microsoft Excel, accompanied 
with the slope equation and R2 value for each curve. Absorbance readings from release 
sample-treated wells were inserted into the equation calculated by the standard curve to 
ascertain cell number. 
 
 In Vivo Techniques 
4.2.1 General Materials   
Ketamine (75mg/kg) Pre-loaded doses in 29g syringes, kept at room 
temperature  
Domitor (1mg/kg) Pre-loaded doses in 29g syringes, kept at room 
temperature 
Atropine (0.05mg/kg) Pre-loaded doses in 29g syringes, kept at room 
temperature 
Amphoprim (10.2mg/mL) Pre-loaded doses in 29g syringes, kept at room 
temperature 
Bupivacaine (2mg/kg) Pre-loaded doses in 29g syringes, kept at room 
temperature 
10% Povidone-iodine Betadine antiseptic topical ointment® 
Filter-sterilised 0.9% saline 9 g NaCl (Merck 1064045000) in 1000 mL milliQ 
water, filter-sterilised in a 0.2 µM syringe filter, 
stored at RT  
Filter-sterilised PBS 100 mL 10x PBS in 900 mL of milliQ water, filter-
sterilised in a 0.2 µM syringe filter, stored at RT 
Sterile surgical equipment Autoclaved surgical drapes, sterile forceps 
Hair removal cream and applicator  - 
Polyvisc™ eye ointment  - 
Zinc Salts Fixative 6.05g TRIS base, 0.25g calcium acetate, 2.5g zinc 
acetate, 2.5g zinc chloride, 500mL milliQ, pH to 7.4 
using concentrated HCl (32%).  
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70% Ethanol 70mL 96% ethanol (MER241003192500) in 30mL 
distilled water 
10x Phosphate-Buffered Saline (PBS)  80g NaCl, 2g KCl, 11.35g Na2H2PO4, 2g KH2PO4, in 
1L milliQ 
1x PBS 100mL 10x PBS in 900mL MilliQ 
10x Tris-HCl Stock (0.5M) 60.55g TRIS base dissolved in 1L dH2O pH adjusted 
using HCl  
10x NaCl Stock (1.5M) 87.66g NaCl dissolved in 1L dH2O.   
Tris-Buffered Saline (TBS) pH 7.6 100mL 10x Tris-HCl stock, 100mL 10x NaCl stock, 
800mL dH2O.  
Staining Diluent 1mL TBS, 10mg BSA, 5uL TritonX-100 
10% Triton-X 100 0.5g Triton-X100 (Sigma X100-500mL) in 5mL 
milliQ.  
 
4.2.2 Ethics, Species and Handling 
Animal procedures were conducted following approval from the Animal Ethics Committee 
of the University of Otago (AUP-19-23) dated 16 June 2019. Animals were sourced and 
housed in the Hercus-Taieri Resource Unit (Dunedin, New Zealand). 
 Female mice were used in the experiment in order to keep continuity from previous 
experiments[227, 229]. There are known sex differences in the skin structure of male and female 
mice including a thicker dermis in males and a thicker hypodermis and epidermis in females, 
contributing to a much thicker skin overall in male mice[321]. For the same reason, species 
and age remained continuous with previous experiments[227, 229].  
Female C57BL/6 mice (8 weeks old) were split into four groups of n=4 as outlined 
in Figure 4.4. Mice were ordered in two groups of 8 (n=2 per group for each experiment), to 
facilitate easier handling and post-operative monitoring. Mice were ordered approximately 7 
days prior to surgery to undergo repetitive handling, to reduce physiological stress at the time 
of the experiment[322].   
 
4.2.3 Cutaneous Wounding  
Mice were anaesthetised using a combination of ketamine (75 mg/kg), domitor (1 mg/kg) 
and atropine (0.05 mg/kg), injected into the inguinal region. Anaesthesia was confirmed 
using the pedal reflex.  Anaesthetised mice were shaved on the dorsal region before injection 
of amphoprim (10.2 mg/mL) subcutaneously into the scruff for prophylactic antibiotic 
administration, as well as bupivacaine (2 mg/kg) subcutaneously around the wounding site 
for localised pain relief. The skin was then disinfected with 10% povidone-iodine and washed 
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with a sterile gauze swab and sterile saline. Once the wounding site was prepared, the skin 
of the dorsal region was isolated by pinching the dorsal skin and pulling upwards. Two full-
thickness excisional wounds were made by applying a 6 mm diameter sterile biopsy punch 
through two layers of the skin. Treatments were applied as described. Anaesthesia was 
reversed using anti-sedan (5mg/kg) injected into the inguinal region and 0.5 mL 0.9% saline 
was administered subcutaneously to the scruff in order to rehydrate.  
 
4.2.4 Wound Treatment with the Cubosome-Alginate Hydrogels  
In order to assess the biocompatibility and efficacy of the dual delivery system in vivo, it was 
compared to direct protein and saline controls. Protein was purified by Gabriella Stuart, 
Department of Pharmacology, and cubosome-alginate hydrogels were synthesised by Jaydee 
Cabral, Department of Chemistry. 16 mice were split into four treatment groups (n=4 per 
group), including topical PBS, topical protein (VEGF-E 4 µg and vIL-10 400 ng), alginate 
hydrogel applied to the wound, hydrated by 15 µL PBS, and VEGF-E (4 µg)-cubosome-
alginate hydrogels applied to the wound, hydrated by vIL-10 (400 ng) in PBS (see figure 
4.4).  
 
Each wound on the mouse received the same treatment to prevent cross-contamination of 
treatments. To administer topical treatments, 50 µL of treatment (PBS alone or PBS 
containing VEGF-E (4 µg) and vIL-10 (400 ng)) was applied to the wound using a sterile 
Figure 4.4. Methods of Cutaneous Wounding for In Vivo Experiments. 16 mice were randomly allocated 
into four groups: topical saline, cubosome-alginate hydrogel, topical protein and VEGF-E Cubosome vIL-
10-Alginate Hydrogel (n=4 per group). Made using Biorender.  
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pipette. Wounds were then dressed with TegadermTM , an occlusive but clear acrylic dressing, 
with one dressing per wound, taking care not to apply the TegadermTM over the midline. 
To administer hydrogel treatments, 4 mm diameter freeze-dried samples were placed into 
each wound using sterile forceps, then 25 µL of sterile PBS, with or without vIL-10 (400 ng), 
was added to hydrate the sample. Lyophilised discs were hydrated in situ to aid hydrogel 
attachment. The hydrogels were then left on the wound for 5-10 min to adhere. Wounds were 
then dressed with TegadermTM , an occlusive but clear acrylic dressing, with one dressing 
per wound, taking care not to apply the TegadermTM over the midline. 
 
4.2.5 Post-Operative Monitoring 
Following surgery, monitoring for adverse events in the mice was continued every 30 
minutes for 4 hours after activity was restored. From days 1-5, mice were monitored twice 
daily for weight changes, pain or other post-operative complications as outlined in Table 4.4.  
 
Table 4.4. Parameters Measured During Post-Operative Monitoring of Mice Following Cutaneous Wounding 
Post-Operative Parameter Symptoms Proposed Treatment 
Weight loss Significant (>20%) loss of weight 
compared to pre-operative values.  
>20% weight loss 
considered endpoint, 
animal must be 
euthanised.  
Dehydration Skin turgor test shows skin does not 
bounce back quickly  
Subcutaneous saline 
injection at the scruff.  
Bleeding Significant blood around the wound. Cleaning of the wound.  
Pain Squinted eyes, high BAR score, 
twitching, belly pressing, writhing, 
staggering. 
Bupivacaine (2mg/kg) to 
the site under gaseous 
anaesthesia.  
Wound infection Significant pus at the wound site. Amphoprim (10.2mg/kg) 
to the wound site under 
gaseous anaesthesia, 
drainage of fluid.   
Bandage irritation Redness or scabbing around the 
dressing border from chewing or 
scratching.  
If there are any signs of 
pain or infection 
associated with the 
irritation, treat as above.  
Bandage loss Chewing or ripping of the 
TegadermTM around the wound site, 
exposing the wound.   
May require replacement 
of the bandage under 




Pain was monitored using the BAR (bright, alert, responsive) score and the mouse 
grimace scale[323]. Weight loss exceeding 20% of the original weight was considered a critical 
endpoint and required euthanasia. Bleeding, pain, infection and irritation could be managed 
with pharmacological intervention or drainage in the case of infection. Bandage loss, often 
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due to chewing, could be rectified by replacing the Tegaderm™ as soon as possible after 
removal. If the wound was dried out and had contracted, it was removed as a data point. 
 
4.2.6 Euthanasia and Harvesting  
Mice were euthanised in a CO2 chamber, before the wounded skin was excised. Any 
subcutaneous fat was removed using a scalpel before wounds were cut in half. The lateral 
side of each wound was placed in a cassette before being fixed in zinc salts fixative for 48 h. 
Cassettes were then transferred to 70 % ethanol to dehydrate for 24 h before being transferred 
for embedding.  
 
4.2.7 Tissue Processing  
Tissues were embedded in paraffin wax and sliced into 4 µM sections using a microtome. 
Wounds were sectioned to the centre of the tissue for histology and immunohistochemistry, 
and sections from the outer edges were discarded.  
 
4.2.8 Histology  
Martius Scarlet Blue (MSB) is a trichrome stain consisting of Martius Yellow Solution, 
Brilliant Crystal Scarlet and 0.5% Methyl Blue. MSB was used to stain collagen blue, red 
blood cells yellow, and fibrin and muscle fibers red. The protocol for MSB staining is 
described in table 2.5.  
 
Table 4.5. Reagents and Steps Required for MSB Staining 
Step Duration 
Wash in tap water 30 seconds 
Gill Hematoxylin 5 minutes 
Wash in tap water 2 minutes 
Scott’s tap water 2 minutes 
Wash in tap water 2 minutes 
95% alcohol 1 minute 
Martius Yellow Solution 3 minutes 
Distilled water 3 ´ 1 minute 
Brilliant Crystal Scarlet 10 minutes 
Distilled water 3 ´ 1 minute 
1% Phosphotungstic acid 4 minutes 
Distilled water 1 minute 
0.5% Methyl Blue 45 seconds 
1% Acetic Acid 1 minute 
 
After staining, sections were dehydrated in 100% ethanol and xylene before being mounted 
using DPX mounting medium. Once the slides were dry, they were imaged using an Olympus 
BX51 microscope at 10´ magnification under white light, using a digital camera and 
CellSens software (https://www.olympus-lifescience.con/en/software/cellsens). The 
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individual images were merged into an image of the entire section using Adobe Photoshop 
(https://www.adobe.com/nz.products/photoshop).  
 
4.2.9 Immunohistochemistry General Protocol 
Paraffin-embedded 4 µm sections were dried overnight at 37oC before being deparaffinised 
and rehydrated by immersing in xylene for 15 minutes, then 100% ethanol, 100%, 90% and 
70% propan-1-ol for 30 seconds each, 0.85% NaCl solution and PBS for 30 minutes. After 
deparaffinisation and rehydration, antigen retrieval was conducted either in tris-buffered 
saline (TBS, pH 7.6) at 37oC for 20 minutes, or in a sodium citrate buffer (pH 6.0) at 95oC 
for 20 minutes in a Decloaking apparatus, and were then cooled before subsequent steps. To 
prevent non-specific antibody binding to Fc receptors on immune cells within the sections, 
40µL of Fc block (1:700 dilution in PBS, BD Bioscience, No. 553141) was added followed 
by 30 minutes incubation in a humidity chamber.  
Anti-CD206 antibody was used to detect M2 macrophages. Antibodies against 
MAC387 and iNOS were used to detect M1 macrophages. Antibodies against vimentin and 
alpha-smooth muscle actin (aSMA) were used to detect fibroblasts and myofibroblasts. 
Antibodies against CD31 and collagen IV were used to detect endothelial cells and the 
basement membrane of blood vessels, respectively. Primary antibodies were diluted as 
described (table 4.6) in staining diluent (10mg BSA, 1mL TBS, 5µL TritonX-100 (10%)), 
then 20µL was mixed with the Fc block. The slide was then incubated in a humidity chamber, 
either overnight at 4oC, or for 2 hours at room temperature. Slides were then washed 3 times 
in TBS at room temperature. Where needed, secondary antibodies were diluted as described 
in staining diluent, then 20µL was added to the slide, followed by incubation for a further 2 
hours at room temperature. Slides were washed again 3 times in TBS before adding 20µL 
4’,6-diamidino-2-phenylindole (DAPI, diluted 1:50 in staining diluent, Invitrogen No. 
D3571) to each slide and left for 30 minutes at room temperature. Slides were then washed 
3 times in TBS, then the sections were mounted in 7µL Slow Fade Gold (Invitrogen No. 
S36936), covered with a coverslip and sealed. Slides were stored at 4oC before imaging using 
the Olympus BX-51 microscope and the CellSens software. Digital photographs were taken 
using the Olympus BX51 microscope at 20 ´ magnification using a digital camera and 
CellSens software ((https://www.olympus-lifescience.con/en/software/cellsens). 
Dylight®488 or FITC antibodies were imaged at 488 nm, Dylight®594 antibodies at 594 
nm, and DAPI at 405 nm. The individual images were merged into an image of the entire 
section using Adobe Photoshop (https://www.adobe.com/nz.products/photoshop). 
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Table 4.6. A Description of the Antibodies Used for Immunofluorescent Staining of Mouse Wound Sections 
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Topical delivery of growth factors and cytokines to wounds within the clinical context has 
largely failed due to the incompatibility of the wound environment. Low active 
concentrations of proteins due to proteolytic degradation, as well as stimulation of the 
immune response and systemic leakage have contributed to the large-scale failure observed. 
Biomaterials have been proposed as a means to overcome these shortcomings, allowing for 
controlled and tailorable delivery of growth factors and cytokines to the wound, while also 
providing protection against degradation. Combinations of the biocompatible natural 
biomaterials, mechanically strong synthetic biomaterials, and composite nanoparticles create 
an opportunity for a diverse range of specific delivery systems that can target different 
aspects of the healing cascade within the same treatment.  
 The aim of this section was to develop and test a composite growth factor and 
cytokine delivery system to enable phasic regulation of wound inflammation and repair. 
VEGF-E and vIL-10 are viral proteins that have been shown to enhance wound repair in vitro 
and in vivo, as monotherapies and as a combination[182, 222, 227-230, 324]. vIL-10 was chosen 
because it has been shown to limit excessive inflammation and fibrosis, while VEGF-E has 
been shown to promote wound re-epithelialisation and re-vascularisation. Together, these 
proteins modulate three phases of wound healing, accelerating wound closure while reducing 
scarring.  
It was hypothesised that biphasic release of these proteins would allow for more 
specific targeting of the wound healing cascade, and therefore an enhanced response. vIL-10 
was targeting the inflammatory phase of healing, therefore it required faster release than 
VEGF-E, which targets the proliferative phase. To enable this, the proteins were encapsulated 
within a calcium alginate cubosome hydrogel system. Alginate is a biocompatible, non-
immunogenic,  naturally-derived hydrogel that degrades to release proteins relatively quickly 
– optimal for vIL-10 targeting of inflammatory responses. Incorporation of a lipid cubosome 
particle encapsulating VEGF-E would allow for more delayed release of this protein to target 
the later proliferative phase of healing.  
 The first aim of this section was to prepare a calcium alginate hydrogel system 
encompassing vIL-10 and VEGF-E-laden cubosomes, and to determine the in vitro release 
profile for VEGF-E and vIL-10 from this delivery system. The release kinetics of the gel 
were first assessed using fluorescent test proteins before assessing VEGF-E and vIL-10. 
Next, the biocompatibility of the system and its components were tested on human skin cells 
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to ascertain any toxicity. Finally, the biocompatibility and efficacy of the system was 
assessed in a murine full-thickness excisional wound model.  
 
 Development and In Vitro Testing of a Cubosome-Alginate Hydrogel for Delivery of 
vIL-10 and VEGF-E 
5.2.1 Optimisation of Dylight®488 and Dylight®594 Conjugation to BSA and CA 
The first aim of this section was to produce a labelling protocol that produced the best quality 
conjugation of the fluorescent dye to the protein. A strong association of dye particles to the 
protein was required to allow for the most sensitive detection of low concentrations of protein 
in the release experiments. The control proteins bovine serum albumin (BSA) and carbonic 
anhydrase (CA) were used to develop these protocols. Three different amounts of protein 
were used in the reaction – 5, 20 and 100µg, with the same amount of dye used per reaction.  
Figure 5.1A and B show the absorbance spectra for Dylight®594-conjugated BSA 
protocols 1-3 (Fig. 5.1D) and Dylight®488-conjugated CA protocols 1-3 (Fig. 5.1E). 
Figure 5.1. Optimisation and Assessment of Dylight®594 and Dylight®488 Conjugation to Test Proteins. 
Conjugated proteins were prepared using three different protocols (P1-P3), and analysed for quality of 
labelling (A) absorbance spectra of Dylight®594-BSA and (B) Dylight®488-CA, measured using a 
fluorometer at increments of 1nm in wavelength. (C) Degree of labelling for each protocol was calculated 
using the A280 and Amax for both proteins (D,E) 4 µg of Dylight®594-BSA and Dylight®488-CA were 
resolved by SDS-PAGE and then transferred to a nitrocellulose membrane. Fluorescent dye on the protein 
was detected by fluorescent imaging using a 610BP filter, for fluorescence between (D) 593-681nm (E) 493-
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Absorbance peaks at 280nm are representative of the protein concentration, while absorbance 
peaks at Amax are representative of the protein fluorescence (Amax 488= 493nm, Amax 594= 
595nm).  
In figure A, increasing BSA concentrations across the protocols are correctly 
reflected in the A280 peaks, with the 5, 20 and 100µg protocols showing fluorescence 
intensities of 23.69, 40.25 and 56.95nm, respectively. Figure B shows the same for increasing 
CA concentrations, with 5, 20 and 100 µg protocols showing fluorescence intensities of 3.78, 
4.35 and 4.92nm, respectively. CA consistently showed a much lower absorbance than the 
BSA for both A280 and Amax but showed the same trend across protocols.  
While protocol 3 showed the highest absorbance at Amax for both proteins (Fig. 5.1A 
and B), the degree of labelling decreased from protocol 1 to protocol 3, as shown in figure 
5.1C. BSA conjugated in protocol 1 had 6.34 moles of dye per mole of protein, while protocol 
3 had 3.46 moles of dye per mole of protein. CA labelling had a similar trend, with protein 
conjugated in protocol 1 having a high degree of labelling (9.35 moles of dye per mole of 
protein) compared to protocol 3 (2.46moles dye per mole of protein).  
Imaging of the Dylight®594-BSA and Dylight®488-CA following western blotting 
showed that in both cases, protocol 1 (using 5µg protein) produced the greatest fluorescence 
intensity when an equivalent amount of protein was loaded per lane (Fig. 5.1). The 
fluorescence intensity associated with each protein then decreased with the labelling 
protocols that contained increased amounts of protein (Fig. 5.1). This was consistent with the 
number of moles of dye per mole of protein calculated (Fig 5.1). The amount of BSA and 
CA labelling was considered sensitive enough to use for in vitro protein release experiments, 
with protocol 1 selected for further labelling procedures. 
 
5.2.2 In Vitro Release of Test Proteins from a Cubosome-Alginate Delivery System  
Dylight®488-CA and Dylight®594-BSA were chosen to replicate VEGF-E and vIL-10, 
respectively. Dylight®488-CA was encapsulated within lipid cubosomes for delayed release, 
and Dylight®594-BSA was used to hydrate the lyophilised hydrogel films for fast release. 
Release was measured in vitro over 6 days, with samples taken at day 1, 2, 4 and 6. 
Fluorescence of release samples were measured using a fluorometer and converted to protein 
amount using standard curves for both proteins. 
As shown in figure 5.2A, Dylight®594-BSA showed a small burst release within 1 day, 
peaking at 46.37 ± 7.5 ng, with continued release across the 6-day time frame. Dylight®488-
CA showed delayed release that peaked at day 4 (14.9 ± 2.7 ng). While the release kinetics 
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matched the hypothesised pattern, cumulative release (figure 5.2B) showed a maximum 
release of 121.8 ± 21.5 ng for Dylight®594-BSA and 33 ± 6 ng for Dylight®488-CA, when 
the actual loaded amounts were 40 µg and 30 µg, respectively. This considerably smaller 
amount of fluorescent protein detected in the system could be explained by poor sensitivity, 
which would be problematic in detecting VEGF-E and vIL-10. Therefore, it was concluded 
that fluorescent conjugation was not an appropriate method of measuring protein release, and 
that alternatives should be sought.  
 
5.2.3 In Vitro Release of VEGF-E and vIL-10 from a Cubosome-Alginate Delivery System 
5.2.3.1 Purification and Concentration of VEGF-E and vIL-10 
VEGF-E and vIL-10 were produced using transfected HEK293 cell lines, and the proteins 
were purified from the cell supernatant by affinity chromatography using anti-FLAG M2 
affinity gel specific to the protein-FLAG fusions. Protein quantitation was done using SDS-
PAGE and Coomassie R-250 staining to ascertain the protein concentrations for further 
experiments. VEGF-E produced a final concentration of 300.02 ng/µL, while vIL-10 
produced a final concentration of 327.47 ng/µL. Under reducing conditions, a wide band of 
24KDa was observed for VEGF-E, consistent with its homodimeric nature[218] (Fig. 5.3). 
vIL-10 was observed in a singular band around 20KDa.  
  
Figure 5.2. In Vitro Release of Dylight®594-BSA and Dylight®488-CA From a Cubosome-Alginate 
Delivery System. Calcium alginate hydrogels containing 40 µg Dylight®594-BSA (fast release) and 30 µg 
cubosome-encapsulated Dylight®488-CA (slow release) were incubated in 5 mL PBS for 6 days, and 
samples taken on days 1, 2, 4 and 6. Fluorescence measurements were taken for each sample using a 
fluorometer at wavelengths of 593-681nm (Dylight®594-BSA) and 493-518nm (Dylight®488-CA). 
Absorbances were converted to protein amount using standard curves for both proteins. Data presented as 
(A) actual and (B) cumulative release, mean ± SEM, n = 2 experimental replicates.  
(A) (B)
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5.2.3.2 Measuring VEGF-E Release In Vitro 
 Due to the lack of sensitivity encountered with the release of Dylight®594-BSA and 
Dylight®488-CA, and issues in the supply of labelling reagents, a competitive VEGFR-2 
binding ELISA and Ba/F3 bioassay were tested for their ability to detect VEGF-E. The 
VEGFR-2 binding ELISA measures direct receptor binding of protein-containing samples, 
and using a standard curve, the amount of protein released over a time course could be 
ascertained. The Ba/F3 bioassay is based on cell proliferation in the VEGFR-2-dependent B-
cell line, where a standard curve could be used to measure VEGF-E amounts in a sample.  
 Firstly, standard curves for both VEGF-A and VEGF-E were tested in both assays to 
optimise experimental conditions. In the VEGFR-2 ELISA, VEGF-A showed good receptor 
binding activity, similar to that previously published[212] (Fig. 5.4A). However, consistent 
issues were encountered with VEGF-E samples over a number of purifications, with no 
receptor response observed (Fig. 5.4A). A number of potential error points were identified 
after the first trial, and 3 modifications proposed – firstly, reduction of incubation time to 
control for any receptor disassociation, secondly, conducting the assay with fresh 
purifications. Unfortunately, neither of these modifications restored the expected receptor 
response, beyond a decrease to 42% with the third purification, a reduction of capture time 
to 20 minutes. Despite achieving a trend towards the sigmoidal decrease that has been 
previously observed, values were still variable and unreliable.  
The Ba/F3 bioassay was more successful, showing a good proliferative response with 
both proteins from 0.2-100ng, and proliferation plateauing at 25 ng/mL (Fig. 5.4B).  
CA 
3µL   8µL  20µL
VEGF-E 
3µL   8µL  20µL 
vIL-10 





Figure 5.3. Quantification of vIL-10 and VEGF-E Using Affinity Chromatography and SDS-PAGE. 
Supernatant from HEK-293s transfected with vIL-10  and VEGF-E plasmids were collected and protein 
purified using affinity chromatography. Protein was concentrated and then run on SDS-PAGE. SDS-
PAGE gel was stained with Coomassie R-250 and OD read. Concentrations of vIL-10 and VEGF-E were 
calculated by comparing to a CA standard.  
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While the competitive VEGFR-2 binding ELISA was not sensitive enough to detect 
VEGF-E, the Ba/F3 bioassay looked promising at higher concentrations, therefore, release 
samples were next trialled in this assay.  Cubosome-alginate hydrogels were made and 
released in vitro as previously described. Release samples from cubosome-alginate hydrogels 
were titrated in PBS from 1 to 1/64.  
Three different hydrogels were tested – cubosome-alginate hydrogels (no protein, 
hydrated with PBS), cubosome-alginate hydrogels hydrated with 1 µg VEGF-E, and 
cubosome-alginate hydrogels containing 1µg VEGF-E, hydrated with PBS. When release 
samples were incubated with Ba/F3 cells, dramatically reduced cell number was observed as 
far as the ¼ dilution factor (Fig. 5.5). This toxicity was consistent across all three hydrogel 
types, indicating that it was not a VEGF-E-dependent response and was more likely related 
to a component of the cubosome-hydrogels themselves.  







































Figure 5.4. Detection of VEGF-E Using (A) Competitive VEGFR-2 Binding ELISA and (B) Ba/F3 
Bioassay. (A) Soluble VEGFR2-Ig fusion protein was incubated with increasing concentrations of VEGF-
A and VEGF-E. The mixture was then added to VEGF-A-coated wells to capture unbound VEGFR2-Ig, 
which was detected with an anti-human IgG-HRP antibody. Results are presented as the percentage of the 
maximal absorbance of VEGFR-Ig bound minus the background (no receptor). +ve control shows no 
VEGF-E + receptor. Values are represented as the mean ± SEM (n=3 technical replicates). (B) Proliferative 
response of VEGFR2-dependent Ba/F3 by VEGF-A and VEGF-E. Cells were seeded at a density of 
1.25x104 per well and incubated for 48 hours with VEGF-A or -E serially diluted from 1000ng/mL to 
2ng/mL. WEHI supernatant was used as a positive control. 10µL/well alamarBlue™ was added and 
incubated for 4 hours at 37oC (5% CO2). Fluorescence intensity at 595nm was measured on the ClarioStar 
multi-mode microplate reader. Data is represented as cell number ± SEM, calculated by a standard curve 
and normalised to media only fluorescence readings (n=3 technical replicates).   
(A) (B) 
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5.2.3.3 Measuring VEGF-E and vIL-10 Release In Vitro Using Immunoprecipitation 
Western Blotting  
Immunoprecipitation of release samples using anti-FLAG®M2 affinity gel allowed for 
concentration of the protein contained within large volume release samples, increasing the 
sensitivity of detection of VEGF-E and vIL-10. Cubosome-alginate hydrogels rehydrated 
with 1 µg vIL-10 or VEGF-E-cubosome-alginate hydrogels (containing 1 µg VEGF-E) were 
released in 3mL PBS for 6 days, with 550 µL samples taken at 10 minutes, 1 hour, then days 
1 through 6. 550 µL samples (thus containing 550ng of each protein) were 
immunoprecipitated using anti-FLAG®M2 affinity gel, before being run on SDS-PAGE, and 
incubated with anti-FLAG® antibody in order to detect the protein contained within the 
samples.  
As shown in figure 5.6, the actual and cumulative releases for both VEGF-E and vIL-
10 were considerably lower than the expected amount (550 ng). VEGF-E had a peak release 
of 65.2 ± 6.39 ng on day 1, with a total cumulative release of 286 ± 37.6 ng over the 6-day 
period. vIL-10 had a peak release of  9 ± 1.1 ng at day 1, with a total cumulative release of 
12.65 ± 1.7 ng over the 6-day period. This meant only 52% of the loaded VEGF-E was 
detected and 2.3% of the loaded vIL-10 was detected. Despite the drastically reduced 
Figure 5.5. Cubosome-Alginate Hydrogels Released In Vitro Appear to Produce Toxicity in Ba/F3 B-cells. 
Release samples of blank cubosome-hydrogels, cubosome hydrogels gels hydrated with 1ug VEGF-E, and 
VEGF-E-cubosome-hydrogels, blank cubogels wetted with 1ug VEGF-E were collected and titrated 1/2 in 
PBS. Samples were incubated for 48h with Ba/F3 cells seeded at a density of 1.25x104 per well. 10µL/well 
alamarBlue™ was added and incubated for 4 hours at 37oC (5% CO2). Fluorescence intensity at 595nm was 
measured on the ClarioStar multi-mode microplate reader, and converted to cell number using a standard 
curve. Data is presented as the mean minus the media only background (negative control), n = 1.  


















Cubosome-Alginate Hydrogel Cubosome-Alginate Hydrogel + VEGF-E
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amounts of protein detected, the vIL-10 was released in a burst pattern, with 82.82 ± 13.38 
% being released within the first day. The VEGF-E was released faster than expected, despite 
the addition of the lipid cubosome, with 59.13 ± 2.8 % released by day 2, however release 
was sustained until day 6.  
It is apparent that while the release of VEGF-E and vIL-10 could be considered 
biphasic, in the sense that burst release occurred for vIL-10 and sustained release for VEGF-
E, the amount of protein that can be detected in the release samples is considerably lower 
than the loaded amount. Therefore, increased concentrations of protein are most likely 
required in order to deliver an effective dose. 
Figure 5.6. In Vitro Release of VEGF-E and vIL-10 from a Cubosome-Alginate Hydrogel Delivery System. 
Cubosome-alginate hydrogels rehydrated with 1 µg vIL-10 or VEGF-E-cubosome-alginate hydrogels 
(containing 1 µg VEGF-E) were released in 3mL PBS for 6 days, with 550 µL samples taken at 10 minutes, 
1 hour, then day 1 through 6. Samples were immunoprecipitated using anti-FLAG®M2 affinity gel, before 
being run on an SDS-PAGE, and protein detected using an anti-FLAG® antibody. (A, B) western blots of 
(A) VEGF-E-cubosome-alginate hydrogels and (B) cubosome alginate hydrogels hydrated with vIL-10. (C, 
D) actual release of (C) VEGF-E and (D) vIL-10 from hydrogels. (E, F) cumulative release of (E) VEGF-
E and (F) vIL-10 from hydrogels. Graphed data is presented as mean ± SEM, n = 3 experimental replicates 
for vIL-10, n = 2 experimental replicates for VEGF-E.  
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5.2.3.4 Testing the Toxicity of the Cubosome-Alginate Hydrogel System In Vitro  
As previously shown in figure 5.5., when release samples were incubated with BaF3 B-cells, 
toxicity was observed as far as the ¼ dilution factor. In order to confirm this toxicity and its 
implications on the development of this gel, release samples needed to be tested on skin cells, 
as the gel system was to be used in cutaneous wounds.   
HaCaT keratinocytes were cultured in the presence of serially diluted pluronic F127, 
calcium chloride, sodium alginate and monoolein cubosomes. These components of the 
calcium alginate hydrogel allowed for isolation of the toxic component. Pluronic F127 is a 
block copolymer used to synthesise the lipid cubosomes in combination with monoolein[325, 
326]. Sodium alginate is the hydrogel base, which is crosslinked with 5% calcium chloride 
solution. Components were serially diluted either side of the predicted concentration per 
release sample.  









































































Figure 5.7. Monoolein in Cubosome-Alginate Hydrogel Release Samples Produce Toxicity in HaCaT 
Keratinocytes. 1x105 keratinocytes were incubated for 48 hours with  serially diluted (A) calcium alginate 
cubogel release samples (B) pluronic F127 (C) sodium alginate (D) CaCl2 (E) monoolein. 10% DMSO was 
used as a cytotoxic control (indicated by red line). Viable cells were fixed with methanol and stained with 
0.025% crystal violet. Cells were solubilised with 33% acetic acid and the absorbance read at 595nm. Data 
is represented as mean cell number ± SEM, as calculated by a standard curve, n = 3 technical replicates.  
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As shown in figure 5.7A, B and C, pluronic F127, CaCl2 and sodium alginate had no effect 
on HaCaT viability compared to the cytotoxic control.  
Monoolein had a prominent toxic effect at concentrations as low as 0.625 ug/mL (Fig. 
5.7D). It should be noted that 10, 20 and 40 µg/mL concentrations showed an apparent 
increased viability.  
Figure 5.8 shows the effect of cubosome-alginate hydrogel release samples on HaCaT 
cell number. Release samples were taken at 24 hours, before replacing the whole release 
volume and collecting a sample again at 72 hours. This was done to observe if toxicity was 
time-dependent.  
 
Both 24 and 72 h release samples showed toxicity in their most concentrated form, with 
viability increasing with 0.5 and 0.25 dilution factors. Viability plateaued at the 0.125 
dilution factor. The results from figure 5.7 confirm that this toxicity is monoolein-dependent, 
and it is likely that the non-toxic PF127, CaCl2 and sodium alginate are mitigating these 
effects, explaining the lessened toxicity observed with the gels as a whole. Because these 
release samples were highly concentrated, containing 3 gel discs in 3 mL PBS, the effect of 
the cubosome-alginate hydrogels in vivo was predicted to be negligible compared to the cell 
toxicity observed. Therefore, it was considered appropriate to move to assessing in vivo 









































Figure 5.8. Cubosome-Alginate Hydrogels Show Concentration-Dependent Toxicity in HaCaT Keratinocytes. 
1x105 keratinocytes were incubated for 48 hours with  serially diluted release samples taken at 24 and 72 hours. 
10% DMSO was used as a cytotoxic control. Viable cells were fixed with methanol and stained with 0.025% 
crystal violet. Cells were solubilised with 33% acetic acid and the absorbance read at 595nm. Data is 
represented as mean cell number ± SEM, as calculated by a standard curve, n = 3 technical replicates.  
Chapter 5: Development and Testing of a Composite Biomaterial for  
Dual Delivery of a Growth Factor and Cytokine Combination 
 
 101 
 In Vivo Testing of the Cubosome-Alginate Delivery System 
5.3.1 Application of Cubosome-Alginate Hydrogels to Skin Wounds  
After the cubosome-alginate hydrogels were considered safe based on in vitro data, the next 
step was to assess the safety and practicality of the cubosome-alginate hydrogels containing 
4 µg VEGF-E and 400ng vIL-10 for applications in skin wounds. This was tested in a 
C57BL/6 excisional wound mouse model. The sex, species and age of mice was kept 
consistent with previous experiments[227, 229].  
 Mice were split into groups of 4, with each mouse receiving two 6mm full-thickness 
excisional wounds in the dorsal region. In addition to protein-cubosome-alginate hydrogels, 
separate groups received blank cubosome-alginate hydrogels (no protein), topical saline and 
topical VEGF-E and vIL-10. Topical delivery at these doses has been shown to reduce 
macrophage and myofibroblast populations within the wound, increase revascularisation, 
improve scarring responses, and decrease gene expression of pro-inflammatory and -fibrotic 
mediators[229].  
 Following wounding, mice were monitored for adverse events every 30 minutes for 
4 hours after activity was restored, then monitored twice daily for weight changes or other 
post-operative complications. More than 20% weight loss, significant pain or infection was 
considered a critical end-point. As shown in figure 5.9, animals across all groups lost weight 
following surgery, but this was recovered by post-operative day 2. No animals in any group 
lost more than 10% of their initial body weight. Table 5.1 summarises the post-operative 
complications recorded during monitoring, which include infection, lost or irritated 
bandages, pain or discomfort, and bleeding. Bleeding occurred in one animal in the topical 
saline group, with no associated signs of pain (table 5.1, fig. 5.10D). Large amounts of wound 
fluid, indicative of infection, was observed beneath the bandage in a saline gel mouse on day 
2 (table 5.1, fig. 5.10C). The wound was drained using a syringe, and amphoprim 
(10.2mg/mL) was administered to the wound site under gaseous anaesthesia (5% isoflurane). 
In the days following drainage, no more fluid was produced and there were no systemic signs 
of infection.  
The most common complication observed across treatment groups was irritation of 
the Tegaderm™ around the dressing border (table 5.1, fig. 5.10A). This did not interfere with 
the healing process but was observed in at least one animal per treatment group. Symptoms 
of pain, including belly pressing, low bright active responsive (BAR) score, wincing or 
twitching, was observed in 3 mice (table 5.1). It was hypothesised that in cases where mice 
were simply presenting with pressing, that this behaviour was discomfort-driven in response 
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to the bandage, rather than pain-driven. However, pain and discomfort could not be 
distinguished, so all three cases, the animal was immediately treated with bupivacaine 
(2mg/kg) under gaseous anaesthesia (5% isoflurane).   
 
Table 5.1. Post-Operative Complications Observed in Mice Following Treatment 
 













Infection 0 0 1 0 
Lost bandages 0 0 0 2 
Bandage irritation 2 4 4 1 
Pain/discomfort 0 1 2 0 
Bleeding  1 0 0 0 

































































Figure 5.9. VEGF-E + IL-10 Treatment Does Not Cause Excessive Post-Operative Weight Loss. 16 mice 
(n=4 per group) were subjected to excisional cutaneous wounding using a biopsy punch. Treatment groups 
included (A) VEGF-E-cubosome-alginate hydrogel + vIL-10 (B) cubosome-alginate hydrogel (C) topical 
saline (D) topical VEGF-E + vIL-10.  Following surgery, mice were weighed twice daily to monitor any 
changes. Mice were euthanised on day 5 for tissue harvesting. Data is presented as the weight change for 
each individual animal.   
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5.3.2 Assessing the Biocompatibility of Cubosome-Alginate Hydrogels with Skin Wounds 
The next aim was to assess the biocompatibility of the system, which included looking at 
retention of the gels within the wound, cell invasion, and the immune response to the protein-
cubosome-alginate hydrogels relative to the saline cubosome-alginate hydrogels.  
 
5.3.2.1 Alginate Hydrogel Adherence to Murine Excisional Wounds  
 Retention of cubosome-alginate hydrogels gels within the wound was poor, with 33% of 
protein-cubosome-alginate hydrogels and 50% of saline cubosome-alginate hydrogels being 
lost over the 5-day experimental period (Fig. 5.11).  While the protein gels had an increased 
adherence, it cannot be concluded whether this was a result of the VEGF-E and vIL-10 or 
not. It should be noted that the n per group decreased from 8 wounds to 6, due to incorrect 
cutting of tissue blocks during the tissue processing phase.  
  




Figure 5.10. Post-Operative Complications Observed in Mice Treated with Cubosome-Alginate Hydrogels. 
16 mice (n=4 per group) were subjected to excisional cutaneous wounding using a biopsy punch. Following 
surgery, mice were monitored twice daily for any signs of (A) bandage irritation (B) bandage loss, (C) 
infection or (D) bleeding.  
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Figure 5.11. Cubosome-Alginate Hydrogels Have Poor Adherence to the Wound Surface, Regardless of VEGF-
E + vIL-10. Representative images of (A,C) intact and (B,D) lost cubosome-alginate gels on day 5 mouse wound 
sections stained with MSB trichrome. (E) number of wounds that fully or partially retained, or lost, alginate gels. 
Intact, partial and lost wounds were counted for protein and saline treatments. Data are presented as the mean, 
n=6 per group.  
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5.3.2.2 Analysis of Murine Full-Thickness Skin Wounds Treated with Protein- and Saline-
Cubosome-Alginate Hydrogels. 
Immunohistochemical staining for M1 (CD206) and M2 (MAC387/iNOS) macrophages, 
fibroblasts and myofibroblasts (vimentin/𝛼-sma), and blood vessels (collagen IV/CD31) was 
conducted. 
 There was no notable difference in infiltration of MAC387/iNOS+ pro-inflammatory 
M2 macrophages between the two alginate groups (Fig 5.12). There did not appear to be any 
M2 macrophages in the alginate, indicating that there was not pro-inflammatory monocyte 
migration into the gel for either treatment.  
(B)   Secondary Only Control(A)   Positive Staining
(D)  Cubosome Alginate Hydrogel (C) VEGF-E-Cubosome Alginate 
Hydrogel + vIL-10
Figure 5.12. In Murine Excisional Wounds, Calprotectin+/iNOS+ Cells Were Not Observed in or 
around the Cubosome Alginate Hydrogels, Irrespective of the Presence of VEGF-E and vIL-10. 
Representative images of wound sections, taken at day 5 post-wounding, stained with antibodies 
against calprotectin (green), iNOS (red) and the nuclear stain DAPI (blue). (A) Calprotectin+/iNOS+ 
cells in an untreated wound. Co-stained cells are indicated by arrows. (B) Background staining from 
FITC-conjugated mouse IgG1 (green) and Dylight®594-conjugated goat anti-rabbit (red) polyclonal 
antibodies. Gel/epidermal-dermal junction of wounds treated with (C) VEGF-E-cubosome vIL-10-
alginate hydrogel or (D) cubosome alginate hydrogel. Junction is indicated by a dotted line. Scale 
bar = 50 µM.  
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When looking at vimentin/aSMA+ myofibroblasts, there was no notable myofibroblast 
banding migrating near the wound margin in either of the alginate treated wounds (Fig 5.13), 
unlike that previously observed with topical VEGF-E and vIL-10[229]. Vimentin+ fibroblasts 
and co-stained myofibroblasts were identifiable in the wound adjacent areas, although in very 
low frequency. Some vimentin+ fibroblasts were identified near the gel/epidermal junction 
in cubosome-alginate hydrogel-treated wounds (Fig. 5.13). No positively stained cells were 
identified within the gel for either treatment.  
 
CD206+ reparative macrophages appeared to increase in frequency in the granulation tissue 
below wounds treated with VEGF-E-cubosome-alginate hydrogels + vIL-10 compared to 
saline cubosome-alginate hydrogels (Fig 5.14). Positively stained cells were heavily located 
(C) VEGF-E-Cubosome vIL-10-
Alginate Hydrogel
(D)  Cubosome Alginate Hydrogel  
(B)   Secondary Only Control (A)   Positive Staining
Figure 5.13. In Murine Excisional Wounds, Vimentin+/aSMA+ Myofibroblasts Were Not Observed in or 
around the Cubosome Alginate Hydrogels, Irrespective of the Presence of VEGF-E and vIL-10. 
Representative images of wound sections, taken at day 5 post-wounding, stained with antibodies against 
vimentin (green) and aSMA (red), as well as the nuclear stain DAPI (blue). (A) vimentin+/aSMA+ positive 
cells in an untreated wound. Co-stained cells are indicated by arrows. (B) background staining from 
Dylight®488-conjugated goat anti-rabbit and Dylight®594-conjugated goat anti-rabbit polyclonal antibodies. 
Gel/epidermal-dermal junction of wounds treated with (C) VEGF-E-cubosome vIL-10-alginate hydrogel or 
(D) cubosome alginate hydrogel. Junction is indicated by a dotted line. Scale bar = 50 µM.   
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the area below the granulation tissue rather than in the granulation tissue itself and could not 
be visualised within the alginate gel in either of the gel groups.  
 
 
When looking at vascular infiltration to the wound bed, there appeared to be an increase in 
infiltration of Collagen IV/CD31+ blood vessels in the granulation tissue of wounds treated 
with VEGF-E-cubosome-alginate hydrogels, compared to saline-cubosome-alginate 
hydrogel (Fig. 5.15). It also appeared that the blood vessels in the granulation tissue treated 
with the protein gel had larger lumens than that of the saline gel, although no comparisons 
can be made between the blood vessel areas due to low n. No neovessel were identified within 
the hydrogel, only forming below the wound bed.   
Figure 5.14. In Murine Excisional Wounds, CD206+ Cells Were Not Observed in or around the Cubosome 
Alginate Hydrogels, Irrespective of the Presence of VEGF-E and vIL-10. Representative images of wound 
sections, taken at day 5 post-wounding, stained with antibodies against CD206 (green) and the nuclear stain 
DAPI (blue). (A) CD206+ positive cells in an untreated wound. Co-stained cells are indicated by arrows. 
(B) background staining from Dylight®488-conjugated goat anti-rabbit polyclonal antibody. Gel/epidermal-
dermal junction of wounds treated with (C) VEGF-E-cubosome vIL-10-alginate hydrogel or (D) cubosome 
alginate hydrogel. Junction is indicated by a dotted line. Scale bar = 50 µM.  
(C) VEGF-E-Cubosome vIL-10-
Alginate Hydrogel
(D)  Cubosome Alginate Hydrogel 
(B)   Secondary Only Control (A)   Positive Staining
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In summary, in vitro data showed a biphasic release pattern, demonstrating fast release of 
vIL-10 and delayed release of VEGF-E. This release was, however, at very low 
concentrations compared to the loaded amounts, suggesting that protein loss is occurring at 
some point. Toxicity of the gels in vitro impaired the ability to measure the bioactivity of 
released proteins, as samples needed to be concentrated due to the low-level release. This 
cytotoxicity can be attributed to the lipid component of cubosomes, monoolein.  
 In vivo, the gels were safe and well-tolerated, with minimal adverse effects reported. 
Adherence of the hydrogels to the wound surface was poor, and it did not appear as though 
there was significant cell migration into the gel itself. CD206+ reparative macrophages and 
Collagen IV+/CD31+ blood vessels appeared to be upregulated in the granulation tissue 
below wounds treated with the protein cubosome-alginate hydrogel. 
Figure 5.15. In Murine Excisional Wounds, Collagen IV+/CD31+ Cells Were Not Observed in or around 
the Cubosome Alginate Hydrogels, Irrespective of the Presence of VEGF-E and vIL-10. Representative 
images of wound sections, taken at day 5 post-wounding, stained with antibodies against collagen IV 
(green), CD31 (red) and the nuclear stain DAPI (blue). (A) Collagen IV+/CD31+ positive cells in an 
untreated wound. Co-stained cells are indicated by arrows. (B) background staining from Dylight®488-
conjugated goat anti-rabbit and Dylight®594-conjugated donkey anti-goat polyclonal antibodies. 
Gel/epidermal-dermal junction of wounds treated with (C) VEGF-E-cubosome vIL-10-alginate hydrogel 
or (D) cubosome alginate hydrogel. Junction is indicated by a dotted line. Scale bar = 50 µM.  
(B)   Secondary Only Control
(C) VEGF-E-Cubosome Alginate 
Hydrogel + vIL-10 
(D) Cubosome Alginate Hydrogel  
(A)   Positive Staining
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Skin repair is a complex process regulated by numerous cell types, ECM components, growth 
factors and cytokines[39]. Wound healing can be broken into specific phases – haemostasis, 
inflammation, granulation tissue formation, contraction, re-epithelialisation and remodelling. 
Each of these phases requires specific drivers in the form of growth factors and cytokines to 
initiate its onset and allow for timely transitioning to the next phase[13, 14]. Disruption in the 
phasic progression of healing can contribute to negative healing outcomes such as wound 
chronicity and excessive scarring[14, 46]. Both types of wound complication represent 
healthcare burdens[48], and current treatment options include strategies that have questionable 
efficacy and are non-specific to the pathophysiology of the condition. Because of the critical 
role that they play in normal and impaired healing, delivery of growth factors and cytokines 
has been trialled to enhance healing across a wide number of wound indications. Despite 
promising preclinical results, human trials have been met with limited success, with only 
three products currently approved globally[116].  
 A systematic literature search of clinical trials investigating the use of growth factors 
and cytokines for wound healing revealed that poor and inconsistent trial design, strict FDA 
endpoints, immunogenicity, and incompatibility of the wound environment with topical 
delivery are all contributing factors to clinical trial failures. A systematic literature search of 
experimental studies of biomaterial delivery systems to deliver growth factors and cytokines 
concluded that the most effective strategy appeared to be delivery of one or more growth 
factors to target multiple phases of healing.  While many different biomaterial systems have 
shown the ability to modulate healing, evidence suggesting which biomaterial and growth 
factor combination may be most appropriate for different wound healing indications is still 
lacking. More evidence is also required as to whether biomaterial systems do actually provide 
proteolytic protection and retention within the wound.  
 The development of an alginate hydrogel delivering cubosome-encapsulated VEGF-
E and vIL-10 provided phasic delivery in vitro and was biocompatible in vivo, however it 
had poor integration with the wound bed in vivo which produced issues with practicality.  
 This chapter will discuss the implications of findings from previous chapters, 
limitations of the thesis, and suggest directions for future research.  
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 Clinical Delivery of Growth Factors and Cytokines as a Therapy for Wound Healing 
Complications 
A comprehensive search was conducted to assess the current literature regarding biologic 
therapies to treat wound and scarring disorders. The growth factors and cytokines included 
PDGF-bb, EGF, FGF, VEGF-A, TGF-b3, G-CSF, GM-CSF and IL-10. These proteins all 
have varying roles in the inflammatory, proliferative and remodelling phases of healing, and 
are implicated in negative healing outcomes[15, 115]. Therefore, restoring the balance of these 
proteins in pathological conditions was hypothesised to be an effective treatment strategy. 
Analysis revealed that a large number of growth factors and cytokines have been tested in 
clinical trials for a broad range of wound indications, and most were delivered via basic 
topical hydrogels and injection. The issues identified with clinical delivery included poor 
trial design and reporting, and factors relating to the protein delivery itself, including 
immunogenicity and proteolytic degradation, and these issues can complicate a number of 
points in the drug development pathway (Fig 6.1). Issues with the cost of production will be 
discussed as an additional factor in this section.  
 
6.2.1 Issues with Clinical Trial Design and Reporting  
Study design, analysis and execution flaws have contributed to the failure of growth factor 
and cytokine therapies to be approved for wound and scar indications. For example, rhGM-
CSF was tested in burns[265-267], pressure ulcers[252], venous leg ulcers[130] and mixed chronic 
ulcers[129, 264]. For burns, rhGM-CSF was delivered via a gelatin hydrogel at a dose of 10 ug/g 
gel[265-267], and successfully enhanced healing by day 7[267], 14[266] and 20[265]  in each study. 
In studies of chronic mixed ulcers, one study delivered 10 ug rhGM-CSF per g/alginate 
dressing and successfully enhanced healing at day 21[264], and 400 ug rhGM-CSF injected 
intralesionally enhanced healing by day 8[129]. For venous leg ulcers,  200 or 400 ug injected 
intralesionally significantly enhanced healing much later, at week 13[130]. Pressure ulcers 
Figure 6.1. Stages of the Drug Development Pathway and Contributing Factors to the Failure of Growth 
Factor and Cytokine Approval for Wound Healing. Made using Biorender.   
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treated with 2 ug rhGM-CSF spray daily for 35 days had no effect on healing[252]. The varied 
dosing, indications, and time frames measured makes it very difficult to compare the 
treatments.     
Avotermin (rhTGF-b3) was a leading candidate in anti-scarring treatment[135], but 
failed to progress further than Phase III clinical trials[131]. A clear statement on why the trials 
ended is not available[131]. But it is likely that variation in study design across the trials, as 
with the four papers reporting use of avotermin for scarring, each had different study 
parameters[131, 133, 134, 136]. Dosing regimens varied, with a dose range from 0.25-500 ng/100 
µL/linear cm with administration 10-30 min before incision[131], at the time of incision[133, 
134] and/ or 24 h after incision[131, 133, 136]. A paired dosing regimen of 5 ng administered 
immediately before and 24 h after incision was most successful[131]. But in the Phase III trial, 
100 ng and 250 ng of Avotermin was administered immediately and 24 h after incision. 
Therefore, the doses used in the Phase III trial were higher than the efficacious dose identified 
in previous trials[131, 133, 134, 136], and previous data suggested that a 250ng dose only provided 
transient benefits. The dose and delivery method were the worst choices based on the 
previous evidence[131, 133, 134, 136]. Primary study outcomes in the Avotermin trials involved 
lay panels assessing visual scar scores, but the timing of this measurement ranged from 6 
weeks to 12 months[131, 133, 134, 136]. The phase III study involved investigating the efficacy of 
Avotermin for scar revision surgery at 12 months following surgery using a clinical scar 
assessment panel[327], when previous studies had shown good efficacy in scar prevention, 
with efficacy shown at earlier timepoints[131, 133, 136].  
These examples highlight the risk of variable study designs across clinical studies 
investigating the same growth factor and cytokine therapy when working towards its 
approval. There should be a focus on selecting and proving the most effective dose, dose 
regimen and assessment timing for a specific wound indication.  
 Most trials have attempted to standardise protocols, but as evidence in the trials with 
Regranex (rhPDGF-bb)[116], differences in ulcer duration, size, and intrinsic healing capacity 
greatly influence healing. Regranex was effective in mixed diabetic ulcers after 20 weeks of 
treatment[239-241], but not severe pressure[242, 243] or hypertensive ulcers[244] with shorter dosing 
regimens. EGF was tested in a consistent cohort of patients with diabetic foot ulcers (I-II) 
and reported complete healing across a number of studies despite different delivery 
methods[118-120, 248, 251]. Interpatient variability, with regard to this wound microenvironment, 
also results in differences in responsiveness to growth factor and cytokine interventions. The 
ability to stratify wounds into those likely to be responsive to a specific growth factor or 
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cytokine treatment is thus critical to clinical success. Identification of molecular biomarkers 
that may indicate whether wounds are likely to heal or not heal will greatly help selection of 
trial participants[328]. Such biomarkers may include IL-1, IL-6, and MMP/TIMP ratio[328].  
FDA-designated endpoints are also a very likely contributor to the failings of growth 
factors and cytokines for the treatment of wound healing complications[139, 140]. As a 
consequence of this, 44% of the clinical trials assessed in the systematic literature review 
used complete wound closure as their primary outcome. This is evident with the phase II trial 
of Telbermin (rhVEGF-A) for treatment of neuropathic diabetic foot ulcers, which illustrates 
that if a treatment is well-tolerated and enhances progression towards healing, failure to 
achieve the primary endpoint prevents the treatment from progressing[236]. This is a well-
acknowledged barrier to the approval of growth factors and cytokines for wound healing 
indications[140], and many have called for the introduction of surrogate endpoints as in cancer, 
where there are three direct endpoints and five surrogate[329]. This is important as chronic 
diabetic foot ulcers have morbidities equivalent to or exceeding common cancers[330]. For 
cancer the surrogate endpoints include objective response rate, complete response, 
progression-free survival, time to progression, and disease-free survival. Establishment of 
surrogate endpoints for approval of wound healing products, such as time to heal, rate and 
wound size reduction, reduction in seroma, infection or dehiscence, or improved quality of 
life, may enable the approval of more therapies.  
Trials of scar therapies are also limited in that there is at present no standardised 
outcome measure to indicate treatment success[331]. Measurements that are currently used 
include colour (Vancouver scar scale), scar height, surface texture, and surface area[332, 333], 
and while it is important to assess the physical characteristics of the scar, impacts on quality 
of life can be affected by factors such as pain, sensation or pliability – a contracted scar can 
prevent movement at joints, for example[332, 334]. Differences between the trials with 
Avotermin indicate how scar assessment protocols can alter trial outcomes[136, 268].  
 Clear clinical trial reporting is critical to making sure future research is valuable and 
additive to the existing literature, rather than repeating shortcomings in study design, analysis 
or execution[335]. CONSORT criteria were introduced in 1996 as a standardised method of 
reporting clinical trials, but adherence to these guidelines remains variable [233]. While some 
trials included in the analysis occurred prior to 1996, 73% of studies occurred post-2000. 
CONSORT was one of the first of what is now a collection of reporting standards, preceding 
later initiatives such as the Standards for Reporting of Diagnostic Accuracy (STARD)[336] 
and Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)[337].  
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Analysis of CONSORT adherence by clinical trial reports for growth factor and 
cytokine therapies revealed issues in reporting randomisation procedures. Randomised 
clinical trials are well known as the ‘gold standard’ of trial design due to the ability to control 
for confounding factors across treatment groups[338]. Adhering to good randomisation 
practice will warrant greater confidence in trial outcomes[339].   
A bias towards reporting clinical trial success was also identified, particularly with 
reporting subsequent trials that failed, such as in the case of avotermin[131, 133, 134, 136]. This is 
a concern as it is equally as important for trials that failed to achieve their primary outcome. 
There is a well-established bias towards publication of positive results[269]. It should be 
acknowledged that the research community is further disadvantaged if the negative results 
that do get published are not only scarce, but poorly documented[340].  Critical analysis of 
work is a valuable skill that was executed poorly in the studies examined, with over half of 
the reports failing to adequately address limitations of their work, for example weaknesses 
in study design and execution.  
  In the future, it is critical that researchers employ accurate and consistent study 
design, particularly when investigating the same treatment, as this will allow for more 
accurate comparisons, thereby making a solid foundation for future research to be based on.  
 
6.2.2 Issues with Topical Administration  
Reducing the amount of active protein by proteolytic degradation, systemic or immunogenic 
clearance, can threaten their therapeutic efficacy. Increasing dosage or frequency can 
overcome this, but this strategy does not come without risks – such as hypersensitivity 
reactions or systemic leakage.  
In the case of chronic wounds, proteolytic activity is heavily upregulated due to 
overexpression of MMPs and expression of proteases by bacterial biofilm communities[61, 62, 
341]. This has been observed in chronic pressure ulcers[62, 63] and chronic leg ulcers[64]. The 
effect of heightened proteolytic activity on growth factor bioactivity has been demonstrated 
in a small study, which incubated PDGF-AB with wound fluid from three patients with 
chronic venous leg ulcers[143]. Significant degradation of protein and reduction of bioactivity 
was observed, and this response was fully reversible with the addition of a serine proteinase 
inhibitor[143]. Proteolytic degradation of topically delivered growth factors and cytokines into 
chronic wounds is very likely to reduce the efficacy of the proteins. Although this is less 
likely to affect treatments delivered to acute wounds for scar prevention due to the lower 
proteolytic activity in acute wounds[62].  
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Attempts to enhance the bioactivity of topically delivered growth factors or cytokines 
have been made by increasing the therapeutic dose and period of exposure[116, 255, 260]. But 
these changes in the treatment regimen may have an effect on patient compliance[59, 146, 147]. 
Higher doses and more frequent delivery can also increase the risk of systemic spread, which 
can produce hypersensitivity and immunogenic responses[342, 343]. B-cell production of anti-
drug antibodies can compromise the therapeutic efficacy of the protein when neutralising 
activity occurs[342]. Hypersensitivity[344] and immunogenicity was observed with chronic 
subcutaneous administration of rhGM-CSF (Leucomax) to immune-competent 
individuals[142], where 95% of patients developed binding antibodies to treatment, 40% of 
which were neutralising antibodies[142, 345]. The source of this immunogenicity was proposed 
to relate to the lack of rhGM-CSF glycosylation resulting from an Escherichia coli 
production system, which exposed an immunogenic epitope in the protein structure[346, 347]. 
Protein production methods impact not just glycosylation, but also stability, bioactivity and 
pharmacokinetics of the end product[348]. Methods of production that involve Sacromyces 
cerevisiae and mammalian cell-lines, such as HEK293 cells and Chinese hamster ovary 
(CHO) cells, are becoming more popular than traditional E. Coli purification, as these 
preserve glycosylation patterns on the protein[349, 350]. But care should be taken, as 
immunogenicity can be introduced at a number of other points in the production cascade, 
such as formulation[351]. Formulating proteins via methods of pasteurisation, freeze-drying 
and pegylation can also increase immunogenicity via inducing conformational changes and 
oxidisation[351]. In addition to immunogenicity, increased risk of death from cancer was also 
observed in the case of Regranex[148], which was postulated to result from systemic leakage 
of PDGF-ββ from the wound stimulated the growth of preexisting cancers expressing its 
receptor. As a result, Regranex was issued a black-box warning by the FDA in 2008, but this 
was removed in 2018 in response to post marketing analysis that showed no increased risk 
of cancer or cancer mortality[247]. Such cancer risks relating to systemic leakage has been 
identified in other biologics, such as growth hormone[352]. 
Given the extreme clinical need, and the promise offered by growth factor and 
cytokine therapies across a broad range of wound complication, it is critical that the issues 
identified with their clinical application be addressed. Natural biomaterials may be able to 
retain growth factors and cytokines within the wound, while providing sustained local 
delivery and a physical environment supportive of healing processes. Innovative combination 
therapies may therefore offer greater efficacy, safety, and patentability, thus addressing many 
of the limitations associated with direct GF or cytokine administration. Such growth factor 
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and cytokine delivery systems are in development, with the first in human clinical trials. 
These include collagen sponges for FGF-2[258, 259], alginate dressings[264] and gelatin 
hydrogels[265-267] for GM-CSF, and a silicone hyaluronate cream for TGF-b3[132]. Growth 
factor and cytokine delivery systems therefore offer potential as therapies for cutaneous 
wound indications. But to ensure their success, it is critical to evaluate which biomaterials 
are most compatible with specific growth factor and cytokine delivery systems, and to prove 
their superior efficacy and safety relative to direct protein therapies 
 
6.2.3 Issues Relating to Cost  
Financial implications can also influence whether and how growth factor or cytokine wound 
healing therapies are trialled[353]. Recombinant protein production and preclinical and clinical 
testing are very costly and investors are looking for strong intellectual property, and the 
shortest, most cost-effective route to the largest potential market for a given product.  
The manufacture of recombinant proteins is associated with a large cost, 
approximated at an excess of $1 billion per product[141]. The intricacies of maintaining 
biological activity through ensuring the correct structural conformation of large proteins, 
including growth factors and cytokines, requires a more complex and costly system than 
small molecule drugs, which can be synthesised chemically[141]. Clinical trials are also 
associated with high costs, both pre- and post-marketing[141].  
Much of the knowledge regarding growth factors and cytokines is already in the 
public domain presenting limited scope for patents, which is likely to reduce investment. HA-
based dressings such as Hyalofill®, Hyalomatrix® and Hyiodine® are commercially 
available for chronic wounds[197], other hydrogels such as Nu-gel™ and Aquaform™ are also 
available[197]. Silver-loaded dressings such as Silvasorb® gel deliver antimicrobial silver to 
chronic wounds[197]. As previously mentioned, Regranex is the only growth-factor delivering 
system currently available for wound indications. Thus innovative production or delivery 
systems and novel treatment combinations tailored for specific indications are essential to 
maximizing patent claims and obtaining trial sponsorship[354].  
Commercial considerations can also influence clinical trial design, neglecting to base 
study design on previous evidence and scientific reasoning[353]. Instead of choosing the subset 
of patients most likely to benefit from the treatment, a study population maybe chosen to 
support future marketing claims, or adjusted during the course of the trial to meet enrolment 
targets[353].  
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Improvements in study design, particularly by including consistent measures across 
treatments and using more accurate controls to prove the benefit of biomaterial-based 
delivery over topical, and improvements in study reporting, by critically analysing and 
accurately reporting limitations, are achievable advancements for scientists and clinicians in 
this research field. However, changes in manufacturing, commercialisation and marketing 
require concerted efforts to engage with pharmaceutical companies and regulatory agencies 
in order to induce change[139-141].  
 
 Biomaterials as a Means for Growth Factor and Cytokine Delivery to Wounds 
As described above, 3 major issues with clinical trials were highlighted that may have 
contributed to failures. These included issues with protein delivery, study design and 
regulation/marketing. Of these challenges, improving strategies for protein delivery is an 
emerging focus in wound therapy. The use of biomaterials has been explored as a strategy to 
tackle the incompatibility of the wound environment, which often leads to degradation[61, 62, 
341]. By interacting with key cell types, undergoing degradation and remodelling, natural 
materials are able to both delivery growth factors and cytokines to the wound as they break 
down, but also contribute to regulation of healing and reconstruction of the extracellular 
matrix.  
A systematic literature review of the use of biomaterials as repositories for growth 
factor and cytokine delivery to wounds concluded that hybridised natural composite systems 
are the most common method of delivery, with collagen and chitosan most often used for 
targeting of the proliferative phase by delivering FGF-2 and EGF. Materials such as alginate, 
HA and fibrin were more commonly used to target angiogenic processes via delivery of 
VEGF-A and FGF-2. Of the 33 studies that studied the efficacy of their systems in vivo, the 
most common model was a rat full-thickness excisional model, and all 33 studies reported 
positive effects on healing parameters such as re-epithelialisation, granulation, 
vascularisation and wound closure.  
 Sustained release of growth factors and cytokines was achieved using biomaterials, 
however no studies compared different biomaterials, and very few compared material-based 
delivery to topical delivery of the proteins[291]. Creating release environments that accurately 
represent the proteolytic nature of wounds was a neglected factor, only being considered in 
a few studies[281, 282, 284, 295, 296, 307]. In addition to this, analysing systemic leakage of proteins 
from the wound in vivo was overlooked in all of the studies. Assessing the biocompatibility 
of systems in regards to cell growth, migration and toxicity in and around scaffolds was also 
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neglected in many studies. Based on this, it is very difficult to conclude which biomaterials 
are best suited to which indications, and whether these delivery systems do indeed provide 
enhanced efficacy compared to topical delivery of the proteins.  
 All of the studies evaluate the effect of biomaterial systems on healing processes, but 
very few looked at processes relating to scarring. It is also important to note that while all of 
the treatments were able to modulate healing, only two studies[291, 302] assessed topical protein 
as a control. Without adequate controls, especially those that replicate how growth factors 
and cytokines have been delivered in clinical trials, evidence to support the superiority of 
biomaterial-based deliveries over topically delivered treatments is still unclear. 
As described in chapter 3, growth factors and cytokines could be used with natural 
materials alone for rapid burst release[271, 279, 283], but for more complex and phasic release, 
the best strategy is using a hybrid system, which either combines a natural material with a 
synthetic one for enhanced strength, and therefore a longer degradation rate[300], or more 
commonly, combining materials of natural[289, 304] or synthetic[297, 309] origin that possess 
different kinetic properties (e.g. fast-release hydrogel with slower-release nanostructure) for 
multiphasic release of more than one protein. The use of nanostructures, such as nanoparticles 
and nanofibres, in combination with biomaterials for controlled delivery was discussed. 
Nanoparticles provide an additional layer of customisation to a delivery system, allowing for 
multiphasic release, thus enabling targeting of more than one phase of healing by delivering 
different therapeutic proteins at different phases[156]. These complex delivery systems have 
proven effective in preclinical trials, with a good example being the work of Lai et al[304], 
who encapsulated FGF-2, VEGF-A, EGF and PDGF-bb within a single system for targeting 
of re-epithelialisation, vascular sprouting and vascular maturation. Fast and sustained release 
was achieved within the same system by using different biomaterials. However, all four of 
these growth factors target the repair phase, with three specifically targeting angiogenesis[15]. 
For more expansive targeting, EGF could be released early to promote re-epithelialisation, 
but both FGF-2 and VEGF-A may not be required – one of these could be released early with 
EGF from fibres to promote vascularisation, followed by nanoparticle encapsulated-PDGF-
bb later to promote vessel maturation. A final protein, such as IL-10 or TGF-b3, could be 
released via nanoparticles last, in order to target the remodelling phase and reduce the risk of 
pathological scarring. 
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6.3.1 Selecting the Right Growth Factor and Biomaterial  
The work of Lai et al provides an excellent framework for the ‘ideal delivery system’ – where 
a fast-release base is hybridised with synthetic and nanoparticle components to allow for 
targeting of multiple phases of healing, by incorporating different growth factors into 
different release components of a single system. When it comes to choosing what growth 
factors, cytokines and biomaterials to use, these choices are dependent on the system that is 
being developed and the target. The systematic literature review in chapter 3 revealed that 
biomaterials including chitosan, alginate, HA, collagen, gelatin and fibrin have been used to 
deliver VEGF-A, VEGF-E, EGF, FGF-2, PDGF-bb, GM-CSF, FGF-7, and Orf Virus vIL-
10. Almost all of these targeted only the repair phase (i.e. re-epithelialisation or granulation) 
– excluding the VEGF-E and vIL-10 combo[182], which targeted inflammation, granulation 
and scarring processes. Selecting the appropriate combinations of these for use in a complex 
delivery system should be involve consideration of which phases of healing are being 
targeted, and which growth factors best target these phases (see Figure 6.2).  
 
 
Wound healing is characterised by distinct but overlapping healing phases that are tightly 
regulated by growth factors and cytokines[14]. Imbalances in growth factor and cytokine 
levels can disrupt the transitions between phases, resulting in chronicity, where inflammatory 
stasis prevents granulation and re-epithelialisation[14], and scarring, where prolonged 
inflammation drives excessive fibrotic and vascular responses[55]. Delivering more than one 
growth factor or cytokine, each targeting different wound phases, is likely to have a greater 
therapeutic efficacy than a single target. For chronic wounds, use of growth factors and 
cytokines which reduce inflammation and promote granulation tissue formation and re-
epithelialisation  would be the best approach, e.g., a combination of IL-10 + VEGF-A + 
Figure 6.2. Targeting of Specific Wound Healing Phases Using Growth Factors and Cytokines. A healing 
wound can be characterised by phases, including inflammation, granulation, re-epithelialisation and 
remodelling. Disruption in these phases via growth factor/cytokine imbalances can promote negative healing 
outcomes, and therefore restoring normal growth factor or cytokine levels provides a good therapeutic 
strategy.  
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PDGF-bb + EGF. Distinct temporal release of these proteins would allow for IL-10 to first 
drive down excessive inflammation, VEGF-A to then promote vascular sprouting, PDGF-bb 
to promote vascular maturation and then EGF to promote re-epithelialisation. The closest to 
this multiphasic combination that has been tried in the literature includes VEGF-A and 
PDGF-bb in a fibrin matrix[200], and quad release of VEGF-A, PDGF-bb, EGF and FGF-2 
from collagen and HA nanofibres[304] For scar prevention, both fibrotic and vascular 
responses would need to be normalised, therefore a therapy containing growth factors and 
cytokines that first reduces inflammation and then promote normal vascular regeneration 
would be most appropriate. VEGF-E and vIL-10 have previously been paired for scar 
prevention, with preclinical data showing an improvement in healing and scar quality in 
wound models[182, 227, 229].  
 Which biomaterials to combine with these growth factors is another important 
consideration. Both the release kinetics and biocompatibility of the biomaterials needs to be 
considered. As previously mentioned, natural materials are generally good for fast release, 
with materials like alginate[283] gelatin[287] and fibrin degrading particularly quickly[149, 288]. 
Nanoparticles can be used for more sustained release, and the properties of these can be easily 
modified, by altering ratios or production methods, to accelerate or slow release[160, 355]. For 
example, gelatin sheets containing FGF-2 released cumulatively over 7 days[287], and in a 
different study, when a gelatin hydrogel was combined with gelatin microspheres and a 
collagen matrix, release of EGF from the microspheres was sustained up to 14 days[293]. 
Microspheres were commonly used for sustained delivery, and these derived from both 
synthetic and natural materials, such as PLGA[309], PCL[297], alginate[299] and gelatin[286]. 
Nanoparticles were sometimes combined with fibres, such as gelatin nanoparticles with 
collagen and HA nanofibres[304] and chitosan nanoparticles with PCL nanofibres[301]. 
The mechanically weak nature of collagen[170] further supports its use for fast-to-mid 
rate release[279], although hybrid materials containing collagen have been shown to sustain 
release up to 25 days[304]. HA showed sustained release up to 14 days in vitro in culture 
medium[284], however HA may be incompatible with delivery of anti-inflammatory cytokines 
due to its pro-inflammatory breakdown products[178].   
Delivery of vIL-10 and VEGF-E to equine bandaged limb wounds via a collagen-HA 
hydrogel enhanced granulation tissue formation, but did not display potent anti-inflammatory 
activity[182]. It was proposed that the well-characterised anti-inflammatory vIL-10 effect[227-
229] was mitigated by the pro-inflammatory small molecular weight byproducts generated as 
the high molecular weight hydrogel degraded[182]. HA may therefore provide a good delivery 
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vehicle in acute wounds in healthy patients, but perhaps not chronic wounds with an 
established inflammatory imbalance, or patients with predisposition to abnormal scarring. 
Collagen-based biomaterials promoted proliferation of fibroblasts, and endothelial 
cells, keratinocytes[279-281]. Collagen has been suggested to support proliferation of 
macrophages, although this was not tested[166]. Based on these results, collagen-based 
biomaterials could be suited as a delivery vehicle for growth factors targeting earlier phases 
of healing, such as granulation tissue formation and re-epithelialisation – this is supported by 
in vivo data, which shows that a collagen membrane containing CBD-conjugated PDGF-bb 
enhances granulation tissue formation, re-epithelialisation and vascularisation in a rabbit 
ischaemic full-thickness excisional wound model[277]. Alginate has a very large capacity to 
absorb water[176], and provides a good means for exudate absorption in high fluid-producing 
chronic wounds[14].  Alginate-based biomaterials were commonly used to deliver VEGF-
A[282, 283],  and when used to treat an ischaemic model of chronicity, an alginate hydrogel 
containing VEGF-A enhanced healing when compared to control[283]. Alginate showed good 
biocompatibility with fibroblasts, with alginate-based biomaterials either supporting[291] or 
promoting[299] growth of these cells, although no other cell types were tested.  
 
6.3.2 Proving Retention and Proteolytic Protection of Growth Factors and Cytokines  
The appeal of using biomaterials for growth factor and cytokine delivery lies not only with 
the ability to deliver one or more proteins at multiple phases of healing, but also the prospect 
of protecting these proteins from degradation and systemic spread[160]. However, very few of 
the studies included in the systematic literature review actually proved protection of proteins 
when encapsulated in biomaterials in comparison to protein alone. Most measured in vitro 
release in physiological buffers or culture medium, with only a few studies adding enzymatic 
mixes[289, 300] and one measuring release in wound fluid[296] - no other studies incorporated 
proteolytic elements into their in vitro release measurements. In the case of the study using 
wound fluid, as much as 63% more FGF-2 was preserved after 24 h of incubation when 
encapsulated within liposomes compared to unencapsulated FGF-2[296]. In vivo measurement 
of protein levels becomes more difficult, but these could be measured by extracting wound 
fluid and ascertaining protein amounts using ELISA, as in Trengrove et al, who measured 
degradation of EGF in wound fluid[61]. Trengrove et al also used the azocasein assay to 
measure protease activity, and confirm efficacy of specific protease inhibitors, thereby 
isolating the source of degradation to specific enzymes[61]. Understanding the sources and 
extent of degradation in a clinically relevant context (i.e. with patient samples of wound fluid) 
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would be a good future strategy to confirm the benefit of biomaterial usage, and ensure the 
system design is appropriate to protect proteins from enzymatic degradation.  
 Reducing systemic spread is another factor that has been claimed as a benefit of 
biomaterial use, but at present is founded on little evidence. Systemic leakage can induce 
systemic immunogenic responses and increase cancer risk, as observed in humans with 
topically delivered rhGM-CSF[142] and Regranex[116, 148, 247]. Retaining proteins within a 
biomaterial and localising their release to the wound site may limit the systemic spread linked 
to immunogenicity and cancer risk[142, 247]. However, none of the studies included in the 
systematic literature review measured antibody production or serum levels, or cancer risk in 
vivo. Confirming retainment of the proteins within the wound site and checking for systemic 
responses in vivo should be done in the future in order to predict the likelihood of these side 
effects occurring in human patients.   
It should be noted that treatment success in humans is evaluated as the time until 
complete wound closure, and while this measurement is possible in porcine wound models, 
it is less clear in rodents due to skin contraction[356]. In addition, while wound inflammation, 
vascularisation, re-epithelialisation, and scarring can be observed macroscopically to a 
certain extent in humans and pigs, the size of rodent wounds compromises these measures, 
meaning that wound biopsies must be taken from euthanised animals to facilitate each type 
and stage of wound analysis[313]. Thus large numbers of animals are required to fully assess 
phasic wound responses to a given treatment. 
Skin contraction has been considered a confounding factor in measuring wound 
healing in rodents, with concerns that contraction is the major driver for wound closure, 
rather than re-epithelialisation – the panniculus carnosus layer beneath the dermis contracts 
to assist in approximation of the wound edges[356]. Recent data suggests that the role of 
contraction in rodent wound healing is less than previously described, but should still be 
considered in excisional wound models[356]. Other models include splinted models, where 
physical barriers prevent contraction (Fig 6.2)[312]. Splinting was employed in a few 
papers[294, 303, 309], such as measuring FGF-7 and EGF from a collagen membrane, with 
improved healing observed[303]. Splinted models can be enhanced by inoculation with 
Staphylococcus aureus to mimic an infected chronic wound; this has been used to measure 
improved healing with controlled delivery of VEGF-A and vancomycin (Fig 6.2)[309]. 
Considering the large burden of diabetic chronic wounds[48], replicating the 
pathogenesis of these wounds in animal models is important. STZ-induced diabetic mice and 
leptin-deficient db/db mice have shown delayed healing of excisional wounds[313], and are 
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capable of detecting enhanced healing in response to controlled growth factor delivery[198, 
274, 304]. It should, however, be noted that these animals do not accurately represent type 2 
diabetes, which is a polygenic metabolic disorder involving hyperglycaemia, vascular 
insufficiency and neuropathy among others, that can occur in the absence of obesity. It might 
be more relevant to therefore investigate growth factor and cytokine delivery systems in 
TALLYHO/JngJ or NONcNZO10/LtJ mice (Fig 6.3)[357]. These mice better represent the 
polygenic nature of type 2 diabetes and exhibit impaired wound re-epithelialisation and 
granulation tissue formation, which in the case of NONcNZO10/LtJ mice is accelerated by 
topical administration of FGF-1[358, 359].  
 Rodent models are inadequate for measuring scar formation, because they heal with 
very little scarring or fibrosis due to the lack of tension in their loose skin[314]. In rodents, the 
minimal scar size and hair regeneration around the wound limit the use of macroscopic 
assessments such as scar scales[331]. Considering this, large animal models may better 
represent scarring in humans. For example, skin wounds in the Duroc pig produce raised, 
hyperpigmented scars with collagen organization similar to that in hypertrophic scars (Fig 
6.2)[360]. No growth factors or cytokines have been tested in this model. By contrast, horses 
are the only animal, other than humans, to naturally develop fibroproliferative skin lesions 
known as exuberant granulation tissue (EGT), which are reminiscent of keloids[231]. The 
rabbit ear model may also provide an appropriate alternative, as surgical wounds in this 
model have been shown to produce raised, hyperproliferative scars with excessive fibrosis 
and vascularisation characteristic of hypertrophic scars[361]. Contraction is not a concern in 
this model because the rabbit ear has no panniculus carnosus[361]. The VEGF-E and vIL-10 
cubosome-alginate hydrogel would need to be tested in one of these models in order to 
accurately measure the effect on scarring, rather than just measuring histological parameters.  
 
Figure 6.3. Animal Models for Chronicity and Scarring. represented from simple models to more clinically 
relevant complex models.   
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 Development and In Vitro Testing of a Cubosome-Alginate Hydrogel for Biphasic 
Release of vIL-10 and VEGF-E 
The review of clinical trials identified issues associated with topical administration of growth 
factor and cytokine proteins as a contributing factor to their failures to progress as chronic 
wound or scar therapies. The review of developments in biomaterial-based delivery systems 
highlighted the need for controlled release of one or more therapeutic proteins to target 
phases of healing dysregulated in specific to wound or scar complications. A composite 
growth factor and cytokine biomaterial-based delivery system was therefore developed and 
tested to enable phasic regulation of wound inflammation and repair.  
The Orf Virus-derived proteins, VEGF-E and vIL-10, were selected because they had 
been shown to individually and synergistically enhance wound repair and limit scarring in a 
number of wound models, including murine excisional, murine thermal and equine bandaged 
limb wounds[182, 227-229]. Intradermal and subcutaneous injections of these proteins were 
efficacious in previous studies, but the topical nature of delivery may become an issue in 
chronic or more complex wounds. Therefore, the proteins were incorporated into a delivery 
system utilizing an alginate hydrogel encompassing lipid cubosome nanoparticles for 
controlled, biphasic release. Sodium alginate crosslinked with calcium chloride was trialled, 
due to its good biocompatibility and highly modifiable release kinetics[362]. A fast-release 
matrix of alginate was prepared to deliver vIL-10 to wounds within the early phases of 
healing, with the intent of dampening excessive early inflammation that may compromise 
repair. VEGF-E was encapsulated within lipid cubosome nanoparticles for sustained release. 
Cubosomes were selected because of their ability to release loaded drugs in a sustained 
manner and the tailorability of their release kinetics[363], with the objective of delaying 
VEGF-E release to promote wound revascularisation and vascular maturation in the later 
phases of healing. 
An alginate hydrogel encompassing vIL-10 and VEGF-E-laden cubosomes was 
synthesised, demonstrating biphasic release of the two proteins, with in vitro release of vIL-
10 peaking at day 1, and VEGF-E releasing cumulatively over the 6-day period. However, 
only 52% of VEGF-E and 2.3% of vIL-10 was detected following release. This made it 
difficult to detect the bioactivity of the proteins in vitro. Toxicity was also observed when 
keratinocytes were exposed to high concentrations of release samples, and this toxicity was 
identified as being caused by monoolein, the lipid component of the cubosomes.  
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In a mouse full-thickness excisional wound model, the cubosome-hydrogel system 
was well tolerated, however, there was a lack of retention and integration with the wound 
tissue, irrespective of the presence of VEGF-E and vIL-10. 
 
6.4.1 Detection of vIL-10 and VEGF-E Release In Vitro  
Establishing the utility of a controlled delivery system first involves measuring the release 
rate of any proteins from the system. Successful multiphasic targeting of multiple growth 
factors is dependent on each protein being released within the hypothesised time frame, so 
that each growth factor can act on the phase of healing it is designed to target. Different 
wound types and species require different release timings, so tailorability is key. In this study, 
acute wounds in mice were targeted, where inflammation occurs within the first 12 hours to 
6 days, and proliferative processes occur between 3 and 9 days[213]. This type of progression 
could be linked to surgical wounds in humans[39], where VEGF-E and vIL-10 release could 
act to promote healing and limit scar development.  
A number of methods were trialled to detect release of vIL-10 and VEGF-E release 
from the cubosome-containing alginate hydrogels. The first method of detection trialled was 
fluorescent conjugation, which has been successfully used to measure IL-10[364], EGF[365], 
and BSA[366] release from biomaterials. The test proteins, CA and BSA, were conjugated to 
Dylight®488 and Dylight®594 amine-reactive dyes. Dylight®594-BSA encompassed 
directly in the alginate hydrogel showed burst release within 24 h Dylight®488-CA 
encapsulated within cubosomes, then in the alginate hydrogel, showed delayed release over 
6 days. This matched the desired biphasic release for vIL-10 and VEGF-E, however, the 
amount of protein detected was significantly lower than the loaded amounts, with only 0.32% 
of BSA detected and 0.1% of CA being detected.  
Dylight® fluorescent tags are stable between pH 4-10[367], and have shown stability 
both in vitro and in vivo at 37oC for up to 7 days[365, 366]. Based on this evidence, degradation 
of the fluorescent conjugate is unlikely. Another explanation for the low sensitivity of 
detection could relate to the fluorescent tags. Three protocols were tested, each using 80 µL 
dye, but containing different amounts of protein – 5, 20 and 100 µg. A decrease in degree of 
labelling was observed with increases in protein concentration, and this was supported by the 
decrease in fluorescence detected in the fluorescent western blot for both Dylight®488-CA 
and Dylight®594-BSA. Protocol 1 was selected for both Dylight®594-BSA and 
Dylight®488-CA as the optimum protocol, producing degrees of labelling of 6.34 and 9.3, 
respectively. While western blotting suggested that the protocols producing the highest 
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degree of labelling produced the most fluorescence, the literature suggests that the fluorescent 
lifetime and bioactivity of labelled proteins decreases with high degrees of labelling due to 
fluorescent quenching[368-370]. The long-term fluorescence of the conjugated proteins may 
have been compromised because of their higher degrees of labelling.  
In previous experiments conducted by the Cabral laboratory, the same system 
delivering two different fluorescent-labelled proteins showed the same biphasic release 
pattern, but 100% of the loaded protein was detected by day 7. The degree of labelling for 
the proteins was 0.20 moles of dye per mole of protein, significantly lower than the degrees 
of labelling calculated for Dylight®488-CA and Dylight®594-BSA. The lower degree of 
labelling may explain the increased protein detection in this experiment compared to the 
experiment detecting Dylight®488-CA and Dylight®594-BSA. Further optimisation of 
labelling protocols, and testing of long-term detectability of the proteins, would assist in 
confirming the optimal labelling conditions for detection. Unfortunately, issues with the 
supply of Dylight® conjugates meant that alternative methods had to be trialled with VEGF-
E and vIL-10.  
 Immunoprecipitation paired with western blotting was tested as an alternative 
measure of protein release. This technique was able to successfully detect release of VEGF-
E and vIL-10 from the alginate-cubosome hydrogels, by detecting the FLAG tag on the C-
terminus of each protein. Again, the amounts of protein detected in the release samples were 
less than loaded into the cubosome-alginate hydrogels, with 52% of VEGF-E and 2.3% of 
vIL-10 detected. While this was an improvement on the sensitivity of fluorescent labelling, 
protein loss was still occurring at some point during the experimental process.  
There are two potential explanations for this protein loss – the first is that protein is 
being retained within the hydrogel, and the second is that the protein is degrading at some 
point in the process. While the alginate hydrogel visibly degraded in vitro, the microscopic 
nature of the cubosomes mean that VEGF-E could be retained within the cubosome particles, 
and not be detected by anti-FLAG antibodies. While this may have contributed to the reduced 
amount of VEGF-E detected, it does not explain vIL-10 loss, as it was not encompassed 
within the lipid particle. Investigating whether VEGF-E is retained within the cubosome 
could be done by imaging of fluorescent-labelled protein or scanning electron microscopy to 
visualise the cubosomes.  
Lyophilisation of the hydrogels may also have contributed to protein loss. 
Lyophilisation consists of three phases – freezing, primary drying, and secondary drying[371], 
and it has been suggested that exposure to cold temperatures both prior to and during ice 
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formation may degrade protein[371, 372]. Freeze-drying can also oxidise proteins or change 
their secondary structures, contributing to immunogenicity and inactivity[351, 372]. It is 
possible that VEGF-E may have been degraded during freeze-drying, but vIL-10, which was 
added after this point, could not have been.  The addition of excipients, such as sucrose, could 
be used to decrease degradation of VEGF-E due to freeze drying[371]. 
 VEGF-E and vIL-10 may also have degraded during the release experiment. 
Proteases may have been introduced into the system via any of the solutions used, including 
PBS, 5% CaCl2, and milliQ water. All stock solutions were filter-sterilised prior to use, 
however, experiments were not conducted in a completely sterile environment, such as a 
biosafety cabinet. Any proteases introduced to the system would rapidly degrade the protein, 
reducing the detectable amount in release samples. This could be confirmed by running 
another experiment with two aligned groups – one release as previously conducted, and one 
release with protease inhibitors added. The addition of protease inhibitors would suppress 
any degradation driven by proteinase activity[373], thereby confirming the introduction of 
proteases to the system and its role in the observed protein loss.  
 VEGF-E and vIL-10 loss may have also occurred during the detection stage. Anti-
FLAG® M2 affinity gel was used to bind protein contained within release samples, before 
eluting and running concentrated samples on SDS-PAGE gels. M2 affinity gels were 
transferred to a nitrocellulose membrane and the FLAG antibody detected using anti-FLAG-
HRP. There are a number of challenges with the M2 affinity gels that may have contributed 
to protein loss. Firstly, gels could have become saturated with protein, preventing detection 
above a certain level. However, the manufacturer[374] cites the binding capacity to be 600 µg 
per 500 µL packed M2 affinity gel, more than 200-fold lower than the protein-gel ratio in the 
in vitro release. Therefore, saturation was unlikely to be a contributor. Bead loss could also 
have occurred during any of the washing steps.  
 The most common alternative for protein detection in the literature appears to be 
protein-specific ELISA, which has been used to measure VEGF[286, 295, 304], IL-10[375], 
BMP2[286], FGF-2[302, 375], PDGF-bb and EGF[304]. However, no commercial ELISA kits are 
available for VEGF-E and vIL-10. Other methods include radioligand labelling, which has 
been demonstrated with VEGF[376] and PDGF-bb[377]. This was a possibility in this study, but 
was not trialled.  
 A VEGFR-2 competitive binding ELISA was utilised in this study as a dual method 
of detecting VEGF-E concentration and bioactivity[212, 218]. This assay has been previously 
optimised to measure VEGF-E binding to VEGFR-2[212, 218]. Detection of VEGF-A and 
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VEGF-E binding in this assay was consistent with that previously been reported[212, 218]. 
However, the level of VEGF-E released from the cubosome-alginate hydrogel, as determined 
by Western blotting, would be below the threshold of detection, so this assay wasn’t used to 
detect VEGF-E release. A VEGFR-2 Ba/F3 bioassay was trialled as an alternative. This assay 
measures B cell proliferation in response to VEGFR-2-activation, and has been shown to 
detect VEGF-E responses at relevant concentrations[212]. Standards for VEGF-E and VEGF-
A showed proliferative responses, but toxicity was observed with the least diluted release 
samples (>25%). Thus, the ability to measure protein release in in vitro samples was affected. 
Thus, the bioactivity of VEGF-E following release from the cubosome-alginate hydrogels 
was unable to be ascertained. 
 A further limitation of this study was that the bioactivity of vIL-10 was not 
determined. Time constraints and the negligible amount of vIL-10 detected in by Western 
blotting meant that a bioassay to detect vIL-10 was not optimised. An IL-10R1 binding 
ELISA[324] would not be sufficiently sensitive because of low vIL-10 release, and a bioassay 
cell line (IL-10R1-TF1)[378] was unable to be imported. In the future, a panel of bioassays 
would be advised for both VEGF-E and vIL-10. VEGF-E-cubosome-alginate hydrogels 
could be placed in a cell culture membrane support over endothelial cells and keratinocytes, 
with measurements of cell number showing its mitogenic activity[219]. Alginate hydrogels 
containing vIL-10 could also be applied in the same way to activated monocytes, with 
measurement of cytokine levels showing its anti-inflammatory activity[222].  
 
6.4.2 Toxicity of Cubosome-Alginate Hydrogels In Vitro 
As mentioned above, toxicity of the cubosome-alginate hydrogels was observed when 
evaluating release sample using the Ba/F3 bioassay cell-line. To confirm the extent and 
source of this toxicity, a more comprehensive toxicity experiment was conducted by 
incubating HaCaT keratinocytes with cubosome-alginate hydrogel release samples and their 
components, including pluronic F127, CaCl2, sodium alginate and monoolein.  
No toxicity was detected in HaCaT cells for the hydrogel components, CaCl2 or 
sodium alginate. For sodium alginate, this is consistent with reports of no toxicity in skin 
cells[176, 191]. CaCl2, when used as a crosslinker for sodium alginate, reduced the viability for 
Schwann cells[379], at high concentrations. The mechanism for this was proposed to be 
osmotic dysregulation resulting in cell damage[379]. In this study, a proliferative effect was 
observed at low concentration of CaCl2, matching reports in the literature[380].  
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For the cubosome components, a reduction in HaCaT cell viability was observed for 
monoolein cubosomes, and release samples from cubosome-alginate hydrogels, but not for 
the pluronic F127. Reduced viability in HaCaT cells treated with pluronic F127-derived 
hydrogels has been reported, although the concentration was not stated[381]. Monoolein 
cubosomes exhibited potent toxicity in HaCaT cells in this study, at concentrations as low as 
0.625 µg/mL. Release samples were concentrated, with three gels released in one preparation, 
and the expected amount of monoolein released per gel was 4 µg/mL. A reverse toxicity trend 
was observed, where there was an apparent increase in viability at 10, 20 and 40 µg/mL. This 
is likely to be a false positive, as monoolein at high concentrations was extremely viscous, 
and even vigorous washing did not remove all of it from the well. The crystal violet dye used 
to quantify cell number is also dissolved in monoolein[382], therefore the high reading can be 
explained by an increase in monoolein staining, rather than an increase in cell number.  
 Toxicity has been reported with monoolein-derived cubosomes stabilised with PF127 
in vitro across a number of cell lines[204]. Toxic concentrations ranged from 25 µg/mL in 
rabbit corneal epithelial cells[383] up to over 1000 µg/mL in HeLa cells[384]. The viability of 
HaCaT cells treated with monoolein-derived cubosomes does not appear to have been 
tested[204], but the results of this study suggest that HaCaT cells are very sensitive to 
monoolein toxicity.  
 When considering monoolein alternatives, the other most commonly used 
amphiphilic lipid for cubosome synthesis is phytantriol, but it should be noted that this is 
reported as much more cytotoxic than monoolein, with reported toxic concentrations below 
50 µg/mL across a number of cell lines[204]. For both monoolein and phytantriol, the 
cytotoxicity of the cubosomes is confirmed to be due to the lipid, rather than the stabiliser[204]. 
This is consistent with the results of this study, as pluronic F127 showed no toxicity on its 
own. It has been suggested in the literature that monoolein can influence the cellular 
internalisation of pluronic F127, and upon entering the cell it can produce damage to 
mitochondrial and nuclear membranes[385]. Due to its viscosity, the effect of monoolein alone 
on HaCaT viability could not be tested, however, the fact that pluronic F127 was non-toxic 
on its own suggests that monoolein was indeed the toxic component.   
 The toxicity of monoolein on HaCaT keratinocytes should be confirmed, with the 
viability examined for primary human keratinocytes, and other key healing cells, including 
endothelial cells, monocytes and dermal fibroblasts. This would build a picture of the extent 
of monoolein toxicity in the context of wound healing. If considerable toxicity was observed 
in all of these cell lines, future studies may look into monoolein alternatives for sustained 
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delivery of VEGF-E. Using phytantriol as an alternative to monoolein would not be 
appropriate in this case, as it is even more cytotoxic[204]. Instead, gelatin nanoparticles or 
microspheres might provide a suitable alternative, as these are well-characterised as non-
cytotoxic[386] and have shown sustained delivery of a number of growth factors[286, 293, 387]. It 
should be noted that glutaraldehyde, a crosslinker commonly used in the synthesis of gelatin 
nanoparticles, has exhibited toxicity, but alternatives such as genipin are biocompatible[388].  
 
 Biocompatibility of the Cubosome-Alginate Hydrogel In Vivo 
The alginate hydrogel containing vIL-10 and cubosome-encapsulated VEGF-E was tested in 
a murine full-thickness excisional wound model. The hydrogel was well tolerated, with no 
greater adverse effects, however, there was very poor retention and cellular infiltration. 
Hydrogels encompassing vIL-10 and cubosome-encapsulated VEGF-E showed similar levels 
of tolerance and retention, and although there was no increase in cell infiltration of the 
hydrogel, increased numbers of CD206+ cells and CD31+/aSMA+ blood vessels were 
observed in the underlying granulation tissue, which is indicative of an enhanced reparative 
response mediated by VEGF-E. No differences in wound re-epithelialisation, or the number 
of calprotectin+/iNOS+ cells or vimentin+/aSMA+ cells were observed between hydrogels 
with or without vIL-10 and VEGF-E-cubosomes. These histological observations were 
unable to be further validated due to the limited number of wounds that had retained the 
hydrogel.  
 Post-operative monitoring indicated that the hydrogel treatments were tolerated, as 
no significant adverse events occurred following surgery, relative to topically-treated 
wounds. Major issues with bandage irritation and bandage loss as a result of mice chewing 
at the Tegaderm™ dressing were however noted and likely impacted hydrogel retention and 
healing responses. Interference with bandaging can be reduced by individual housing[389] or 
the use of commercial or novel rodent jackets[358, 390], and these strategies could be employed 
in the future to prevent bandage irritation from occurring.  
 Poor adherence of the alginate hydrogels to wounds in vivo suggests that this system 
may not be suitable for further use. Many gels were lost from the surface of the wound, either 
during rodent interference or during bandage removal. Alginate hydrogels have a high 
capacity to absorb water, making them ideal for fluid-producing wounds[176, 191]. The full-
thickness excisional wound used in this study is not a high fluid-producing wound, and 
although the hydrogel disc was hydrated upon application to the wound, this may not have 
been enough fluid to help the hydrogel adhere. Alginate adherence to wounds has been 
Chapter 6: Discussion and Conclusions 
 
 131 
enhanced by oxidising functional groups[391-393]. Acylhydrazone bonds added to the alginate 
chain enhanced adherence, however, the success of this reaction is dependent on an acidic 
environment (pH 4.2)[392], and considering the basic nature of chronic wounds and neutral 
nature of acute wounds[394], this method of functionalisation may not be appropriate. Imine 
bonds maybe better suited as they favour basic environments[393, 395]. It should, however, be 
noted that oxidised alginates have a faster degradation rate[391] and therefore, oxidisation of 
the hydrogel used in this study would increase the release rate of vIL-10. Incorporation of 
vIL-10 into a nanoparticle with faster release kinetics than the VEGF-E cubosome may be 
warranted to maintain the biphasic release pattern. Alternatively, fast release-electrospun 
nanofibres for vIL-10 and slow-release nanoparticles for VEGF-E could be used as described 
in Lai et al[304].  
 Low cellular infiltration into the alginate hydrogel was also observed. In cases where 
the alginate hydrogel remained adherent to the wound surface, the newly forming epithelium 
often grew underneath rather than on top. There was minimal evidence that the system acted 
as a scaffold, supporting the migration of the neo-epidermis through the hydrogel. This 
suggests that the cubosome-alginate hydrogel is functioning purely as a delivery vehicle for 
vIL-10 and VEGF-E, rather than dual delivery and structural support for extracellular matrix 
regeneration during healing. Alginate lacks mammalian cellular interaction domains[396, 397], 
which may explain the lack of cellular infiltration into the hydrogel. Alginate-cell interactions 
can be enhanced by functionalisation with an RGD (arginine-glycine-aspartic acid) 
peptide[398], as has been shown in vitro and in vivo with endothelial cells[399], 
chondrocytes[400], and myoblasts[396], among others[401]. This being considered in hand with 
monoolein toxicity, gelatin nanoparticles may be an attractive alternative, as the gelatin 
structure is naturally comprised of RGD sequences and therefore has an inherent capability 
for cellular interactions[386].   
 Immunohistochemical analysis of sections from the treated wounds, suggested that 
inflammatory MAC387+/iNOS+ monocytes or vimentin+/⍺SMA+ myofibroblast infiltration 
was not affected by protein addition to the alginate hydrogel day 5 post-wounding. In 
unbandaged full-thickness excisional wounds, these cells are present from day 3 to day 6[213, 
229]. The lack of cells may indicate that inflammation and fibrosis is reduced due to the 
alginate hydrogel, and some research has suggested that alginic acid modulates inflammatory 
processes in arthritic models[402, 403] and inhibited activation of macrophages in vitro[404]. The 
potent effect of vIL-10 from previous studies[213, 227-229] could not be observed when 
compared to the alginate hydrogel alone, potentially because of anti-inflammatory action of 
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alginate. A more likely explanation is that the inflammatory healing processes have been 
delayed by bandaging.   
Immunohistochemical analysis also indicated that blood vessels and CD206+ 
macrophages were increased at day 5 post-wounding. These effects have been linked to 
VEGF-E activity[213, 229], and these responses often occur after the inflammatory and fibrotic 
responses, after day 9.  VEGF-E therefore may be accelerating these processes.  
In the future, an extend time course analysis of a greater number of wounds over a 
number of different timepoints would show if VEGF-E and vIL-10 are exerting their 
expected effects on wound healing processes. The efficacy of VEGF-E and vIL-10 will be 
dependent on achieving the appropriate dose and timing of release, and this was not examined 
in vivo. Moving forward, it will be important to test protein release in vivo, as it will likely 
differ from in vitro release due to a complex interplay of cell types and systemic responses. 
As previously mentioned, measuring protein release in vivo could be executed by measuring 
fluorescent protein release using a bioimager, or ELISA quantification of wound fluid. 
Evaluating the efficacy of vIL-10 could be done by looking at inflammatory cell infiltration, 
such as monocytes and myofibroblasts, and the extent of fibrosis by collagen staining or 
tensile strength analysis. A VEGF-E response could be measured by looking at blood vessel 
growth and maturation, granulation and re-epithelialisation. Human-relevant measures of 
wound closure, re-epithelialisation and scar strength are the most important for future work, 
but studying these outcomes will require different model systems. 
This study used a murine full-thickness excisional wound model, representative of an 
acute wound. This model is well-characterised[313], and has been used before to study 
mechanisms by which VEGF-E and vIL-10 modulate healing[213, 227, 229]. However, this 
model does have its limitations – skin contraction confounds re-epithelialisation[356], and 
rodent models do not scar to the same extent as humans[314, 331]. Based on previous studies, 
the best clinical indication for the VEGF-E and vIL-10 combination would most likely be 
acute surgical wounds to reduce pathological scarring. However, future research would need 
to employ more complex models to better evaluate the effect on healing and scarring. As 
mentioned earlier, splinting[312] would be a good first step to observe the effect on healing 
without contraction. Better methods for observing the effect on scarring include the Duroc 
pig[360] or EGT horse model[231], which produce hyperproliferative scars reminiscent of 
hypertrophic scars and keloids[231, 360].  
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 Conclusions and Future Perspectives 
Wound healing complications are multifactorial, with dysregulation of growth factors and 
cytokines across multiple phases of healing. Therapies therefore need to target multiple 
phases in impaired healing states to promote progression towards wound closure and limit 
scarring.  
The first objective of this study was to identify why delivery of growth factors and 
cytokines for wound healing complications has thus failed, and to evaluate strategies for 
improving their delivery using biomaterials. Following the comprehensive literature search, 
it can be concluded that the large-scale clinical failure of growth factor and cytokine delivery 
to wounds is likely due to the additive effects of poor and variable trial design (i.e. lack of 
consistent parameters, populations and endpoints) and reporting, issues with topical 
administration (proteolysis, immunogenicity and cancer), and issues relating to cost. 
Biomaterials are an emerging novel strategy for tailored phasic and multiphasic release of 
proteins to wounds. However, there is still a lack of evidence that they actually provide 
proteolytic protection and structural support, and accurate comparisons suggesting that they 
have improved efficacy compared to topical delivery of growth factors and cytokines. 
Limitations in this area of research are centered around translatability, with inconsistent 
model choices and non-human relevant outcome measures. Careful consideration needs to 
be applied when selecting which growth factors, cytokines and biomaterials to use, and these 
choices need to relate to targeting of multiple phases and appropriate release kinetics (Fig. 
6.4). In vitro testing will include testing for cellular compatibility and physical support, and 
proteolytic factors incorporated into in vitro release experiments to mimic the enzymatic 
activity within the wound. Combining natural and synthetic biomaterials with nanostructures 
provided possibilities for delivery of multiple growth factors or cytokines to target varied 
wound indications, including chronicity and scarring. While it has been claimed that 
biomaterials reduce degradation and immunogenicity of proteins compared to topically-
delivered methods, there is still little evidence to support this, and more comprehensive 
studies are needed in order to draw a conclusion.  Selection of more clinically relevant 
models, including appropriate controls and measuring relevant outcomes would be key in 
ensuring the translatability of in vivo results when assessing the efficacy of VEGF-E and vIL-
10 delivery.   
 The second objective of this study was to develop and test a composite VEGF-E and 
vIL-10 delivery system to enable phasic regulation of wound inflammation, repair, and 
scarring. Biphasic release of vIL-10 and VEGF-E was hypothesised to enhance healing of  




Figure 6.4. Proposed Preclinical pathway for the Development of Growth Factor and Cytokine Delivery 
Systems. System design needs to account for what phases are being targeted, which growth factors or 
cytokines will execute that targeting, and what biomaterials are appropriate to deliver the growth factors or 
cytokines. In vitro testing needs to focus on measuring cellular compatibility, physical support and protection 
from proteolysis. Release kinetics also need to be assessed. In vivo studies should be conducted with attention 
paid to selecting the correct model for the clinical indication (i.e., chronicity or scarring), and should measure 
safety and efficacy by measuring protein concentration in vivo, generation of antibodies or systemic 
responses, and assessing the effect of healing by using clinically relevant outcomes. Made using Biorender. 
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excisional wounds, however, more optimisation of protein loading is required. Despite the 
toxicity associated with the cubosome component of the system, the hydrogel was well-
tolerated when applied to skin wounds, with no significant adverse effects observed. 
However, retention and cellular integration into the alginate hydrogel was poor, so 
modifications are required to improve adherence and cell adhesion.  Functionalisation of 
alginate hydrogels could be used to improve adherence and cell interactions, but changes in 
degradation rate due to these changes will need to be mitigated by altering the release 
methods of vIL-10 – incorporation into fast-release fibres may be an appropriate strategy.  
Despite protein loading issues, the presence of macrophages and blood vessels in the 
granulation tissue of treated wounds suggests that VEGF-E delivery from cubosomes within 
the alginate hydrogel had reparative effects on healing. Further work is needed to optimise 
dose and release timing to ensure the best suitability for acute surgical wounds. For better 
translatability, the delivery system should be tested in more clinically relevant models such 
as the Duroc pig or EGT horse model.  
Overall, this study highlighted many challenges in the development of growth factors 
and cytokines for the treatment of wound healing and scarring indications. There is a clear 
need for streamlining of the preclinical and clinical pathways, with standardised methods for 
development, and in vitro, in vivo and human testing. A more comprehensive and 
methodological approach to the development of growth factor and cytokine delivery systems 
that target the phasic dysregulation of chronic wounds or excessive scars will facilitate the 
approval of much needed therapies for human wound indications. 
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